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1. Crohn’s Disease 
The concept of inflammatory bowel diseases (IBD) comprises Crohn’s disease (CD) and 
ulcerative colitis (UC). Both disorders are characterized by chronic, relapsing intestinal 
inflammation (1). UC is limited to the colon whereas CD can affect the whole gastrointestinal 
tract with preference for the terminal ileum. Inflammation in CD is transmural, asymmetrical 
and segmental. 
Although the exact pathogenesis is still unclear, it is supposed that an inadequate 
immunologic response towards certain environmental (microbial) factors in genetic 
susceptible individuals leads to a dysregulated cytokine balance and subsequently to 
uncontrolled inflammation (2).  
1.1. Clinical Features 
1.1.1. Epidemiology 
Important geographic differences have been noted considering prevalence and incidence of 
CD. The highest incidence and prevalence rates can be found in northern Europe, the United 
Kingdom and North America, whereas clearly lower rates are seen in southern and central 
Europe, Asia (except Israel), Latin America and Africa (except South Africa), indicating a 
“North-South gradient” (table 1) (3, 4). Incidence rates seem to stabilize in many high-
incidence areas whereas they increase in developing countries becoming “Westernized” or 
industrialized. These findings reflect the importance of environmental factors in the 
pathogenesis of CD (e.g. diet, lifestyle, bacterial or parasitic infections, etc) although ethnicity 
also plays a significant role (e.g. Ashkenazi Jews). 
There is a slight female predominance in CD and an incidence peak is found in the second or 
third decade in life. Whether this is followed by a second, smaller peak between the fifth and 
eighth decades has become uncertain. Recent studies rather suggest a gradual decrease in 
incidence following the first peak (5).   
Numerous epidemiological studies have demonstrated cigarette smoking as a risk factor for 
the development of CD (6). Whether dietary antigens, appendectomy, oral contraceptives, 
vaccination or infections (e.g. measles, mycobacteria) play a role, is still uncertain.
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Table 1. Incidence and Prevalence rates for CD 
Geographic area Incidence* Prevalence** 
Northern Europe 3.6 – 8.3 54 - 213 
United Kingdom 5.6 - 9.8 144 - 214 
North America 3.6 - 15.6 26 - 198.5 
Southern/Central Europe 0.7 - 3.4 8.3 - 40 
Africa 0.3 - 1.8 NA
Asia 0.5 3.6 - 5.8 
Latin America 0.03 NA 
* cases per 100,000 person-years;  ** cases per 100,000 persons 
1.1.2. Clinical Findings & Diagnosis 
The most common presenting symptoms are increased stool frequency and decreased stool 
consistency with or without loss of mucus or blood, abdominal pain, weight loss and fatigue. 
Possible complications represent (sub)obstruction due to intestinal fibrostenosis, 
intraabdominal or perianal fistulas and abscesses, toxic megacolon and extraintestinal 
manifestations.  Diagnosis of CD is based on clinical, endoscopical, histopathological and 
radiological findings. Nevertheless, a clear differentiation from UC is not always possible 
(indeterminate colitis). Irritable bowel syndrome, intestinal infections, microscopic colitis, 
appendicitis and non-steroidal anti-inflammatory drug induced mucosal lesions represent 
other important differential diagnostic syndromes. 
1.1.3. Extraintestinal Manifestations 
Extraintestinal manifestations (EIM) occur in 21-36% of IBD patients (7). Joint involvement 
and cutaneous lesions are most frequent, but also ophthalmologic and hepatobiliary 
manifestations are not uncommon. Furthermore, a list of possible and often rare complications 
“at distance” of the gut is quite extensive (8). 
¾ Articular
Articular involvement represents the most frequent extraintestinal manifestation of IBD and 
can be divided into peripheral and axial arthropathy (7-9). According to the European 
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Spondyloarthropathy Study group (ESSG) criteria, the presence of inflammatory low back 
pain and/or peripheral arthritis in IBD patients is classified as spondyloarthropathy (SpA) 
(10).
Peripheral arthritis occurs in 15-20% of IBD patients and is mostly pauciarticular and 
asymmetrical, involving predominantly the large and small joints of the lower limbs (fig 1A). 
It is frequently transient, migratory and usually non-deforming (11). It has been associated 
with colonic involvement and usually coincides with intestinal activity. Often, other 
extraintestinal manifestations like erythema nodosum or uveitis occur simultaneously. This 
type of arthropathy has been classified as type 1 by Orchard et al (12). Type 2 arthropathy 
was defined as polyarticular and symmetrical with persistence of symptoms and not 
associated with IBD activity. Besides a different clinical phenotype and course, both types of 
peripheral arthropathies could be distinguished immunogenetically according to different 
associated HLA genotypes (13). The prevalence of type 2 arthropathy found by this group 
however could not be confirmed (14, 15). 
Peripheral enthesopathies have also been associated with IBD and usually affect the Achilles 
tendon or the insertion of the fascia plantaris (11). 
Axial involvement consists of spondylitis or sacroiliitis (fig 1B) (16). Up to 10% of IBD 
patients fulfil the criteria for ankylosing spondylitis (AS) (17, 18). Symptoms of spondylitis
tend to be unrelated to the bowel activity. Usually a chronic progressive course is seen. 
Clinical features comprise morning stiffness, inflammatory low back pain or alternating 
buttock pain, limited Schober index and reduced chest expansion. However, asymptomatic 
sacroiliitis has been described in up to 32% of patients (15, 19, 20). In contrast to idiopathic 
AS, the association of axial involvement with HLA-B27 is much weaker in IBD. Whereas 
more than 90% of patients with idiopathic AS carry HLA-B27, the prevalence decreases to 
25-75% in IBD associated AS and to even normal prevalences in asymptomatic sacroiliitis 
(15, 20). These findings point at a different genetic background. 
     1A        1B  
Fig 1. A. synovitis of the left knee      B. sacroiliitis at the right sacroiliac joint. 
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¾ Non-articular
Erythema nodosum has been reported in up to 20% of IBD patients (8). These skin lesions are 
usually found on the extensor surface of the lower extremities and appear as tender, red and 
painful nodules. A good correlation with bowel disease activity is known and occurrence is 
often in concordance with peripheral arthritis (21).
Pyoderma gangrenosum is a chronic, ulcerating skin disorder. These sometimes severe and 
debilitating lesions have been described in 1 to 10% of IBD patients (8). Its occurrence is 
usually independent of IBD disease activity.  
Most common ocular complications are episcleritis and uveitis (3.5 – 6.3% in CD) (8). The 
occurrence of episcleritis, presenting as a red eye with irritation or burning, usually correlates 
with IBD activity. Uveitis, which is painful and can be associated with visual blurring, 
photophobia and headache, often coincides with joint and skin manifestations of IBD (22). 
Primary sclerosing cholangitis (PSC) is characterized by progressive inflammation, fibrosis 
and destruction of intra- and extrahepatic bile ducts, usually resulting in an evolution towards 
cirrhosis and portal hypertension. PSC is associated with colonic involvement in IBD. Similar 
rates of hepatobiliary involvement (2.4 to 7.5%) are found in UC and colonic CD patients 
(23).
1.1.4. Serological markers 
Several antibodies have been detected in the serum of IBD patients (24).  Serological markers 
could have a potential role in differentiating CD from UC in patients with indeterminate 
colitis. Theoretically, they might also be useful in a screening test for patients with compatible 
gastrointestinal symptoms or relatives of IBD patients or serve as a predictor of disease course 
or treatment response. However, due to the low and variable sensitivity, the individual use of 
these described serological markers for screening purposes in clinical practice is limited (25).  
¾ Anti-Saccharomyces cerevisiae antibody (ASCA)
ASCA have been associated with CD and are directed against the cell wall mannan of the 
baker’s or brewer’s yeast Saccharomyces cerevisiae (26, 27). These IgA and/or IgG 
antibodies can be found in 40 to 65% of CD patients (25).  Reported specificities for CD 
are higher and vary between 85 and 95%, although ASCA have also been detected in 
celiac disease, spondyloarthropathies, autoimmune liver disorders and cystic fibrosis (28-
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34). An important range in sensitivity and specificity has been described comparing 
different available ASCA assays (35). Consequently, standardization between assays 
concerning the cut-off value is mandatory. The exact pathophysiological role of these anti-
yeast antibodies is still unclear and even cross-reactivity with self-antigens in human gut 
is still not fully excluded (36). Nevertheless, the presence of ASCA has been associated 
with specific clinical phenotypes: ileal involvement, penetrating or stricturing disease, 
younger age at onset and the need for resective bowel surgery (37-41).
Twin and family studies have suggested genetic influences on the formation of ASCA (39, 
42-46). Higher ASCA titers have been demonstrated in healthy monozygotic twins and 
healthy first-degree relatives of CD patients.
¾ Anti-neutrophil cytoplasmic antibodies (ANCA) 
A distinctive subset of ANCA has been related to UC (47, 48). Prevalence of ANCA in 
UC ranges from 45 to 82% compared to 2 to 28% in CD (25). This wide variation is most 
probably due to differences in laboratory techniques and reporting standards between 
different laboratories.  In contrast to cANCA with a cytoplasmic staining pattern (as found 
in Wegener’s granulomatosis), the antibodies in IBD are often defined as pANCA due to 
their perinuclear staining pattern. However, the name “atypical ANCA” would be more 
appropriate since the staining pattern in IBD differs from the classical pANCA seen in 
microscopic angiitis or small-vessel vasculitides (25). Various antigens, recognized by 
IBD-related ANCA, have been put forward varying from nuclear (histone H1) over 
cytoplasmic antigens (e.g. cathepsin G, lactoferrin, lysozyme, elastase and others) to 
epitopes on colonic bacteria (OmpC) (25, 49, 50). 
¾ Others
Anti-OmpC antibodies are directed against the outer membrane porin C of Escherichia
coli (E coli). IgG antibodies have been found in UC, in particular in patients with pANCA 
(50).  In contrast, IgA antibodies can be detected in 55% of CD patients (51). 
A fragment of bacterial DNA (I2), more specifically from Pseudomonas fluorescens, was 
isolated from mononuclear cells of active CD patients (52, 53). IgA antibodies against this 
I2 sequence can be found in 50% of CD patients (51). 
Antibodies to pancreatic antigens (PAB) have also been reported in patients with IBD, in 
particular with CD (54).  PAB can be found in 27 to 39% of CD sera versus less than 5% 
in UC (55, 56).
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Immunoreactivity to flagellin, the primary structural component of bacterial flagella, has 
been observed with the serum of CD, but not UC patients (57, 58).  Anti-flagellin IgA and 
IgG were detected in 52% of CD patients. Flagellin can induce an acute inflammatory 
response by recruiting polymorphonuclear cells via epithelial, TLR5-driven chemokine 
secretion (mainly IL-8) (59). It might however also trigger the adaptive immune system 
via dendritic cell activation and CD4 T-cell driven B-cell response.
The individual usefulness of these described markers is limited in clinical practice. However, 
recent studies suggest that combining ASCA with pANCA, anti-OmpC and anti-I2 antibodies 
may still help in differentiating CD from UC or in predicting the course of the disease (38, 
60). Since the level of immune response seems stable over time and with change in disease 
activity, these antibodies can however not be used for the monitoring of disease activity or 
treatment response (51, 61).  
1.1.5. Disease Classification 
The Vienna classification, proposed at the 1998 World Gastroenterology Congress, represents 
the most widely used clinical classification system of CD (62). Three variables are used to 
allocate CD patients to 24 different phenotypic subgroups (table 2): age at diagnosis, disease 
location and behaviour. Location points at the maximum extent of the lesions at any time 
before the first surgical resection. Stricturing (or fibrostenosing) disease is characterized by 
the presence of radiologically, endoscopically or surgically proven strictures. A history of 
inflammatory masses, abscesses, fistulas or perianal ulcers is defined as penetrating (or 
fistulizing) disease. A hierarchy was defined for stricturing and penetrating disease 
(B1<B2<B3).
Overall, a good intra- and interobserver agreement is found using this classification system 
(62, 63). Location of disease, as defined by this system, seems relatively stable over time, 
however an important change of disease behaviour can be noticed (64). Nevertheless, due to 
the lack of more suitable classification systems, this model is still often used in genotype-
phenotype studies. 
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Table 2. Vienna classification for Crohn’s Disease 
Age at diagnosis A1 <40 years 
 A2 >40 years 
Location L1 Terminal ileum 
 L2 Colon 
 L3 Ileocolon 
 L4 Upper gastrointestinal 
Behaviour B1 Non-stricturing non-penetrating 
 B2 Stricturing 
 B3 Penetrating 
1.1.6. Therapy 
Medical treatment
¾ Aminosalicylates
5-ASA formulations like mesalamine or sulfasalazine are commonly used for the 
treatment of Crohn’s disease. However, evidence for their efficacy in CD is not fully 
convincing and the indications are limited to the management of mild to moderate active 
disease (65, 66). There is no place for 5-ASA drugs in the maintenance of medical 
induced remission (67).
¾ Antibiotics 
Although clear data are relatively scarce, metronidazole and ciprofloxacine seem to have a 
limited efficacy in the treatment of active disease (68, 69). These antibiotics can also be 
used for perianal disease where they can induce a decrease in fistula drainage (70). 
Responses are however mostly incomplete and transient. 
¾ Corticosteroids
Prednisone or prednisolone are quite successful in inducing remission but many patients 
are or become steroid-resistant, -refractory or -dependent (71). Moreover, long-term 
steroid treatment has significant systemic side effects. The use of the topical drug 
budesonide overcomes this partially but does not change long-term outcomes. 
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¾ Immunosuppressives
Immunosuppressive therapy, including azathioprine, 6-mercaptopurine or methotrexate, is 
used in refractory disease to maintain remission (72-74). Due to their toxicity profile, 
close monitoring is mandatory. These agents are slowly acting and hence not useful for 
induction of remission.  
¾ Biologicals
The introduction of infliximab, a chimeric mouse/human monoclonal antibody against 
tumor necrosis factor (TNF)-Į, ushered in a new era in the treatment of CD (75). This 
biologic agent appeared to be very efficient in both induction and maintenance of 
remission and in the management of perianal disease, providing hope for patients having 
left few non-surgical options. Nevertheless, some patients do not respond to infliximab 
and several other biologicals are currently under investigation including humanized and 
pegylated anti-TNFĮ antibodies and antibodies directed against interleukin (IL)-12/IL-23 
p40, integrins, interferon (IFN)-Ȗ and CD25 (76). 
Surgical therapy
Despite significant progress in the medical treatment of active CD, up to two thirds of the 
patients will need surgery during the course of their disease (65, 77). Strictures, perianal 
involvement (fistulas and/or abscesses), unresponsive fulminant disease and perforation are 
the most frequent indications for surgical intervention. 
1.2. Pathogenesis 
1.2.1. Normal mucosal homeostasis 
The gut mucosa represents the largest area of our body in contact with environmental 
(microbial, dietary and other) antigens (ca. 400m²) (78). Only a single layer of epithelium 
separates the luminal content from the internal milieu. Integrity of the surface epithelium with 
its tight junctions is important for an adequate intestinal barrier. Furthermore, specialized 
epithelial cells (goblet cells) produce mucus containing mucin glycoproteins and trefoil 
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peptides (79). This protective mucus layer also contains antimicrobial peptides or defensins 
(produced by Paneth cells) and secretory IgA. The underlying mucosal immune system, 
containing elements of both innate and acquired immunity, also makes part of the intestinal 
barrier.
Interactions between the host and intraluminal flora are mutually beneficial (79, 80). Hence 
the host needs to avoid an overly aggressive response to this microbial population that would 
lead to the elimination of beneficial organisms and could result in inflammation and extensive 
tissue damage. Nevertheless, the capacity to limit the spread of bacteria from the lumen into 
underlying tissues and to respond effectively to episodic challenges with pathogens needs to 
be maintained. Cross-talk between immune and epithelial cells is mandatory to obtain an 
adequate immunological tolerance.
Due to continuous host-flora interactions, a “controlled” or “physiologic” mucosal 
inflammation is present in normal circumstances (80). This is characterized by a perfect and 
tightly regulated balance between pro- and anti-inflammatory cytokines produced by antigen-
presenting cells and T lymphocytes (T-helper (Th) and regulatory T (Treg) cells).  
1.2.2. Sensing the microenvironment 
Several cell types are involved in sensing the microenvironment (78). M-cells overlying 
lymphoid follicles actively transport microbial antigens and deliver them to antigen-
presenting cells (dendritic cells, macrophages and B-cells) within the follicle but also surface 
enterocytes can transport soluble antigens. Dendritic cells can extend their dendrites into the 
lumen between the enterocytes without disrupting the tight junctions and sample luminal 
antigens themselves. The antigen-presenting cells process and present the antigens to 
lymphocytes, initiating an acquired immune response. 
Innate immune cells use different pattern-recognition receptors to recognize highly conserved 
structures of pathogenic microorganisms, called PAMPs (pathogen-associated molecular 
patterns) (81).
Toll-like receptors
Toll-like receptors (TLRs) are transmembrane receptors for PAMPs, expressed in 
monocytes/macrophages, dendritic cells, mast cells, polymorphonuclear cells, epithelial and 
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some endothelial cells (82, 83). The TLR family consists of at least 10 different receptors with 
specific bacterial components as ligands (84, 85). TLR2 recognizes lipoproteins/lipopeptides
and peptidoglycan (PGN). TLR4 senses lipopolysaccharide (LPS). TLR5 binds flagellin while 
CpG DNA is the ligand for TLR9 (fig 2). 
All TLRs contain an extracellular leucin-rich repeat (LRR) domain (that interacts with the 
PAMPs) and an intracellular portion designated TIR (Toll/IL-1 receptor) that activates 
intracellular signalling pathways, including nuclear factor-țB (NF-țB) and mitogen-activated 
protein kinase (MAPK) pathways (86). Binding of the TLR with its ligand gives rise to NF-
țB activation via myeloid differentiation factor 88 (MyD88), interleukin-1 receptor-
associated kinase (IRAK), TNF-receptor-associated factor (TRAF)-6, NF-țB-inducing kinase 
(NIK) and inhibitor of țB kinase (IKK) complex (fig 3) (83). IKK phosphorylates inhibitor of 
țB (IțB), resulting in ubiquination and degradation of IțB and subsequently in the release of 
the active dimer NF-țB (87). NF-țB, a nuclear transcription factor, will translocate towards 
the nucleus where it activates multiple genes resulting in the production of inflammatory 
cytokines. A Myd88-independent pathway has been described as well for TLR4 (88). 
Fig 2. Toll-like receptors and their ligands 
NOD receptors
Both NOD1 (CARD4) and NOD2 (CARD15) are intracellular sensors of bacterial products 
(89). NOD proteins have been found in monocytes/macrophages, dendritic cells, granulocytes 
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 CHAPTER 1 | 23 
and epithelial cells. They have a C-terminal LRR domain, N-terminal CARDs (caspase 
activation and recruitment domains) and a central nucleotide-binding site and detect 
components of peptidoglycan (a component of the bacterial cell wall) in the cytosol with 
specificity for distinct muropeptides (90). NOD1 has been shown to detect a muropeptide 
found mostly in Gram-negative bacteria whereas NOD2 senses another muropeptide found in 
most bacteria (91-93). Similar to TLRs, binding of NOD with its ligand muramyl dipeptide 
(MDP) gives rise to activation of caspases (linking NOD with apoptotic pathways) and NF-țB
although via a signalling cascade different from TLRs (fig 3). Activation of NOD induces 
recruitment of receptor-interacting protein (RIP)-2 (also known as RIP-like CARD-containing 
domain kinase [RICK] or CARD-containing interleukin-1ȕ converting enzyme-associated 
kinase [CARDIAK]) through homotypic CARD-CARD interactions followed by activation of 
the IKK complex and subsequently NF-țB (89, 94, 95). The final result is again production of 
inflammatory cytokines. Some cytokines like TNFĮ and IFNȖ can in turn induce an 
overexpression of the NOD protein (96, 97). 
Fig 3. Nod2 and TLR4 signalling pathways 
NOD/TLR synergy
Cross-talk between NOD and TLR signalling pathways has been demonstrated in several 
studies (98-101). TLR mediated responses are enhanced by simultaneous MDP-costimulation.  
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1.2.3. Intestinal inflammation in Crohn’s disease 
In CD, the normal mucosal homeostasis is disturbed, resulting in a cytokine imbalance in 
favour of pro-inflammatory mediators (fig 4) (1, 2). Dendritic cells, primed by antigens that 
have permeated the epithelial barrier or that are obtained by direct luminal sampling, interact 
with naïve Th cells through CD40/CD40L, resulting in IL-12 release and polarization towards 
the Th1 phenotype (1, 2, 102, 103). These Th1 lymphocytes will in turn produce IL-2 and 
IFNȖ (among others), activating macrophages. Several inflammatory mediators will then be 
secreted by stimulated macrophages: IL-12 and IL-18 will further stimulate Th1 cells, 
creating a self-sustaining cycle, whereas IL-1, IL-6 and TNFĮ will have a broader effect, 
causing inflammatory damage and amplification of a variety of inflammatory cascades by 
stimulating other, diverse cell types. During the process of active intestinal inflammation, an 
infiltration by a large number of lymphocytes, monocytes/macrophages and 
polymorphonuclear cells is seen in the affected mucosa.  
Fig 4. Induction of pro-inflammatory cytokines in CD 
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By inducing a Th1 response, IL-12 related cytokines like IL-12, IL-23 and IL-27 play a 
pivotal role in the mucosal cytokine imbalance found in CD (103, 104). Moreover, the 
activated Th1 cells in CD are resistant to apoptosis, leading to accumulation of T cells in the 
mucosa and perpetuation of the inflammatory response (2, 105, 106). In addition, an 
inadequate activation and/or expansion of regulatory T (Treg) cells has been demonstrated in 
CD (1, 107, 108). Treg cells, producing anti-inflammatory cytokines like IL-10 and TGFȕ, are 
generally considered to be the “peace keepers” in the intestinal mucosa and have an important 
role in controlling local immune responses. 
The exact underlying mechanisms of the immune dysregulation, observed in CD, are still not 
fully clarified but both environmental triggers and genetic susceptibility seem to play an 
important role.  
1.2.4. Environmental factors 
The striking increase in the incidence of IBD, and CD in particular, during the last half 
century points to changes in the environment as major causes for this evolution, since genetic 
variations are negligible in such a short period of time (109).  
Industrialized countries represent high-incidence areas and subsequently the rising emergence 
of IBD was linked to the “westernization” process (109). Almost every new compound 
introduced in the population during the last century has been proposed to play a role in the 
aetiology of IBD including toothpaste, chewing gum, fast food, margarine and cornflakes 
(110). The “hygiene hypothesis” of allergic and auto-immune diseases has also been invoked 
to explain the world-wide spread of IBD (109, 111). Another theory is pointing at the possible 
contribution of domestic refrigeration and subsequently increased exposure to psychotropic 
bacteria (“cold chain hypothesis”) (112). 
Nevertheless, numerous epidemiological studies made it clear that some environmental 
factors indeed contribute to the physiopathogenesis of CD. 
Smoking
As opposed to UC, where smoking seems to have a protective effect, several studies have 
identified cigarette smoking as a risk factor for CD (113-115). Smokers are more than twice 
as likely to develop CD. Even second-hand exposure to cigarette smoke increases the risk 
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(116). Furthermore, smoking also influences the course of the disease. Patients who smoke 
are more likely to have ileal involvement and develop more frequently fistulizing or stenosing 
disease (116, 117). Continued smoking also increases the risk of disease recurrence, the need 
for surgery and the requirement of immunosuppressive drugs, whereas cessation of smoking 
has a beneficial effect (118, 119). The underlying mechanism is unclear but smoking seems to 
influence both systemic and mucosal immunity, altering a wide range of innate and adaptive 
immune functions (120). 
Diet
Since dietary antigens are, in addition to bacterial antigens, the most common type of luminal 
antigen, numerous studies have searched for dietary factors influencing the pathogenesis of 
CD, particularly since elemental diets seem to have some beneficiary effect as primary or 
adjuvant therapy (121). Nevertheless, the studies conducted on dietary factors (including 
sugar and fat intake) could not reach consensus (122-125).  
Socio-economic status
High social, economical, educational and occupational status seems to increase the risk for 
developing CD (110). However, these findings might stand for differences in diet, crowding 
and hygiene (126).
Stress
Although most probably not an initiating factor, stress might modulate the course of disease. 
This belief was provided by clinical observations, animal models of colitis and neuro-immune 
interactions in laboratory animals (127). A complex interplay of nervous, endocrine and 
immune factors is likely to be implicated in the induction of exacerbations by stress (128). 
Appendectomy
Whereas appendectomy would protect against UC, it has been associated with a higher future 
risk for CD (129). Development of CD with a history of perforated appendicitis is 
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characterized by an even worse clinical outcome with increased risk for intestinal resections 
(130). The underlying mechanisms are not clear. 
Microbial factors
¾ Specific infectious agents
Numerous studies have been performed to identify a causative micro-organism for CD. 
Listeria monocytogenes, Chlamydia trachomatis, Escherichia coli, Cytomegalovirus, 
Saccharomyces cerevisiae, Mycobacterium paratuberculosis and (vaccination against) 
Paramixovirus (measles virus) have among others been proposed as potential etiologic agents 
(109, 131, 132). However, results were often conflicting and no convincing data are available 
until now.
¾ Intestinal commensal flora
During the last decade, a shift from infectious to commensal agents was noticed in the search 
for potential microbial triggers of IBD (133). The magnitude and complexity of the 
alimentary ecosystem is striking. It represents a living mass accounting for 1 to 2 kg of body 
weight, a cellular content that outnumbers 10-fold the number of eukaryotic cells of the host, 
a genetic microbiome exceeding the human genome with a 100-fold and an enormous 
metabolic activity (134, 135). There is now increasing evidence that the antigens that drive 
the tissue-damaging response in CD lie within this bacterial flora.
- The most convincing arguments arose from animal models of IBD. Intestinal inflammation 
fails to develop when animals are kept in germ-free conditions (128, 136-138). The presence 
of a normal flora is necessary. This was seen in different species (mouse, rat and guinea pig) 
and occurs in knockout or transgenic animals but also in induced models of IBD. Moreover, 
in some models, disease can be transferred with effector T cells against enteric bacteria (139, 
140).
- Loss of immune tolerance against enteric flora has also been reported in human studies 
(141). T cells isolated from the lamina propria of these patients responded in vitro to the 
antigens of their own flora. This is reflected by a serologic reactivity to enteric bacteria and 
(cross-)reactivity of serum antibodies (such as ASCA, ANCA, anti-I2, -OmpC and –flagellin 
antibodies) to enteric bacterial antigens (52, 57-59, 142, 143). 
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- IBD lesions predominate in the parts of the gastrointestinal tract where the intestinal 
microflora is most abundant (terminal ileum and colon) and differences have been found in 
the bacterial composition of the faecal microflora between CD patients and healthy subjects 
after ileocaecal resection (144, 145, 146). Furthermore, much larger numbers and 
concentrations of (adherent) bacteria have been found in the biofilms covering the epithelium 
of IBD patients compared to healthy subjects (146).  
- Diversion of the faecal stream from inflamed bowel loops induces improvement in CD 
whereas re-anastomosis results in relapse (147, 148). Moreover, direct infusion of luminal 
contents into excluded ileum also causes inflammation (149, 150).  
- Pouchitis, inflammation of a surgically constructed ileo-anal pouch, is associated with a 
dysbiosis caused by the contact of the once near sterile small bowel mucosa with a rich colon-
like flora repopulating the pouch soon after surgery (151). A beneficiary effect of antibiotics 
and probiotics has been demonstrated in the treatment of this pouchitis (152, 153). 
¾ Adherent-invasive Escherichia coli 
Escherichia coli strains with particular adhesion and invasion characteristics have been 
associated with CD (154, 155). These adherent-invasive E coli (AIEC) colonize 
predominantly the ileal mucosa of CD patients. They can be found in the ileum of 30% of 
patients with chronic lesions, in 34% of patients with early lesions (in the neoterminal ileum) 
and in 22% of CD patients with healthy mucosa (156). In contrast, in only 6% of healthy 
controls AIEC can be detected in ileal specimens.  
Adherence to the epithelium by AIEC strain LF82 is mediated by type 1 pili and this active 
phenomenon is a key step in the establishment of its invasive process (157). Indeed, AIEC 
strain LF82 is able to invade cells of different epithelial cell lines in vitro (158). After 
invasion, the bacteria can lyse the vacuole membrane and become free in the host cell 
cytoplasm. Moreover, they can survive and even replicate intracellularly in both epithelial 
cells and (murine and human) macrophages without inducing host cell death (158-160). 
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1.2.5. Genetic factors 
1.2.5.1.Genetic epidemiology 
Multiple lines of evidence derived from epidemiological data have suggested a genetic 
contribution to the pathogenesis of IBD, including racial and ethnic differences, familial 
aggregation and twin studies and association with other genetic disorders (161). 
¾ Incidences and prevalences of IBD vary significantly depending on geographic location 
and racial or ethnic background, although this may be mainly due to differences in 
environmental factors (162). Incidences increase in populations emigrating from low-risk 
geographic ares to those with higher risk (163, 164). A study from the United States reported 
higher prevalence rates for CD (per 100.000) in Caucasians (43.6) compared to African 
Americans (29.8), Hispanics (4.1) and Asians (5.6) (165). However, the incidence in African 
Americans increases and this might be consistent with changing environmental exposures 
(166). Nevertheless, ethnicity seems to play a role since Jews (particularly Ashkenazi Jews) in 
the United States have clearly the highest risk to develop CD (167, 168). 
¾ A large number of studies have reported clustering of IBD within families. Between 6 and 
32% of IBD patients have an affected first- or second- degree relative (161). Risk factors for 
familial aggregation include Jewish ancestry and early-onset disease (169, 170). About 75% 
of multiple affected families with IBD are concordant for disease type with the remaining 
25% being mixed (CD and UC in one family) (171). Relative risks for developing CD in case 
one has a family member with the disease vary significantly between studies. For siblings, the 
relative risk for CD has been estimated between 13 and 36 (172).  High concordance rates for 
pattern of disease (location, behaviour and occurrence of EIM) are found in affected pedigrees 
(173).
¾ Twin studies have provided the strongest evidence for a genetic susceptibility. The 
concordance rate for CD in monozygotic twins varies between 42 and 58%, whereas it is not 
significantly different in dizygotic twins from that for all siblings (174-177). The incomplete 
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penetrance in monozygotic twins is most probably due to non-genetic factors, such as 
environmental triggers. 
¾ Associations have been made between susceptibility to IBD and a number of genetically 
determined syndromes, such as ankylosing spondylitis, psoriasis and eczema (178-180). 
Furthermore, intestinal inflammation resembling IBD has also been reported in several other 
(rare) genetic syndromes (181-185). 
1.2.5.2. Genome-wide scans 
Significant progress was made during the last decade in the understanding of the genetic basis 
of CD. Genetic linkage studies used genome-wide scans to type genetic markers in families 
containing more than one affected member (186). Typically, about 400 microsatellites spaced 
evenly across a chromosome are genotyped. If the actual disease-susceptibility gene is located 
close enough to the marker, it will be co-inhereted. Subchromosomal regions where the 
degree of allele sharing between affected individuals exceeds the statistical expectation will 
then identify regions of interest, implying that a disease gene resides in that particular 
chromosomal region.  
Genome-wide scans have identified putative loci on almost every chromosome, reaffirming 
the concept that inflammatory bowel diseases are complex genetic disorders with several 
predisposing genes (figure 5) (161, 187). However, owing to this genetic heterogeneity, 
linkage results have often not been consistently replicated between studies. Looking at more 
homogeneous populations or subsets of the data (common ethnicity and/or geographic 
characteristics) is a way to reduce this heterogeneity. At least 9 susceptibility loci, designated 
IBD1-9, met the strict criteria for linkage and have been replicated in independent studies 
(188, 189).
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Fig 5. IBD linkage regions 
1.2.5.3.CARD15/NOD2
CARD15 polymorphisms in Crohn’s disease 
Narrowing down these susceptibility loci represents a major challenge and is complicated by 
clustering of multiple candidate genes within one locus. Genetic association studies are used 
to identify the specific disease genes. This candidate gene approach led in 2001 to the 
detection of the first CD susceptibility gene CARD15 or NOD2, within the IBD1 locus (190-
192). This gene on chromosome 16q encodes the intracellular PAMP-receptor 
NOD2/CARD15.
Three single nucleotide polymorphisms (SNPs) including 2 missense and 1 frameshift 
mutation have been independently associated with Crohn’s disease susceptibility:  Arg702Trp 
(R702W, SNP8), Gly908Arg (G908R, SNP12) and Leu1007finsC (1007fs, SNP13) (figure 6). 
These CARD15 gene variants have been found in 30 to 45% of CD patients compared to only 
8 to 16% in the healthy population (190, 192, 193). About 30% of CD patients carry one risk 
allele whereas 8 to 17% carry 2 copies (178). The relative risk of developing CD has been 
estimated as 3-fold in single heterozygotes whereas it increases to 40-fold in compound 
heterozygous and homozygous patients (187). 
Important ethnic differences have been noted. Compared to European, North American, 
Israeli and Australian cohorts, much lower prevalences of CARD15 polymorphisms have been 
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found in Finnish, Irish and Scottish CD populations (194-196). Even striking is the almost 
total absence of these variants in Japanese, Korean and Chinese populations (197-199). 
Fig 6: Structure of the CARD15 gene and location of the CD-associated polymorphisms 
Genotype-phenotype associations 
An extensive clinical heterogeneity is observed in CD, most likely representing a 
heterogeneous subset of disorders, with differing pathogenic mechanisms. Numerous 
genotype-phenotype association studies have been performed to link the presence of CARD15
polymorphisms with clinical disease characteristics (194, 200-210). 
Most of these studies have associated the presence of CARD15 polymorphisms with ileal 
involvement, younger age at onset and stricturing or fibrostenozing disease. It is however 
unclear whether the latter is not just related to the presence of ileal disease. Using multivariate 
analysis, an independent association with stricturing disease could not be confirmed (201, 
211). Associations with familial CD, fistulizing disease and a history of surgical resection, as 
reported in some of these studies, have not been consistently confirmed and it is again unclear 
whether the latter is simply explained by the association with ileal involvement. 
Functional studies 
The intracellular pattern recognition receptor CARD15 or NOD2 binds specifically MDP, the 
minimal naturally occurring motif of PGN (present in the cell wall of all bacteria). Binding of 
CARD15 with its ligand gives rise to activation of caspases (involved in apoptotic pathways) 
and NF-țB, a nuclear transcription factor inducing the transcription of pro-inflammatory 
genes and the subsequent production of several cytokines (212). The mechanism by which 
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MDP enters the cell is uncertain. Possibilities include invasion of pathogens, active 
endocytosis of bacteria or their components and a specialized transporter molecule. The 
protein hPepT1 has been proposed as a transporter molecule for MDP in enterocytes and 
recently its expression was also confirmed in mononuclear cells (213, 214).  
¾ Several in vitro studies have been performed to identify the functional role of the CARD15
polymorphisms. No NF-țB activation could be measured in HEK293T cells transfected with 
the frameshift mutation 1007fs after stimulation with MDP or PGN (91, 92, 215). R702W and 
G908R transfectants also showed a decreased NF-țB activation compared to NOD2 wild-type 
cells but less pronounced than the 1007fs variant (92, 215).
¾ Functional studies have also been performed on isolated mononuclear cells from (mostly 
limited numbers) of CD patients (92, 216, 217). These ex vivo studies confirmed the reduced 
NF-țB activation in response to MDP associated with CARD15 polymorphisms. A decreased 
production of pro-inflammatory cytokines (IL-8 and IL-1ȕ) was demonstrated as well. 
Interestingly, a study from Netea et al also showed a reduced production of anti-inflammatory 
cytokines like IL-10 and transforming growth factor (TGF)-ȕ whereas TNFĮ secretion was 
similar in cells from patients with CARD15 variants stimulated with PGN or heat-killed 
Bacteroides or Salmonella species (218). This actually results in a reduced and thus pro-
inflammatory IL-10/TNFĮ ratio. All the effects in these studies were however only detected in 
patients carrying 2 copies of the mutant alleles (compound heterozygotes or homozygotes) 
with the most pronounced effect in 1007fs homozygotes. Until now no real functional deficits 
could be detected in cells from (the more common) patients being single heterozygous for 
CARD15 variants. 
¾ Two recent studies also described a loss of NOD2/TLR synergy in CD patients carrying 
CARD15 variants (217, 219).  Peripheral blood mononuclear cells from CD patients carrying 
CARD15 polymorphisms respond normally to TLR ligands. However, when co-stimulation 
with MDP is performed, the synergistic effect between MDP and TLR1/2, TLR4, TLR5, 
TLR2/6, TLR7/8 and TLR9 ligands is profoundly impaired.  
¾ Common structural and functional features between human and mouse NOD2 have been 
identified (220). This finding opened the door to the use of animal models, in particular 
CARD15- or NOD2- deficient (CARD
-/-
 or NOD
-/-
) mice, to evaluate the role of NOD2 in 
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chronic inflammatory disorders. Interestingly, NOD2
-/- 
mice are indistinguishable from 
controls and do not develop spontaneous intestinal inflammation (221). Results from animal 
studies are however not consistent. 
 A study of Kobayashi et al reported a strongly reduced NF-țB activation in 
macrophages from NOD2
-/-
mice stimulated with MDP (221). The synergistic effect of 
TLR2 ligand and MDP costimulation was abrogated. These animals were also more 
susceptible to bacterial infection (with Listeria monocytogenes) via the oral route but not 
through intravenous or peritoneal delivery. This may be due in part to the deficient 
production of certain antimicrobial peptides, called cryptdins (the homologue of human 
Į-defensins), in these mice. In vitro infection of NOD-/- macrophages did not result in an 
altered intracellular bacterial growth or killing.
 Pauleau et al showed that NOD2-/- macrophages were indeed refractory to MDP 
stimulation but responded normally to multiple TLR agonists (222). However, these 
mice were protected in intraperitoneal endotoxin challenge assays.
 Watanabe et al reported an increased TLR2-mediated NF-țB activation and IL-12 
production (Th1 response) in splenocytes from NOD2
-/-
mice compared to wild-type 
mice (223). Similar results were obtained in isolated macrophages from NOD2
-/-
mice 
repleted with the mouse construct L908fs, corresponding to the human 1007fs CARD15
mutation. These findings suggest a NOD2-mediated inhibition of TLR2-driven response 
in normal circumstances and an abrogation of this inhibition in the presence of CARD15
polymorphisms, which is in contrast with all studies on NOD2/TLR synergy previously 
reported.
 Macrophages from NOD22939iC mice, another construct corresponding to the human 
1007fs mutation, even exhibited elevated NF-țB activation and increased IL-1ȕ
secretion in response to MDP (224). TLR2-driven responses were normal. Furthermore, 
mortality of these mice was higher in a dextran sodium sulphate (DSS) colitis model 
compared to wild-type mice. This difference in mortality was restored with oral 
antibiotic treatment, reflecting the role of enteric bacteria. 
The “NF-țB paradox” 
NF-țB is a key intracellular signalling molecule in a variety of inflammatory pathways and 
has been shown to be elevated in IBD tissues (225). However, most of the functional studies 
on the role CARD15 polymorphisms point at a decreased NF-țB activation. How these 
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conflicting results can be explained is not yet understood. Nevertheless, certain observations 
can be used to formulate some hypotheses. 
Expression of CARD15 has been demonstrated in mononuclear cells but also in intestinal 
epithelial cells and particularly in Paneth cells and is upregulated in active Crohn’s disease 
(226-228). Paneth cells are specialized intestinal epithelial cells in the base of the crypts of 
Lieberkühn in the ileum. Although they are generally absent in the colon and rectum, some 
metaplastic Paneth cells can be found in IBD (226, 229). They are critically involved in host 
defence against enteric infection and respond to bacterial products by secreting antimicrobial 
peptides including lysozyme, secretory phospholipase A2 (sPLA2) and Į- and ȕ-defensins 
(230, 231). Cytologic study has localized NOD2 in the cytosol in close proximity to the 
granules containing antimicrobial peptides (227). Recently, it was demonstrated that the 
presence of CARD15 mutations in CD patients is associated with a diminished mucosal 
expression of Į-defensins and this might induce a loss of control over bacterial growth (early 
immune pathogen clearance) at the epithelial surface (232). In combination with an increased 
intestinal permeability as reported in IBD patients, it may lead to an enhanced influx of 
bacteria into the mucosa and subsequently to the activation of CARD15-independent 
inflammatory pathways (233-235). Consistent with these findings, mice deficient in TLR 
signalling, resulting in decreased NF-țB activation, exhibit an increased susceptibility to 
pathogen invasion and NF-țB knock-out mice seem to develop colitis (236, 237). Moreover, 
defective eradication of intracellular pathogens (Salmonella typhimurium) has been 
demonstrated in CARD15-negative epithelial cell lines transfected with the CD-associated 
frameshift mutation (238). An altered sensing and handling of intracellular bacteria might lead 
to a prolonged bacterial survival and/or intracellular persistence of antigens, serving as a 
chronic stimulus for other immune cells. 
An alternative hypothesis was postulated by the group of Strober and colleagues (104, 223). 
They showed in mouse splenocytes that stimulation of NOD2 with MDP downregulates the 
production of IL-12, IL-18 and IFNȖ in response to TLR2 ligands in wild-type cells but not in 
CARD15
-/-
cells. The absence of a negative regulation of this TLR2 response (towards PGN) 
by MDP-NOD2 signalling in CARD15
-/- 
mice, could indicate that the “immunostat” for innate 
immune responses to PGN in these mice is set to a lower level, resulting in an excessive Th1 
response with higher basal levels of IL-12 (and other Th1 mediators). However, this 
hypothesis still needs to be proven in humans. Moreover, the results of the Strober group are 
in contradiction with findings of other groups, demonstrating NOD2-TLR synergy and the 
loss of it in the presence of CARD15 polymorphisms (217, 219, 221). 
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1.2.5.4.TLR4
A polymorphism in another PAMP receptor gene, TLR4, has been associated with CD and UC 
(239). The prevalences of the Asp299Gly variant in the separate CD and UC populations were 
about 20% compared to less than 10% in the control population. Carriage of both CARD15
and TLR4 polymorphisms would imply a higher relative risk to develop CD compared with 
CARD15 or TLR4 variants alone. 
Studies on transfected cell lines and isolated mononuclear cells associated homozygous 
carriage of this variant with hyporesponsiveness to the TLR4 ligand LPS (240-243). 
However, Asp299Gly homozygotes are rare and until now no functional defects could be 
linked with heterozygous carriage.
The association of this TLR4 variant with CD and UC were however not fully confirmed by 
other groups. Török et al found a higher prevalence of this polymorphism in German UC 
patients but not in CD whether a recent Greek study demonstrated the opposite (244-246). In 
a Scottish CD population no associations could be found (247).
Genetic heterogeneity may be an explanation for the lack of confirmation of these 
associations (247). However, it is also noteworthy that the associations found between TLR4
and CD and UC result from a primary candidate gene approach. The gene encoding TLR4 is 
located on chromosome 9q where no susceptibility loci have been described. A case-control 
association design in which the allele frequencies of candidate genes are compared in patients 
and matched healthy controls has been subject to considerable criticism because of a lack of 
reproducibility (248-250). This is reflected by a meta-analysis of 370 studies addressing 36 
genetic associations with a number of diseases (251).  
1.2.5.5.Other genetic associations 
Numerous and often non-confirmed genetic associations with CD have been reported during 
the last years. There is however a growing interest in SLC22A4/5 and DLG5, since they have 
been identified as possible susceptibility genes by fine mapping of previously described IBD-
loci.
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The SLC22A4 and SLC22A5 genes are located within the IBD5 locus (on chromosome 5q31) 
and respectively encode the organic cation transporters OCTN1 and OCTN2 (229). These 
membrane proteins are widely expressed and mediate multispecific and bidirectional 
transmembrane transport of carnitine and organic cations. Variants in these genes would 
increase the risk for CD by 2.5-fold when present as a single copy and by 4-fold when present 
as 2 copies (252-254). The relevant susceptibility alleles may however differ among ethnic 
groups (253, 255-257). Several hypotheses on the functional role of these variants are 
currently under investigation. Impaired carnitine transport could inhibit fatty acid oxidation 
which could lead to intestinal inflammation whereas on the other hand, enhanced cation 
transporter activity may engender an aberrant uptake of toxic substrates (188, 258, 259). 
Limited genotype-phenotype studies have been performed and showed associations with ileal 
and perianal disease (253, 260). 
The DLG5 (Drosophila Discs Large Homolog 5) gene is located within an IBD-linked locus 
on chromosome 10q (261). Dlg5 has a putative role as scaffolding protein involved in 
maintenance of epithelial cell structure and regulation of cell growth (262). Associations of 
DLG5 variants with IBD have been reported although not yet replicated (254, 261, 263). 
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2. The Spondyloarthropathy concept 
2.1. Clinical features 
Spondyloarthropathies constitute a cluster of interrelated and overlapping chronic 
inflammatory rheumatic diseases characterized by pauciarticular, peripheral, asymmetrical 
arthritis and/or axial involvement with ankylosing spondylitis as prototype (table 3) (264). A 
clear differentiation among these forms is not always possible. The European 
Spondyloarthropathy Study Group (ESSG) classification criterion has been validated in 
various groups and is currently most widely used to diagnose SpA (265-267).
Table 3. Clinical entities belonging to the Spondyloarthropathy concept 
Ankylosing spondylitis 
Reactive arthritis 
Psoriatic arthritis 
IBD-associated arthritis 
Juvenile spondyloarthropathy 
Undifferentiated spondyloarthropathy 
Prevalences of SpA between 0.2 and 1.9% have been reported (268, 269). Ethnic differences 
are important, since Eskimo and Inuit persons have a much higher prevalence whereas SpA is 
relatively uncommon in the Japanese population (270, 271). Although both sexes can be 
affected, there is overall a male preponderance. Onset of disease is mostly seen in the late 
teens and the early 20s and familial aggregation may occur (272).  
The primary pathologic sites include the entheses, which are the sites of bony insertion of 
ligaments and tendon (particularly the plantar fascia, Achilles and patellar tendon), the 
sacroiliac joints and axial skeleton, the limb joints and some non-articular structures such as 
the gut, the skin, the eye or aortic valve (figure 7) (272).
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Figure 7. Some clinical manifestations of SpA 
Ankylosing spondylitis is the most common and most typical form of SpA. The diagnosis is 
based on the modified New York criteria for AS, combining (unspecific) clinical criteria with 
radiologic evidence of sacroiliitis (SI) (table 4) (18). SI is still considered to be the 
radiographic hallmark of AS.  
Table 4. Modified New York criteria for the diagnosis of AS 
1. Low back pain of at least 3 month’s duration, improving by exercise and not relieved by rest 
2. Limited lumbar spinal motion in sagittal and frontal (Schober index) planes 
3. Chest expansion decreased relative to normal values for sex and age 
4. Bilateral sacroiliitis grade 2-4 or unilateral sacroiliitis grade 3 or 4 * 
The diagnosis of AS is made whenever criterion 4 with any of the other criteria is fulfilled. 
* Grades are 0 - normal; 1 - suspicious; 2 - localized sclerosis, erosion, joint widening; 3 - 
diffuse sclerosis, erosion, widening; 4 - ankylosis 
Reactive arthritis (ReA) is diagnosed when an episode of aseptic peripheral arthritis occurs, 
preceded within 1 month by a genitourinary infection with Chlamydia trachomatis or an 
enteritis with gram-negative enterobacteria (such as Shigella, Salmonella, Yersinia or 
Campylobacter) (273). It is typically an acute, asymmetric and oligoarticular arthritis, 
associated with one or several characteristic extraarticular features, such as ocular 
inflammation (conjunctivitis or acute iritis), enthesitis, mucocutaneous lesions or rarely 
carditis. The rare triad of arthritis, conjunctivitis and urethritis is called Reiter syndrome 
(274).
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Psoriatic arthritis (PsA) is defined by the presence of inflammatory arthritis associated with 
psoriasis, although no internationally agreed-on criteria for this diagnosis are available (275). 
Oligoarticular and polyarticular forms of PsA can be distinguished. PsA has been reported in 
up to one third of patients with psoriasis.
Arthritis associated with IBD, also called enteric arthritis, has been discussed previously. 
Some patients fulfil the ESSG criteria but can not be classified into one of the clear SpA 
subentities. This subgroup is categorized as undifferentiated SpA (276).
2.2. Genetic susceptibility 
There is an undisputed influence of HLA-B27 carriership on the development of SpA (277). 
About 90% of AS patients are HLA-B27 positive whereas the prevalence of HLA-B27 varies 
between 25 and 80% in the other subgroups of SpA patients (15, 272). In contrast, only 8% of 
healthy Caucasian persons carry this genetic marker (278). The exact functional role of HLA-
B27 in the pathogenesis of SpA is however not yet understood. Altered cytokine production 
from monocytes and T cells associated with HLA-B27 positivity has been reported (279). The 
latest data suggest that misfolding of the HLA-B27 heavy chain and dimerization (through 
disulfide linkage) at the cell surface might somehow affect cell function (280).  
However, family and twin studies suggested that also other genes might play a role in the 
genetic predisposition for SpA, determining it as a complex genetic disorder (281, 282). This 
was confirmed by genome-wide scans (282-284). Next to the major histocompatibility 
complex (MHC) locus, these genome-wide studies also provided evidence for non-MHC 
susceptibility loci. Laval et al identified linkage regions in families with AS on chromosomes 
1q, 2q, 6p, 9q, 10q, 16q and 19q (283). Recently, the non-MHC susceptibility locus on 
chromosome 9q was confirmed in SpA patients (284).  
Since one of the linkage regions was located on chromosome 16q, the CD-associated 
CARD15 gene was investigated as putative susceptibility gene. No associations with CARD15
polymorphisms were found in SpA and AS populations (285-290). One study reported an 
association with PsA but this could not be confirmed by other groups (291-293). 
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3. The Gut-Joint axis in IBD and SpA 
Similar to IBD, SpA are currently considered as multifactorial diseases occurring in 
genetically predisposed persons and triggered by environmental factors. Different 
combinations of genes and environmental factors may predispose to variation in disease 
expression (294).
The association of ReA with enteric infections initiated the search for an infectious aetiology 
of SpA. Bacterial antigenic components and DNA have been found in synovial fluid of 
patients with ReA, but also in other SpA subgroups (295-299). However, although carriage of 
Klebsiella pneumoniae in the gut was proposed as a trigger for AS, no definite evidence exists 
for an infectious trigger for AS or SpA (300). 
Nevertheless, several lines of evidence point at a close relationship between gut and joint and 
more specifically between SpA and CD (301).
3.1. Clinical evidence 
As already stated, rheumatic manifestations in IBD are frequent and can often be classified as 
SpA. On the other hand, colonoscopies with ileal and colonic biopsies, performed in SpA 
patients, have demonstrated that up to 60% of these patients had histological signs of 
(subclinical) acute or chronic gut inflammation (302-304). Acute inflammatory lesions were 
similar to those seen in acute self-limiting bacterial enterocolitis whereas the features of 
chronic lesions resembled mucosal alterations found in CD (305). The presence of gut 
inflammation was most frequently seen in AS patients and represented a risk factor for non-
AS SpA patients to develop AS (306, 307). Furthermore, gut inflammation was also 
associated with active rheumatic disease (308).  There was no influence of NSAID intake on 
the occurrence of these lesions (302). 
The high prevalence of intestinal inflammation in SpA was confirmed by several other groups 
(309-313). Interestingly, about 13% of SpA patients having chronic gut lesions (representing 
about half of the patients with intestinal inflammation) will evolve over time towards a 
clinically overt Crohn’s disease (314). 
42 | CHAPTER 1  
Also animal models have provided evidence for the simultaneous occurrence of gut and joint 
inflammation. Both HLA-B27-transgenic rats and TNF
ǻARE
 mice spontaneously develop 
Crohn’s-like gut inflammation and chronic inflammatory arthritis (315, 316). 
3.2. Therapeutic evidence 
Sulfasalazine has a beneficial effect in both CD and peripheral manifestations of SpA but 
more important was the development of anti-TNFĮ monoclonal antibodies. 
The introduction of these antibodies in CD meant an enormous breakthrough in the 
management of both intestinal and articular symptoms. Later on, a similar effect was 
demonstrated in SpA with a rapid and dramatic improvement of arthritis, enthesitis and axial 
symptoms (317, 318). Whether this drug also has a disease-modifying effect in CD or SpA 
needs to be proven. 
3.3. Immunological evidence 
Both types of tissue inflammation (gut and joint) in SpA and CD are characterized by 
increased numbers of T cells and macrophages and a greater expression of pro-inflammatory 
cytokines (like IL-1ȕ, TNFĮ and IFNȖ) at the site of inflammation (102, 319). 
In the intestine of both CD and SpA patients, an enrichment of gut-mucosal T cell lines with 
ĮEȕ7-integrins and an increased expression of its ligand, E-cadherin, were observed (320-
322). An altered expression of ȕ7-integrins was also found on synovial T cells from patients 
with SpA but not with rheumatoid arthritis (RA) (323). This might reflect a recirculation 
between the gut and the joint of T cells, primed in the gut. 
In CD and SpA patients, an augmented infiltration of CD163 positive macrophages 
(producing IL-1ȕ and TNFĮ) has been found in both the gut and synovium (324, 325). This 
finding could reflect a trafficking of antigen presenting cells between the gut and the joint 
(326).
These findings led to the concept that the group of SpA patients with gut inflammation could 
be considered as a model for early immune alterations in CD.
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3.4. Serological evidence 
Antibodies, directed against the cell wall mannan of Saccharomyces cerevisiae, also called 
ASCA, are known to be specific serological markers for CD. Significant higher levels of 
ASCA IgA were also found in SpA patients, particularly in AS patients, compared to healthy 
controls or RA patients (30, 31). 
3.5. Genetic evidence 
A study in 1
st
 degree relatives of AS patients provided evidence for a common, not HLA-B27 
related (and yet unknown) genetic risk factor for the development of subclinical intestinal 
inflammation (327). Moreover, there was a close relationship between the presence of this 
subclinical intestinal inflammation (assessed by measuring fecal calprotectin concentrations) 
and sacroiliac changes, suggestive of early AS.
Overall, there is clear evidence for the close relationship between Crohn’s disease and SpA. 
However, the etiopathogenic mechanisms underlying this link are still unknown and studies 
are needed to elucidate the common genetic and/or environmental triggers, predisposing for 
both disease entities.
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4. Research objectives 
The objective of this work was to investigate the role of genetic alterations in the gut-joint 
axis of CD and SpA. 
4.1. The role of CD associated CARD15 polymorphisms in the relationship 
between gut and joint. 
4.1.1. CARD15 polymorphisms in SpA 
The CD-associated CARD15 gene is located on chromosome 16q which was also found to 
have a linked region in a genome-wide scan of AS patients. 
We wanted to investigate the possible role of CARD15 polymorphisms in SpA patients and in 
particular in SpA patients with chronic gut inflammation, since exactly these patients are at 
risk to develop clinical CD. A genetic association study was conducted in a population of SpA 
patients who underwent an ileocolonoscopy with biopsies between 1983 and 2004. 
4.1.2. Relation between genetic markers and rheumatic phenotypes in patients with CD 
4.1.2.1.CARD15 polymorphisms and rheumatic manifestations in CD 
Despite the numerous genotype-phenotype studies on the role of CARD15 polymorphisms in 
CD, no clear data were available concerning the association with the distinct rheumatic 
manifestations of CD. In a cohort of CD patients, we investigated the relation of these 
polymorphisms with the history or presence of peripheral arthritis, enthesopathies and 
sacroiliitis (with or without AS).
4.1.2.2. Axial involvement in CD: a clinical and genetic association study 
Overall, data on the association of axial disease in CD (including asymptomatic sacroiliitis 
and AS) with other clinical phenotypes and genotypes (except for HLA-B27) are scarce. 
Therefore, we initiated a multicentre study, in cooperation with Leuven and Liège, to 
investigate the association of radiological sacroiliitis and AS in CD with the most common 
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clinical phenotypes of the disease, including other extraintestinal manifestations, and 
CARD15 polymorphisms. 
4.1.3. Influence of CARD15 polymorphisms on cellular and humoral response 
4.1.3.1. The functional impact of CARD15 polymorphisms on peripheral blood monocytes 
in CD 
CARD15 and TLR4 polymorphisms have been linked with an altered innate immune response 
to bacterial components but the exact functional roles (in particular in single heterozygotes) 
are actually unknown. Therefore we investigated the functional role of these genetic variants 
on isolated blood monocytes, stimulated with MDP or LPS or infected with AIEC, an 
enteroinvasive E coli strain specifically associated with CD. Since one of the hypotheses of 
simultaneous gut and joint inflammation includes circulation of microbial antigens between 
both sites, we also looked at intracellular survival and replication of these bacterial strains 
within these monocytes.
4.1.3.2. CARD15 polymorphisms and ASCA formation 
ASCA can be found in both CD and SpA and a genetic influence on the generation of these 
antibodies has been suggested. Since CARD15 polymorphisms and ASCA share associations 
with similar clinical phenotypes (ileal and structuring disease and early age at onset), we 
wanted to investigate the direct link between these polymorphisms and this aberrant 
serological response (ASCA formation) in CD patients. 
4.2. The search for new molecular targets in CD and SpA 
4.2.1. Genetic expression assays on colonic biopsies of CD and SpA patients 
Important immunological similarities have already been found in the gut of both CD and SpA 
patients. We performed macro- and microarrays on non-inflamed colonic biopsies of healthy 
controls, CD patients and SpA patients (with or without subclinical gut inflammation) to 
investigate whether similarities could also be found at the transcriptome level.  
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4.2.2. Identification of new candidate genes for CD by linking gene expression variation 
with known susceptibility genes 
Differentially expressed genes, revealed by transcriptome analysis of colonic biopsies, were 
linked with known disease susceptibility loci for CD in order to identify new putative disease-
modifying genes. We wanted to confirm the altered expression of potentially interesting 
candidate genes at both the RNA and protein level and investigated the functional 
significance. Mutation screening was performed to search for significant polymorphisms 
within the involved genes. 
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Background: The association between spondyloarthropathy and Crohn’s disease is well known. A risk for
evolution to Crohn’s disease has already been shown in the subgroup of patients with spondyloarthro-
pathy associated with chronic gut inflammation.
Objective: To investigate whether the reported polymorphisms in the CARD15 gene, a susceptibility gene
for Crohn’s disease, are associated with the presence of preclinical intestinal inflammation observed in
spondyloarthropathies.
Methods: 104 patients with spondyloarthropathies were studied. All underwent ileocolonoscopy with
biopsies between 1983 and 2004. The prevalence of three single nucleotide polymorphisms in the
CARD15 gene (R702W, G908R, and 1007fs) was assessed using restriction fragment length
polymorphism–polymerase chain reaction (RFLP-PCR); the patients were compared with an ethnically
matched Crohn’s disease population and a control population.
Results: The carrier frequency of R702W, G908R, or 1007fs variants in the spondyloarthropathy
populations (20%) was similar to the control population (17%), but increased to 38% in the
spondyloarthropathy subgroup with chronic gut inflammation. This frequency was significantly higher
than in the other spondyloarthropathy subgroups (p = 0.001) or the control group (p = 0.006), but not
different from the Crohn’s disease group (49%) (NS). This indicates that CARD15 polymorphisms are
associated with a higher risk for development of chronic gut inflammation.
Conclusions: CARD15 gene polymorphisms clearly identify a subgroup of patients with spondyloar-
thropathies associated with chronic intestinal inflammation.
T
he spondyloarthropathies are a group of interrelated
inflammatory diseases characterised by a pauciarticular,
peripheral, asymmetrical arthritis with or without axial
involvement, with ankylosing spondylitis as the prototype.1
Reported prevalences of spondyloarthropathy vary between
0.2% and 1.9%.2 3 Although an association with HLA-B27 is
strong, recent genetic studies suggest a polygenic model of
susceptibility.4–7
In up to 60% of spondyloarthropathy patients, articular
involvement is associated with subclinical histological evi-
dence of chronic or acute gut inflammation in the ileum or
colon.8–10 We described a long term evolution to overt Crohn’s
disease in 13% of patients with initial chronic gut inflamma-
tion.11 12 The presence of chronic intestinal inflammation was
not related to HLA-B27, but a weak association with HLA-
B62 was found.11
The observed immunological similarities between spondy-
loarthropathy with gut inflammation and Crohn’s disease
support the concept that this subgroup of spondyloarthro-
pathy patients can be considered a model for early immune
alterations related to Crohn’s disease. An enrichment of gut
mucosal T cell lines with aEb7 integrin and an increased
expression of its ligand, E-cadherin, is found in the intestine
in Crohn’s disease as well as in spondyloarthropathy
patients.13–15 Recirculation of gut primed T cells to synovial
tissue is one potential mechanism whereby gut and synovial
inflammation could be linked. This hypothesis is supported
by an altered expression of b7 integrins, which are highly
expressed within the gut, on synovial T cells from patients
with spondyloarthropathies compared with rheumatoid
arthritis.16 Another potential mechanism includes trafficking
of antigen presenting cells between gut and joints. Consistent
with this was the augmented infiltration of gut mucosa and
synovium with CD163 positive macrophages (producing
interleukin 1 (IL1) and tumour necrosis factor a (TNFa) in
both Crohn’s disease and spondyloarthropathy.17 18 Finally, a
comparable beneficial clinical effect of infliximab, a mono-
clonal antibody to TNFa, suggests a key role for this cytokine
in both diseases.19 20
In 2001, a correlation was reported between polymorph-
isms in the CARD15 gene and an increased susceptibility to
Crohn’s disease.21–23 Three independent single nucleotide
polymorphisms (SNPs) in CARD15 are associated with
Crohn’s disease in around 30–46% of patients (one frame
shift mutation (1007fs (SNP13)) and two missense muta-
tions (R702W (SNP8) and G908R (SNP12)).22 24 These
variants increase the risk for Crohn’s disease by a factor of
3 for heterozygotes and by a factor of 38 or 44 for,
respectively, homozygous or compound heterozygous indivi-
duals.22 Lower prevalences have been described in Crohn’s
disease patients in Scotland, Ireland, and northern Europe,
whereas no association could be found in Japan.25–28
The CARD15 gene encodes for an intracellular protein,
which is expressed in monocytes, granulocytes, and dendri-
tic, epithelial, and Paneth cells, and has binding affinity for
Abbreviations: CARD, caspase recruitment domain; ESSG, European
Spondylarthropathy Study Group; SNP, single nucleotide polymorphism
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bacterial cell wall components such as muramyldipeptides.29
The CARD15 protein is involved in NFkB activation and in
apoptosis by two N-terminal caspase recruitment domains
(hence the term CARD), although its precise pathogenic role
in Crohn’s disease remains to be determined.29–31
CARD15 gene polymorphisms have also been linked to
another related disorder, Blau’s syndrome, characterised by
granulomatous inflammation of the uvea, skin, and joints.32
Several studies have been carried out to investigate the role
of CARD15 polymorphisms in spondyloarthropathies. These
studies did not show an association with spondyloarthropa-
thies or ankylosing spondylitis in particular.33–37 An increased
prevalence of CARD15 polymorphisms was found in psoriatic
arthritis though not in psoriatic skin disease.38–40 However, a
recent Italian study could not confirm this association.41
Nevertheless, this finding could emphasise the importance
of investigating the possible role of these genetic variants in
specific clinical subpopulations of patients. In Crohn’s
disease, CARD15 polymorphisms also seem to be related to
certain clinical phenotypes.42–46
In view of the apparent correlation between gut inflamma-
tion in spondyloarthropathies and their clinical evolution to
Crohn’s disease, we investigated whether the presence of
polymorphisms in this susceptibility gene for Crohn’s disease
is associated with gut inflammation in spondyloarthropathy.
METHODS
Study population
This study included 104 white patients with spondyloarthro-
pathies (according to the ESSG criteria47), who underwent an
ileocolonoscopy with concomitant ileal and colonic biopsies
between 1983 and 2004. This population consisted of 74 male
and 30 female patients with a mean age of 46 years (range 21
to 77). Spondyloarthropathy patients were systematically
referred by the rheumatologist for an ileocolonoscopy with
biopsies, independent of the presence of gastrointestinal
symptoms.
Patients with a diagnosis of clinical Crohn’s disease or
psoriasis before the diagnosis of spondyloarthropathy were
excluded from the study.
A subgroup of 54 patients with long term follow up since
the time of their diagnosis of spondyloarthropathy (ranging
from 17 to 49 years) was recently clinically reassessed. New
follow up colonoscopies were not carried out.
The total spondyloarthropathy population consisted of 75
patients with ankylosing spondylitis according to the
modified New York criteria48 and 29 with an undifferentiated
form of spondyloarthropathy. Eighteen patients with anky-
losing spondylitis had only axial involvement, while 57 also
had peripheral disease (defined as the history or presence of
peripheral arthritis, enthesitis, or both). Twenty five patients
with undifferentiated spondyloarthropathy had peripheral
disease and four only had axial involvement. These four
patients had inflammatory low back pain and fulfilled the
ESSG criteria but not the modified New York criteria for
ankylosing spondylitis.
HLA-B27 status was known in 81 patients. In 53 patients
both HLA-B27 and HLA-B62 status was known.
A population of 156 consecutive patients with Crohn’s
disease proven on clinical, endoscopic, and histological
grounds was also included. This cohort included 57 male
and 99 female patients with a mean age of 38 years (range 18
to 80). Prevalences were also compared with those in a
control population of 140 individuals.
The study was approved by the local ethics committee. All
patients signed their informed consent.
Histological classification
A classification of histological lesions was used as reported in
previous studies.8 11 12 49 50 Three subgroups were distin-
guished: patients with normal gut histology, and those with
acute and chronic inflammation.51
In acute inflammatory lesions normal architecture was
well preserved. A mucosal and epithelial infiltrate of
neutrophils and eosinophils was present, without a signifi-
cant increase in lymphocytes. Small superficial ulcers covered
with fibrin and neutrophils overlying hyperplastic lymphoid
follicles were occasionally observed. The lamina propria
was oedematous and haemorrhagic and contained mainly
polymorphonuclear cells. The pattern of inflammation
was similar to that seen in acute self limiting bacterial
enterocolitis.
The principal features of chronic inflammatory lesions
were mucosal architectural alterations with crypt distortion
and atrophy in the colon, and villous blunting and fusion in
ileal mucosa. In both ileum and colon there was an increased
mixed cellularity and formation of basal lymphoid aggregates
in the lamina propria. Whenever one of several biopsies
featured chronic lesions, regardless of acute or active
inflammation in other fragments, a diagnosis of chronic
inflammation was made.
Although non-steroidal anti-inflammatory drugs may
induce intestinal disorders, we and others excluded these
drugs as factors in the aetiology of reported chronic
inflammation.8 10 52
CARD15 genotyping (R702W, G908R, and 1007fs),
and HLA-B27 and HLA-B62 typing
Genomic DNA was extracted from whole blood using the
Qiagen blood and cell culture DNA kit (Westburg BV,
Leusden, Netherlands). All patients were genotyped for
R702W, G908R, and 1007fs using restriction fragment length
polymorphism–polymerase chain reaction (RFLP-PCR), fol-
lowed by separation of the DNA fragments on a 2.5% agarose
gel. The missense mutation R702W (GenBank accession
number G67950) abolishes the restriction site for MspI,
resulting in an intact 130 base pair (bp) band for mutant
alleles compared with two bands of 54 and 76 bp for wild
type alleles (forward primer: 59-CAGCCCTGATGACATTT
CTCTT-39; reverse primer: 59-AGCCGCTCCTCCTGCATCTCG
TA-39). The missense mutation G908R (GenBank accession
number G67951) creates a restriction site for HinP1l. The
frameshift mutation 1007fs (GenBank accession number
G67955) creates a restriction site for NlaIV. The presence of a
mutant allele results in two bands of 219 and 41 bp, while the
wild type allele produces a single 260 bp product (forward
Table 1 Prevalence of CARD15 variants in the
populations according to subtypes defined at baseline
n
Carriers of
CARD15
variant(s)
Classification
Controls 140 24 (17%)
Crohn’s disease 156 77 (49%)*
Spondyloarthropathy 104 21 (20%)
Ankylosing spondylitis 75 16 (21%)
Undifferentiated spondyloarthropathies 29 5 (17%)
Gut histology in the spondyloarthropathy population
Chronic inflammation 40 (38%) 15 (38%)`
Acute inflammation 24 (23%) 0 (0%)
Normal histology 40 (38%) 6 (15%)
*x2: p,0.001 (carrier frequency in Crohn’s disease v control population).
x2: p = 0.5 (carrier frequency in general spondyloarthropathies v control
population).
`x2: p = 0.001 (chronic inflammation in patients with CARD15 variant v
chronic inflammation in patients without CARD15 polymorphism).
CARD15 gene polymorphisms in spondyloarthropathy 931
CHAPTER 272 |
primer: 59-CTGAGCCTTTGTTGATGAGC-39; reverse primer:
59-TCTTCCAACCACATCCCCATT-39).
In the patients with known HLA-B27 and HLA-B62 status,
typing of these markers was done using the microlympho-
cytotoxity test, according to Terasaki and McClelland.53
Statistical analysis
Statistical significance was determined by the x2 test and
odds ratios using SPSS (SPSS Inc, Chicago, Illinois, USA).
Multivariate analysis (logistic regression) was carried out to
investigate whether an association found in univariate
analysis was independent of other genetic markers.
Probability (p) values of less than 0.05 were considered
significant.
RESULTS
We subdivided our cohort into three groups according to gut
histology. Forty patients (38%) had normal histology, 24
(23%) had acute gut inflammation, and 40 (38%) had chronic
gut inflammation (table 1).
Univariate analysis
Prevalence of CARD15 polymorphisms in the various
populations
The prevalences of CARD15 polymorphisms in the total
spondyloarthropathy (20%), specific ankylosing spondylitis
(21%), and undifferentiated spondyloarthropathy (17%)
populations did not differ significantly (table 1). All except
one (homozygous for the 1007fs allelic variant) were
heterozygous for at least one mutation. The prevalences of
R702W, G908R, and 1007fs allelic variants in these spondy-
loarthropathy populations were 12%, 4%, and 5% respectively
(table 2). No compound heterozygosity was found. All
carriers of CARD15 polymorphisms in the spondyloarthro-
pathy group had (a history of) peripheral disease (table 3).
There were no significant differences in disease duration or
the duration of the follow up period between the spondyloar-
thropathy patients carrying CARD15 polymorphisms and the
patients without these polymorphisms (data not shown).
In the Crohn’s disease population, a carrier frequency of
49% (77 of 156 patients) was observed (table 1). Forty three
Crohn’s disease patients carried at least one R702W
polymorphism, 14 carried at least one G908R polymorphism,
and 27 carried at least one 1007fs polymorphism. Fourteen
patients carried two polymorphisms, of which seven were
homozygous and seven were compound heterozygous
(table 2).
In the control group, 24 individuals (17%) carried CARD15
polymorphisms (table 1). All except one (compound hetero-
zygous for the R702W and 1007fs variant) were single
heterozygotes (table 2).
The prevalence of polymorphisms in the spondyloarthro-
pathy cohort (20%) was not different from that in the control
group (17%) (p=0.5; odds ratio (OR)=1.22 (95% con-
fidence interval (CI), 0.64 to 2.34)) and significantly lower
than in our Crohn’s disease population (49%) (p,0.001;
OR=3.85 (95% CI, 2.17 to 6.83)).
Association between CARD15 polymorphisms and
intestinal inflammation in spondyloarthropathy
patients
The carrier frequency in the subpopulation of spondyloar-
thropathy patients with chronic gut inflammation was 38%
(15 of 40 patients) which was significantly higher than in the
control population (p= 0.006; OR=2.9 (95% CI, 1.33 to
6.30)) or the other spondyloarthropathy populations
(p=0.001; OR=5.80 (2.02 to 16.68)) and not statistically
different from that in our Crohn’s disease population (49%,
p=0.2; OR=1.62 (0.80 to 3.31)) (table 1).
Of all spondyloarthropathy patients carrying CARD15
polymorphisms, 71% (15 of 21 patients) had chronic gut
inflammation, none had acute inflammation, and 29% had
normal histology (table 1). The only spondyloarthropathy
patient carrying two CARD15 variants also had chronic gut
inflammation. In contrast, only 25 of 83 patients with a wild
type genotype (30%) had chronic gut inflammation, 29% had
acute inflammation, and 41% had normal histology.
Consequently, the presence of CARD15 polymorphisms was
associated with a higher risk of the development of chronic
gut inflammation.
There were no significant differences between the ankylos-
ing spondylitis and the undifferentiated spondyloarthropathy
groups for the prevalence of CARD15 polymorphisms in
patients with normal gut (3/29 v 3/11, respectively; p=0.3;
OR=3.3 (95% CI, 0.5 to 19.4)), acute gut inflammation (0/13
v 0/11), or chronic gut inflammation (13/33 v 2/7; p=0.7;
OR=1.6 (95% CI, 0.3 to 9.7)).
Table 2 Carrier frequency of CARD15 variants in patients with spondyloarthropathies, Crohn’s disease, and controls (%)
Spondyloarthropathy (n=104) Crohn’s disease (n=156) Controls (n =140)
R702W G908R 1007fs Overall* R702W G908R 1007fs Overall* R702W G908R 1007fs Overall*
CARD152/+ 12 (12) 4 (4) 4 (4)
21 (20)
39 (25) 11 (7) 27 (17)
77 (49)
18 (13) 1 (1) 6 (4)
24 (17)
CARD152/2 0 (0) 0 (0) 1 (1) 4 (3) 3 (2) 0 (0) 0 (0) 0 (0) 0 (0)
Data are numbers of patients carrying R702W, G908R or 1007fs variants.
CARD152/+, heterozygous; CARD152/2, homozygous.
Overall, total number of patients in the group carrying at least one variant.
*The sum of all allelic CARD15 variants is greater than the overall number of patients carrying at least one variant, as some patients carry two different single
nucleotide polymorphisms, thus displaying compound heterozygous status.
Table 3 Prevalences of CARD15 polymorphisms
according to the presence of mainly axial or peripheral
involvement in the total spondyloarthropathy group
(n = 104), the ankylosing spondylitis group (n = 75), and
the undifferentiated spondyloarthropathy group (n = 29)
CARD15
Wild type Variant Total
Total spondyloarthropathy group
Axial 22 0 22 p= 0.006
Peripheral 61 21 82
Total 83 21 104
Ankylosing spondylitis group
Axial 18 0 18 p= 0.006
Peripheral 41 16 57
Total 59 16 75
Undifferentiated spondyloarthropathy group
Axial 4 0 4 p= 1.0
Peripheral 20 5 25
Total 24 5 29
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In the subgroup of 54 patients who were clinically
reassessed, four had evolved from histological chronic gut
inflammation towards clinically overt Crohn’s disease. Two of
these four patients carried CARD15 polymorphisms. The other
22 patients with chronic gut inflammation in this group did
not develop clinical Crohn’s disease.
Association between CARD15 polymorphisms and
HLA-B27in spondyloarthropathy patients
There was no significant association between the presence of
these two genetic markers. Six of 34 HLA-B27 negative
patients carried CARD15 polymorphisms v 13 of 47 HLA-B27
positive patients (p=0.3; OR=1.8 (95% CI, 0.6 to 5.3)).
Multivariate analysis
In the subgroup of 53 spondyloarthropathy patients in whom
both HLA-B27 and HLA-B62 status was known, logistic
regression was undertaken (with the presence of chronic gut
inflammation as the dependent variable). This showed that
the association between chronic gut inflammation and
CARD15 polymorphisms (p=0.01; OR=17.3 (95% CI, 2.0
to 152.3)) was independent of HLA-B27 (p=0.42; OR=1.7
(0.5 to 6.0)) and HLA-B62 (p=0.28; OR=2.5 (0.5 to 13.0)).
DISCUSSION
In this study we describe a novel and remarkably strong
association between variants in a host defence gene located
on chromosome 16 (CARD15) and a chronic form of gut
inflammation in patients with spondyloarthropathies. The
prevalence of CARD15 polymorphisms in this subgroup of
spondyloarthropathy patients was not significantly different
from that seen in patients with Crohn’s disease.
Three single nucleotide polymorphisms have been asso-
ciated with Crohn’s disease.21–23 One variant (1007fs) encodes
a truncated protein which results in altered activation of
NFkB in response to bacterial stimuli.29–31 The two other
single nucleotide polymorphisms (R702W and G908R) result
in an amino acid substitution.
More recently, several groups assessed the linkage of
CARD15 variants in Crohn’s disease to particular clinical
phenotypes, but the results of these retrospective studies are
disparate. The presence of two mutations has been linked to
younger age at onset and preferential involvement of small
bowel.43 Preference for ileal involvement was also reported by
Cuthbert et al42 and by Ahmad et al.44 Fibrostenosing disease
was the dominant type in a study by Abreu et al.45 In these
studies, no association of CARD15 variants with extraintest-
inal involvement could be shown.
Our study shows a new association between these three
Crohn’s disease associated variants in the leucine-rich region
of the CARD15 gene and a distinct subpopulation of patients
with spondyloarthropathies. As in previous reports, the
overall prevalence of mutations in spondyloarthropathy
patients was not statistically different from the prevalence
in our control population.33–37 However, unlike the previous
studies, we identified a distinct clinical subgroup—charac-
terised by the presence of chronic inflammatory gut lesions—
with a high prevalence of CARD15 polymorphisms similar to
the Crohn’s disease population and significantly higher than
in the control population or the other spondyloarthropathy
patients. Previous studies from our group showed that these
patients with chronic gut inflammation were at particular
risk for progression to Crohn’s disease.11 12
Strikingly, in the present study none of the spondyloar-
thropathy patients with only axial disease carried CARD15
polymorphisms. Carriers of these polymorphisms all had (a
history of) peripheral disease. This is in accord with previous
studies of patients with ankylosing spondylitis where more
chronic gut inflammation could be found in those with
peripheral disease than in those with strict axial disease.11
One previous study investigated CARD15 polymorphisms in
patients with ankylosing spondylitis, Crohn’s disease, and
ulcerative colitis.54 It did not show a higher prevalence of
CARD15 variants in patients with ankylosing spondylitis plus
Crohn’s disease compared with idiopathic ankylosing spon-
dylitis, ankylosing spondylitis plus ulcerative colitis, or
healthy controls. However, the low prevalence of CARD15
variants in the Crohn’s disease population with ankylosing
spondylitis was not compared with the prevalence in a
general Crohn’s disease population and it unexpectedly
revealed a possible association between the G908R CARD15
variant and ankylosing spondylitis plus ulcerative colitis.
Moreover, in a recent study we found an association
between CARD15 polymorphisms and the presence of radi-
ological sacroiliitis in Crohn’s disease patients, unrelated to
the HLA-B27 status of these subjects. These data already
suggested a role for the CARD15 gene in the link between gut
and joint inflammation.46
Our findings confirm the previous reported clinical,
therapeutic, and immunological links between spondyloar-
thropathies and Crohn’s disease and provide genetic proof for
the association between these two disorders. As chronic gut
inflammation in the majority of spondyloarthropathy
patients remains asymptomatic, this might suggest that
CARD15 polymorphisms could be linked to the development
of (subclinical) chronic gut inflammation rather than to
Crohn’s disease as such.
The underlying pathogenic mechanisms that could explain
the phenotypic expression of CARD15 mutations in spondy-
loarthropathies need to be investigated. CARD15 encodes a
cytosolic protein that could play a role in spondyloarthro-
pathies by interference with transport of antigens by
macrophages from mucosal surfaces to the joints.55 CARD15
seems to function as an intracellular receptor for bacterial
components, where the C-terminal leucine-rich repeat
domain (LRR domain) is crucial for responsiveness. The
cellular response to bacterial products has been shown to be
altered in HEK293T cells transfected with expression
plasmids containing any of the three SNPs.29 31 Moreover,
expression of CARD15 in myeloblastic and epithelial cells is
enhanced by proinflammatory cytokines and bacterial com-
ponents, through NFkB.30 31 56 This response is likely to
mediate cytokine production including TNFa, suggesting
that upregulation of CARD15 may be part of a positive
regulatory loop and facilitate the response of the host to
pathogens. A genetically determined disturbance of
handling of bacterial products in the intestinal tract, leading
to altered transport of antigens by macrophages to synovial
tissue, is an interesting hypothesis that should be investi-
gated in spondyloarthropathy. A further identification
and characterisation of inflammatory cells involved in gut
and joint inflammation may also lead to new therapeutic
targets.
Conclusions
A distinct phenotype associated with the three main Crohn’s
disease associated CARD15 variants is reported in patients
with spondyloarthropathies. Our data show that the presence
of CARD15 variants in spondyloarthropathy patients strongly
predisposes to chronic intestinal inflammation, defining a
population at risk for evolution to Crohn’s disease. However,
the persistence of the subclinical character of the inflamma-
tion in a large proportion of patients may reflect the fact that
Crohn’s disease is a multigeneic disease or alternatively that
the heterozygous carriage of CARD15 polymorphisms predis-
poses only to subclinical inflammation.
CARD15 gene polymorphisms in spondyloarthropathy 933
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Background: Sacroiliitis is a common extraintestinal manifestation of Crohn’s disease but its association
with the HLA-B27 phenotype is less evident. Polymorphisms in the CARD15 gene have been linked to
higher susceptibility for Crohn’s disease. In particular, associations have been found with ileal and
fibrostenosing disease, young age at onset of disease, and familial cases.
Objectives: To investigate whether the presence of sacroiliitis in patients with Crohn’s disease is linked to
the carriage of CARD15 polymorphisms.
Methods: 102 consecutive patients with Crohn’s disease were clinically evaluated by a rheumatologist.
Radiographs of the sacroiliac joints were taken and assessed blindly by two investigators. The RFLP-PCR
technique was used to genotype all patients for three single nucleotide polymorphisms (SNP) in the
CARD15 gene. Every SNP was verified by direct sequencing. The HLA-B27 phenotype was determined.
Results: Radiological evidence of sacroiliitis with or without ankylosing spondylitis was found in 23
patients (23%), of whom only three were HLA-B27 positive. In contrast, 78% of patients with sacroiliitis
carried a CARD15 variant v 48% of those without sacroiliitis (p = 0.01; odds ratio 3.8 (95% confidence
interval, 1.3 to 11.5)). Multivariate analysis (logistic regression) showed that the association between
sacroiliitis and CARD15 polymorphisms was independent of other CARD15 related phenotypes (ileal and
fibrostenosing disease, young age at onset of disease, familial Crohn’s disease) (p = 0.039).
Conclusions: CARD15 variants were identified as genetic predictors of Crohn’s disease related sacroiliitis.
An association was demonstrated between these polymorphisms and an extraintestinal manifestation of
Crohn’s disease.
T
here is increasing evidence that Crohn’s disease is a
multigenic disorder resulting in different phenotypes.1
Although several susceptibility loci have been described,
only one gene has been clearly identified as being associated
with an increased susceptibility to Crohn’s disease. Three
single nucleotide polymorphisms (SNP) in the CARD15 gene
(R702W, G908R, and 1007fs) increase the risk for Crohn’s
disease by a factor of 3 for heterozygotes and by about a
factor of 40 for homozygotes or compound heterozygotes.2–4
The identification of associated phenotypes remains
unclear and controversial but suggests an association with
ileal and fibrostenosing disease, familial predisposition, and
earlier age at onset.5–8
No association has been reported between CARD15
polymorphisms and extraintestinal manifestations of
Crohn’s disease. However, data on articular involvement are
scarce and limited to two studies.6 7 Lesage et al reported
articular involvement in only 6% of the patients, but without
a clear definition and without separation between peripheral
and axial disease.6 Ahmad et al recorded pauciarticular
arthritis in 13% of the patients, also with no information
about axial disease.7 The data in these studies were gathered
through questionnaires and the patients’ clinical records.
Besides Crohn’s disease, CARD15 variants have also been
linked to Blau syndrome and psoriatic arthritis.9 10 Current
data show no association between CARD15 and idiopathic
ankylosing spondylitis (AS)11–14; however, in the Crohn’s
disease variant the HLA-B27 association is weaker than in
idiopathic AS, pointing to another genetic link.15–17 Indeed,
Van der Paardt et al have already suggested that it would be
interesting to determine whether there is an association
between CARD15 and the subgroup of patients with Crohn’s
disease and AS.12
Our aim in this cross sectional clinical and radiological
study was to evaluate, in a cohort of Crohn’s disease patients,
the possible association between CARD15 polymorphisms
and the presence of radiological sacroiliitis, a hallmark of
spondylitis and the most frequent objective rheumatic
manifestation of Crohn’s disease.18
METHODS
Study population
One hundred and two white patients with Crohn’s disease,
attending the gastroenterology department of the Ghent
University Hospital, agreed to participate in this cross
sectional study and were included consecutively over a
period of 13 months. The diagnosis of Crohn’s disease was
based on clinical, endoscopic, histological, and radiological
findings. All patients were seen by both a gastroenterologist
and a rheumatologist. The localisation of the disease was
assessed as ileal, ileocolonic, or colonic. Types and amount of
surgical interventions were recorded. The need for resective
small bowel surgery was used as an index of fibrostenosing
disease. A positive family history was defined as the presence
of at least one first, second, or third degree relative with
Abbreviations: AS, ankylosing spondylitis; CARD, caspase activation
and recruitment domain; IBD, inflammatory bowel disease; RFLP-PCR,
restriction fragment length polymorphism polymerase chain reaction;
SNP, single nucleotide polymorphism
1131
CHAPTER 3 | 79
proven Crohn’s disease. The age at diagnosis of the disease
was also recorded.
For controls, we used a group of 54 patients without any
symptoms or clinical evidence of Crohn’s disease, spondylo-
arthropathies, or sclerosing cholangitis, who were attending
the department of hepatology.
The study was approved by the regional ethics committee
and all patients gave their signed informed consent.
Assessment of articular involvement
All patients were assessed for the presence of inflammatory
low back pain, had measurements of the Scho¨ber index and
chest expansion, and were examined for peripheral arthritis
and enthesopathy (fasciitis plantaris or Achilles tendon
tendinitis).
A history of peripheral arthritis or enthesopathy was
recorded if observed, confirmed by a physician, and noted
in the patient’s medical record. Inflammatory low back pain
was defined by the history or presence of spinal pain in the
neck, dorsal, or cervical region with at least four of the five
following criteria: onset before the age of 45 years, insidious
onset, improvement with exercise, association with morning
stiffness, and duration of at least three months.19 The
modified New York criteria were used to determine the
diagnosis of AS.20
Radiological classification
Radiographs of the sacroiliac joints were made and assessed
blindly by two rheumatologists. They were scored using the
New York grading system: 0, normal; 1, suspicious; 2,
localised sclerosis, erosion, joint widening; 3, diffuse sclero-
sis, erosion, widening; 4, ankylosis.20 Radiological sacroiliitis
was diagnosed by the presence of at least unilateral
sacroiliitis grade 2, and only when agreed on by both
radiological assessors.18 21
CARD15 and HLA-B27 typing
Genomic DNA was extracted from whole blood using a
Qiagen blood and cell culture DNA kit (Qiagen, Valencia,
California, USA).
All patients were genotyped for R702W (SNP8), G908R
(SNP12), and 1007fs (SNP13) using a restriction fragment
length polymorphism polymerase chain reaction technique
(RFLP-PCR), followed by separation on 2.5% agarose gel. The
missense mutation R702W (GenBank accession number
G67950) abolishes the restriction site for MspI (59-CAGCCC
TGATGACATTTCTCTT-39 and 59-AGCCGCTCCTCCTGCATCTC
GTA-39), resulting in an intact 130 base pair (bp) band for
mutant alleles, compared with two bands of 54 and 76 bp for
wild type alleles. The missense mutation G908R (GenBank
accession number G67951) creates a restriction site for
HinP1l. The frameshift mutation 1007fs (GenBank accession
number G67955) creates a restriction site for NlaIV (59-
CTGAGCCTTTGTTGATGAGC-39 and 59-TCTTCCAACCACAT
CCCCATT-39). The presence of a mutant allele results in
two bands of 219 and 41 bp, while the wild type allele
produces a single 260 bp product. We verified every SNP by
direct sequencing of the PCR product in an ABI 377 analyser
(Applied Biosystems, Foster City, California, USA).
HLA-B27 typing was undertaken using Dynal Classic SSP
(Dynal Biotech, Bromborough, Cheshire, UK).
Statistical analysis
Odds ratios were calculated with Pearson’s x2 test or Fisher’s
exact test when the expected count was less than 5 in at least
one cell. A model for multivariate analysis (logistic regres-
sion) was constructed, with sacroiliitis as the dependent
variable. As covariates we included the CARD15 genotype,
HLA-B27, and CARD15 related phenotypes. A probability (p)
value of less than 0.05 was considered to indicate statistical
significance. Statistical analyses was carried out using SPSS
software (SPSS Inc, Chicago, Illinois, USA).
RESULTS
Patient characteristics
In all, 102 patients with Crohn’s disease were included (34
men, 68 women), mean age 41.6 years (range 18 to 71). The
mean age at diagnosis was 28.5 years (range 9 to 57). Twenty
two of the patients (21.6%) had ileal disease, 26 (25.5%) had
colonic disease, and 54 (52.9%) had ileocolonic involvement.
Fifty two patients (51.0%) had needed resection of a small
bowel segment. Fifteen patients (14.7%) had a family history
of Crohn’s disease.
Radiological sacroili i t is and other rheumatic
manifestations
Radiological sacroiliitis was found in 23 patients: eight had
unilateral sacroiliitis grade 2, 14 had bilateral sacroiliitis
grade 2, and one had unilateral sacroiliitis grade 3. Nine
patients fulfilled the criteria for AS. Among the 14 remaining
patients, three had inflammatory low back pain without
fulfilling the AS criteria, and 11 were clinically asymptomatic.
The history or presence of peripheral arthritis was recorded
in 17 patients, of whom five actually had arthritis at the time
of study assessment. Three patients had monoarticular
arthritis and 14 had oligoarticular involvement. A history of
enthesopathy was present in 11 patients, of whom four had
tendinitis at the time of the study.
CARD15 status
The overall prevalence of CARD15 polymorphisms in the
Crohn’s disease group was significantly higher than in the
control group, at 56/102 (54.9%) v 8/54 (15%), p,0.001; odds
ratio (OR) 7.00 (95% confidence interval (CI), 3.00 to 16.31)).
Eighteen of 23 patients with radiological sacroiliitis (78%)
carried at least one CARD15 variant, compared with 38 of 79
patients (48%) without sacroiliitis (p=0.01; OR 3.88 (95%
CI, 1.31 to 11.49)) (table 1). There were two compound
heterozygotes and no homozygotes in the group of patients
with sacroiliitis (table 1). Seven of nine patients with AS
carried a CARD15 variant (table 2).
In another perspective, among all carriers of CARD15
variants, 32% of the patients had sacroiliitis compared with
11% in patients without these variants.
Table 1 Carrier frequency of CARD15 variants in
patients with Crohn’s disease
R702W G908R 1007fs Overall*
Crohn’s disease (n = 102)
CARD15+/– 33 6 21
56
CARD15+/+ 2 1 0
Crohn’s disease with no SI (n = 79)
CARD15+/– 21 6 13
38
CARD15+/+ 2 1 0
Crohn’s disease with SI (n = 23)
CARD15+/– 12 0 8
18
CARD15+/+ 0 0 0
Numbers of patients carrying R702W, G908R, or 1007fs variants.
*Total number of patients in the group carrying at least one variant. The
sum of all allelic CARD15 variants is greater than the overall number of
patients carrying at least one variant, as some patients carry two different
single nucleotide polymorphisms (compound heterozygotes).
CARD15+/2, heterozygous for CARD15 gene; CARD15+/+,
homozygous for CARD15 gene; SI, sacroiliitis.
1132 Peeters, Vander Cruyssen, Laukens, et al
CHAPTER 380 |
There was no significant association between the presence
of CARD15 polymorphisms and peripheral arthritis (p=0.37;
OR 1.6 (95% CI, 0.55 to 4.81)) or enthesopathy (p=0.34; OR
0.5 (0.14 to 1.94)).
HLA-B27 status
Overall, six of the 102 patients with Crohn’s disease (6%)
carried HLA-B27. HLA-B27 positivity was present in three of
the 23 patients (13%) with sacroiliitis. Those three patients
were also carriers of CARD15 variants and fulfilled the
modified New York criteria for AS (table 2).
Multivariate analysis
Logistic regression showed the presence of CARD15 variants
as the only significant predictor of sacroiliitis (p=0.039),
independent of HLA-B27, ileal involvement, need for
resective small bowel surgery, familial Crohn’s disease, or
age at onset (table 3).
DISCUSSION
Our data identify CARD15 variants as a possible genetic
predictor of sacroiliitis in Crohn’s disease. Sacroiliitis is a
distinct extraintestinal manifestation of Crohn’s disease. In
contrast to the clinically evident peripheral arthritis, the
prevalence of axial involvement in Crohn’s disease is
probably underestimated.18 22 Previous studies showed that
10–32% of patients with inflammatory bowel disease (IBD)
have evidence of sacroiliitis, a hallmark of spondylitis, on
conventional radiography.15 17 18 21 23–25 With technetium scin-
tigraphy, tracer uptake in the sacroiliac joints can be seen in
up to 52% of patients.26 Many patients with sacroiliitis remain
asymptomatic.15 17 18 23 27 Only about one quarter of the
patients with radiological sacroiliitis also fulfil the criteria
for AS.18 In contrast to idiopathic AS, involvement of the
sacroiliac joints is asymmetrical in about 25% of the patients
with Crohn’s disease.18 21 22
In our cohort, 23% of patients had evidence of sacroiliitis of
at least grade 2 unilaterally on conventional radiographs.
Diagnosis of AS was retained in 39% of these patients with
sacroiliitis.
In contrast to other forms of spondyloarthropathy, the
association between axial involvement and HLA-B27 is weak
in IBD patients. Whereas HLA-B27 is present in more than
90% of patients with idiopathic AS, the prevalence decreases
to 25–75% in patients with AS associated with IBD, and to
low or even normal prevalences in patients with asympto-
matic IBD-associated radiological sacroiliitis.15–17 24
Recently, the possibility of an as yet undefined common
genetic link between intestinal inflammation and sacroiliac
changes was again suggested in a study assessing first degree
relatives of patients with AS.28 This study showed an
association between asymptomatic intestinal inflammation,
recorded in 41% of these relatives, and sacroiliac changes
suggestive of early AS. The presence of intestinal inflamma-
tion and sacroiliac changes did not relate to the HLA-B27
status of these subjects.
Our data suggest that CARD15 polymorphisms may
predispose to sacroiliac involvement in Crohn’s disease:
78% of Crohn’s patients with sacroiliitis carried at least
one variant, versus 48% of patients without sacroiliitis.
Multivariate analysis showed that the presence of CARD15
variants was the only significant predictor of sacroiliitis,
independent of other known CARD15 related phenotypes
such as ileal involvement, fibrostenosing disease, family
history, and age of onset, and independent of HLA-B27.
Interestingly, the three patients with sacroiliitis who
carried HLA-B27 also carried a CARD15 variant, and all had
clinical AS. In contrast none of the patients with isolated
sacroiliitis carried HLA-B27. Whether or not the presence of
both genetic markers in Crohn’s patients with sacroiliitis
predisposes to evolution to AS cannot be concluded from this
study. It seems interesting, however, to explore this question
with larger studies.
The percentage of Crohn’s disease patients with CARD15
variants was higher in our study (54.9%) than generally
reported. A variation in the methodology was excluded as the
prevalence in our control group was similar to values in
previous reports. Moreover, the prevalence of CARD15
variants in our group was not significantly greater than in
another Flemish population studied by Vermeire et al
(46.1%).29
To the best of our knowledge, no studies are available
about a possible relation between the CARD15 genotype and
sacroiliitis in Crohn’s disease. Until now, studies in idiopathic
AS have not been able to demonstrate a possible association
with CARD15 variants.11–14 However, these studies provided
no information on the possible presence and relative number
of patients with Crohn’s disease who were included. Only one
study included cases of AS with Crohn’s disease and
ulcerative colitis.30 The investigators could not demonstrate
a higher prevalence of CARD15 variants in patients with AS
plus Crohn’s disease compared with idiopathic AS, AS plus
ulcerative colitis, or healthy controls. The low prevalence of
CARD15 variants in their Crohn’s population with AS was
not compared with the prevalence in a general Crohn’s
disease population. Moreover, they unexpectedly showed a
possible association between the G908R CARD15 variant and
AS with ulcerative colitis.
In contrast to that study, we found CARD15 variants in
seven of nine Crohn’s patients with AS. Although it only
represents a small group of patients in our study, a difference
in prevalence of CARD15 variants between Crohn’s disease
related AS and idiopathic AS (and also for HLA-B27) could
reflect a different aetiopathogenetic mechanism.
The CARD15 gene encodes for an intracellular protein that
is found in monocytes, macrophages, epithelial cells, gran-
ulocytes, and dendritic cells. The gene product acts as a
Table 2 Carrier frequency of CARD15 variants and
HLA-B27 in patients with Crohn’s disease
CARD15 +/2 or +/+ HLA-B27+
Total (n = 102) 56 (55%) 6 (6%)
No sacroiliitis (n = 79) 38 (48%) 3 (4%)
Sacroiliitis (n = 23) 18 (78%) 3 (13%)
AS (n = 9) 7 3
Non-AS (n = 14) 11 0
CARD15 +/2 or +/+: carriage of at least 1 CARD15 variant
HLA-B27+: carriage of HLA-B27
AS, Crohn’s disease patients with sacroiliitis fulfilling the ankylosing
spondylitis (AS) criteria; non-AS, Crohn’s disease patients with sacroiliitis
not fulfilling the AS criteria.
Table 3 Multivariate analysis (logistic regression) with
‘‘sacroiliitis’’ as the dependent variable
Covariate p Value OR 95% CI
CARD15 variants 0.039 3.38 1.06 to 10.75
HLA-B27 0.201 3.48 0.51 to 23.81
Ileal involvement 0.517 1.84 0.29 to 11.49
History of small bowel resection 0.145 2.56 0.72 to 9.09
Family history of Crohn’s disease 0.857 1.14 0.28 to 4.65
Age at diagnosis 0.706 0.99 0.94 to 1.04
Logistic regression shows that the association between sacroiliitis and
CARD15 variants is independent of known CARD15 related phenotypes
or HLA-B27.
CI, confidence interval; OR, odds ratio.
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receptor for bacterial cell wall components like muramyldi-
peptides derived from peptidoglycan and lipopolysaccharides,
resulting in the activation of NF-kB. The polymorphisms
described could cause a disturbed cellular response to
bacterial components, leading to intracellular persistence of
pathogens.31 Previous studies have suggested that recircula-
tion of inflammatory cells between the gut and peripheral
joints might contribute to inflammation at a distance.32–36
Conclusions
In Crohn’s disease, CARD15 variants could play a role in the
development of sacroiliitis, as an extraintestinal manifesta-
tion of the disease. However, the exact mechanism of the link
between gut and axial joints remains to be elucidated.
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ABSTRACT 
Radiographic sacroiliitis (SI), often asymptomatic, is considered to be the most frequent 
extra-intestinal manifestation (EIM) of Crohn’s disease (CD). Data on the association of SI 
with other clinical features of CD are limited. Association of SI with CARD15 polymorphisms 
has recently been suggested. In a cross-sectional, multicentre study, we investigated the 
association of SI in CD patients with clinical phenotypes, other EIM and CARD15
polymorphisms. 
Radiographs of the sacroiliac joints were taken in 251 CD patients from 3 Belgian university 
hospitals and blindly scored by 2 rheumatologists. Clinical features were obtained from 
medical records. Forty-three percent of patients carried at least one CARD15 polymorphism. 
Sacroiliitis, defined as the presence of at least grade 2 unilateral changes, was diagnosed in 65 
of the 244 scorable radiographs (27%). Only 16 of these patients were previously diagnosed 
with ankylosing spondylitis (AS). HLA-B27 positivity was observed in 53% of patients with 
AS and 7% of patients with radiographic SI. In univariate and multivariate analysis, 
associations between the presence of SI and peripheral arthritis (P=0.005) and between AS 
and uveitis (P=0.005) were found. No associations with other recorded clinical features or 
with CARD15 polymorphisms were observed.  
In conclusion, we confirm the high prevalence of radiographic sacroiliitis in a multicentre CD 
cohort. Uveitis is only associated with AS whereas all patients with SI are more prone to 
develop peripheral arthritis during their disease course, suggesting similar pathogenetic 
mechanisms in the development of these EIM. The previously reported association between 
SI and CARD15 polymorphisms was not confirmed. 
KEY WORDS 
Sacroiliitis, Crohn’s disease, extraintestinal manifestation, association, CARD15 
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INTRODUCTION
Extraintestinal manifestations (EIM) are quite common in inflammatory bowel disease (IBD) 
and prevalence rates vary between 21 and 36% (1). Rheumatic (peripheral and/or axial) 
articular involvement and cutaneous lesions (erythema nodosum and pyoderma gangrenosum) 
are commonly seen but ocular and hepatobiliary complications can also occur (2).  
According to the European Spondyloarthropathy Study Group (ESSG) criteria, the presence 
of peripheral arthritis and/or axial inflammatory complaints in IBD patients is classified as 
spondyloarthropathy (3). Peripheral arthritis is usually pauciarticular and asymmetrical and 
occurs in 5-20% of IBD patients (4, 5). It is mostly transient, migratory and non-deforming 
and often coincides with intestinal activity. Associations have been described with colonic 
involvement, uveitis and erythema nodosum (5-10).  
Axial involvement consists of inflammatory low back pain, spondylitis and sacroiliitis (SI) 
(6). The criteria for ankylosing spondylitis (AS) are fulfilled in 1.1 to 11% of IBD patients (6, 
11-14). The clinical symptoms, including morning stiffness, inflammatory low back pain or 
alternating buttock pain, are often unrelated to the bowel disease activity. Usually, a chronic 
and progressive disease course is observed. Radiographic SI, often asymptomatic, has been 
described in 10 to 32% of patients and can be considered the most frequent extraintestinal 
manifestation of IBD (11, 13, 14). Unilateral involvement of the sacroiliac joints is not 
uncommon (11, 13). The prevalence rate of radiographic SI is probably underestimated as 
reflected by higher prevalence rates found in studies using more sensitive imaging techniques 
than plain radiographs, such as quantitative SI scintigraphy, computed tomography (CT) and 
magnetic resonance imaging (MRI) (15-19). However, these newer techniques are not useful 
for screening purposes and plain radiographs remain the first line of imaging investigation. 
Despite the high prevalence of SI in IBD, data on the association with different clinical 
phenotypes are scarce. 
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Although IBD associated AS is clinically and radiologically indistinguishable from idiopathic 
AS, the association with HLA-B27 is much weaker. Whereas more than 90% of patients with 
idiopathic AS carry HLA-B27, it decreases to 25-75% in IBD associated AS and to normal 
prevalence rates in asymptomatic SI (11, 18, 20, 21). An association between radiographic SI 
in Crohn’s disease (CD) and polymorphisms in CARD15, a well-known susceptibility gene 
for CD, was observed by our group in a first cohort of patients (22). 
The aim of the present study was to further investigate in a Belgian multicentre cohort of 
Crohn’s disease patients the association of SI with different articular and non-articular clinical 
phenotypes of the disease and the CARD15 genotype. 
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METHODS
Study population 
A total of 251 CD patients from 3 Belgian university hospitals (Gent, Leuven and Liège) were 
randomly included in this study, independent of the presence of articular symptoms.  
Clinical features were obtained from medical records including sex, age, age at onset of CD, 
disease duration, family history of CD (1
st
 or 2
nd
 degree relative), maximal location of the 
disease (ileal, ileocolonic or colonic), upper GI involvement, history of ileal resections, 
fistulas (abdominal or perianal), peripheral arthritis, AS, uveitis, erythema nodosum, 
pyoderma gangrenosum, primary sclerosing cholangitis (PSC) and smoking habit. In 5 
patients, smoking history was unknown. Peripheral arthritis was distinguished from 
arthralgias (articular pain without evidence of joint swelling or effusion). 
Two hundred thirty-three patients were genotyped (by RFLP-PCR) for the presence of the 
three common CD associated CARD15 polymorphisms (R702W, G908R and 1007fs). There 
were 136 wild-type patients, 77 heterozygotes (38 R702W, 15 G908R, 24 1007fs), 12 
compound heterozygotes (4 R702W/G908R, 8 R702W/1007fs) and 8 homozygotes (4 
R702W, 2 G908R, 2 1007fs). DNA was not available in the remaining 18 patients. 
Table 1 shows the patient characteristics from the cohorts of the 3 different centres. The 
disease duration in Leuven and Liège was longer compared to Gent and the cohort from Liège 
had more (ex-)smokers compared to the other 2 cohorts. There was also a higher prevalence 
of uveitis in Leuven compared to Liège. No other significant differences in clinical 
phenotypes or CARD15 genotype were observed between the 3 different centres.
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Diagnosis of sacroiliitis 
Radiographs of the sacroiliac joints were taken in all 251 patients and blindly and 
independently scored by 2 senior rheumatologists from 2 different centres using the New 
York grading system: 0, normal; 1, suspicious changes (no specific abnormalities); 2, 
localised sclerosis, minimal erosions and joint narrowing; 3, diffuse, definite sclerosis on both 
sides of the joint, blurring and indistinct margins and erosive changes with loss of joint space; 
4, complete fusion or ankylosis (23). Radiographic SI was diagnosed by the presence of at 
least unilateral SI grade 2 and only when agreed on by both radiological assessors (11, 13). 
For discordant scores, a consensus score was obtained after rereading the radiographs. HLA-
B27 typing was performed by PCR using Dynal AllSet SSP HLA-B27 (Dynal Biotech, 
Invitrogen, Merelbeke, Belgium) in patients with pathological sacroiliac joints. 
Statistical analysis
For univariate analysis, X
2
test, Fisher’s exact test (when at least 1 cell had an expected count 
less than 5) and Mann-Whitney U test (for continuous variables) were used where needed. 
Multivariate analysis was performed using logistic regression with SI, non-AS SI and AS as 
dependent variables (compared to non-SI patients). Clinical phenotypes and CARD15
genotype were included as covariates. A probability value (P) of less than 0.05 was 
considered to indicate statistical significance. Statistical analysis was performed using SPSS 
software (SPPS Inc, Chicago, Illinois, USA). 
Based upon the previous study on the association between sacroiliitis in CD and the presence 
of CARD15 polymorphisms, a sample size calculation was performed. The number of patients 
needed to obtain a power of 95% was calculated as 228. 
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Ethics Approval 
The local ethical committees approved the collection of all clinical data and the genotyping 
for CARD15 polymorphisms and all patients gave their informed consent. 
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RESULTS
Prevalence of radiographic sacroiliitis 
The sacroiliac joints of seven patients were not scorable due to insufficient quality of the plain 
radiographs. Sixty-five (27%) of the remaining 244 patients had radiographic SI. The 
radiographs of all 16 patients, previously classified as having concomitant ankylosing 
spondylitis, were recognized as being pathological. 
Twenty-five of the 65 patients (42%) with positive sacroiliac radiographs had unilateral SI 
grade 2 whereas 40 patients (58%) had a score more than unilateral grade 2 or bilateral 
sacroiliitis.
Association of SI with clinical phenotypes and CARD15 genotype
Age, age at onset of CD, duration of CD, familial CD, ileal or colonic involvement, upper GI 
involvement, history of ileal resection, fistulas, smoking history, erythema nodosum and 
CARD15 genotype were not associated with the presence of SI (Table 2).
In relation to other extraintestinal manifestations, there was a significantly higher prevalence 
of peripheral arthritis and uveitis in patients with SI. No significant difference was found for 
erythema nodosum. One of the 2 patients with a history of pyoderma gangrenosum had 
radiolographic SI, whereas the 2 patients with PSC had normal sacroiliac joints. 
In both subgroups of patients with non-AS SI and AS, the association with peripheral arthritis 
was confirmed, whereas uveitis only seemed to be related to AS. 
Association of AS, uveitis and peripheral arthritis with HLA-B27 
Conclusive results on the HLA-B27 phenotype could be obtained in 60 of 65 patients with SI. 
Eight of 15 patients (53%) with AS, of whom DNA was available, were positive for HLA-
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B27, whereas this was only the case in 3 of 45 patients (7%) with pure radiographic SI 
(P=0.0003, OR 16, 95% CI 3.4-75.3). 
Within the group of patients with SI, no relationship with HLA-B27 could be found for 
uveitis (P=0.37, OR 2.3, 95% CI 0.5-10.6) and peripheral arthritis (P=0.75, OR 0.8, 95% CI 
0.2-2.9) (data not shown). 
Multivariate analysis 
Logistic regression was performed to investigate whether peripheral arthritis and uveitis could 
be identified as independent predictors for SI or AS. Three models were fit, using three 
different dependent variables: the presence of radiographic SI (n=65), non-AS SI (n=49) or 
AS (n=16) (Table 3). As covariates we included sex, disease duration (more or less than 10 
years), familial CD, ileal involvement, history of ileal resection, fistulas, peripheral arthritis, 
uveitis, smoking (ever versus never) and CARD15 genotype (wild-type versus polymorphism 
carrier).
The multivariate analyses confirmed that the presence of radiographic SI is associated with 
the occurrence of peripheral arthritis (independent of the presence of AS). Furthermore, CD 
patients with AS also have a higher risk of developing uveitis. 
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DISCUSSION
The present study confirms the high prevalence of radiographic SI in CD (6, 11, 13, 14, 22).  
Overall, we found radiographic signs of SI in 27% of patients. The prevalence of AS in our 
population was 6%, which is consistent with previously reported prevalence rates (11-14).
In our study, patients with CD associated AS have a higher risk of developing peripheral 
arthritis and uveitis compared to CD patients without axial involvement, confirming previous 
findings (5, 6, 12, 18, 24). Peripheral arthritis and uveitis are also known to be mutually 
associated (5-7, 25). However, multivariate analysis confirmed that both EIM were 
independently associated with AS. This finding might point to similar pathogenetic 
mechanisms in the development of AS, peripheral arthritis and uveitis.  
Patients with non-AS SI also had a higher prevalence of peripheral arthritis in their medical 
history. Previous data on this association have been reported in only 2 studies and are 
somewhat conflicting. No association was found between non-AS SI and peripheral arthritis 
in a study by de Vlam et al (in a population of 78 CD and 25 UC patients) (11).  In a study by 
Queiro et al, a higher incidence of peripheral arthritis (40%) was found in a population of 15 
CD patients with subclinical SI compared to 47 patients without SI (27%), although statistical 
significance was not reached (probably due to the low number of patients) (13). As in the 
latter study, we found no association between non-AS SI and the incidence of uveitis (as 
opposed to AS). 
Similar to a study by McEniff et al, we found no association between SI and disease duration. 
This is in contrast to the study by de Vlam et al (where the mean disease duration was slightly 
longer, 10.6 years versus 8 years in our study). We found no associations with other clinical 
characteristics such as age, sex, disease location or behaviour.
An association with CARD15 polymorphisms, as suggested in a recent paper from one of the 
centres in this study, could not be confirmed in this larger, multicentre cohort (22). This may 
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reflect issues of poor reproducibility in genetic association studies. In complex multigenic 
diseases, many potential confounding factors, including lack of power, population 
stratification, genetic heterogeneity, environmental interactions, genotype and phenotype 
quality control and the choice of statistical models, can lead to inconsistent results between 
different genetic association studies (26-29). In the numerous genotype-phenotype studies 
concerning CARD15 polymorphisms, several conflicting data have been reported considering 
associations with fibrostenosing and fistulizing disease, familial occurrence of CD and early 
onset of disease, even in ethnically similar populations (30, 31).  
Although SI is generally seen as the hallmark of ankylosing spondylitis, isolated radiographic 
SI and AS are considered separate entities in IBD. HLA-B27 positivity has been described in 
25-75% of IBD patients with AS (11, 18, 20). On the contrary, isolated radiographic SI is not 
related to HLA-B27. In our study, 53% of patients with AS were positive for HLA-B27. 
HLA-B27 was found in only 7% of patients with non-AS SI, which corresponds to the 
prevalence rates reported in the normal population (12, 13). Furthermore, the clinical 
evolution and importance of radiographic SI is still unclear. To our knowledge, only one 
follow-up study has been performed addressing this question (13). Sixty-two IBD patients 
were followed up for 4 years and no significant change in radiological score was observed. In 
the present study there was no association between disease duration and the presence of AS or 
SI. To determine whether radiographic SI is clinically insignificant or whether it represents a 
fruste form of AS or a partially resolved SI in response to treatment, larger and longer follow-
up studies are necessary.  
Recognition of SI on radiographs of the sacroiliac joints is difficult and requires experience. 
Many studies have addressed the inter- and intra-observer variability of this technique and CT 
and MRI scans have proven to be more sensitive and specific (3, 15-17, 32). Nevertheless, 
due to the limited availability, high radiation exposure and/or relative high cost of these 
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techniques, plain sacroiliac radiographs remain the initial diagnostic tool (11, 28). Moreover, 
no validated classification criteria for SI based on these newer techniques are available (13). 
CT or MRI scan may be particularly helpful in patients with a high probability of SI in whom 
conventional radiographs are negative or inconclusive. 
In conclusion, we confirm the high prevalence of radiographic SI as an EIM of CD. 
Furthermore, the presence of (both non-AS and AS) SI is associated with a higher incidence 
of peripheral arthritis, suggesting common pathogenetic factors in the occurrence of arthritic 
manifestations of CD. Uveitis is associated with AS but not with isolated radiographic SI. The 
clinical importance of radiographic SI is still uncertain and future studies are needed to 
identify those patients at risk for development of AS.  
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 Table 1. Patient characteristics according to the 3 participating centres. 
Centre
Gent Leuven Liège Total
N=100 N=97 N=54 N=251 
male/female (%) 44/56 (44/56) 41/56 (42/58) 15/39 (28/72) 100/151 (40/60) 
age (median in years; range) 33 (16-80) 36 (20-66) 37 (18-78) 35 (16-80) 
age at onset of CD (median in years; range) 24 (9-76) 24 (12-65) 27 (10-70) 24 (9-76) 
disease duration (median in years; range) * 5 (0-34) 9 (0-30) 8 (0-41) 8 (0-41) 
familial CD (%) 15 (15) 20 (21) 5 (9) 40 (16) 
location     
x ileal (%) 20 (20) 25 (26) 18 (33) 63 (25) 
x ileocolonic (%) 60 (60) 54 (55.5) 30 (56) 144 (57.5) 
x colonic (%) 20 (20) 18 (18.5) 6 (11) 44 (17.5) 
upper GI involvement (%) 4 (4) 10 (10) 3 (6) 17 (7) 
ileal resection (%) 33 (33) 42 (43) 24 (44) 99 (39) 
fistulas (%) 55 (55) 48 (50) 22 (41) 125 (50) 
x abdominal (%) 13 (13) 13 (13) 8 (15) 34 (14) 
x perianal (%) 48 (48) 40 (41) 18 (33) 106 (42) 
extraintestinal manifestations     
x peripheral arthritis (%) 29 (29) 31 (32) 13 (24) 73 (29) 
x AS (%) 5 (5) 7 (7) 4 (7) 16 (6) 
x uveitis (%) ** 7 (7) 13 (13) 1 (2) 21 (8) 
x erythema nodosum (%) 9 (9) 11 (11) 3 (6) 23 (9) 
x pyoderma gangrenosum (%) 1 (1) 1 (1) 0 (0) 2 (1) 
x PSC (%) 2 (2) 0 (0) 0 (0) 2 (1) 
 N=100 N=92 N=54 N=246 
Smoking ***     
never (%) 54 (54) 48 (52) 17 (31) 119 (48) 
ever (%) 46 (46) 44 (48) 37 (69) 127 (52) 
 N=100 N=92 N=41 N=233 
CARD15 genotype     
wild-type (%) 55 (55) 56 (61) 25 (61) 136 (58) 
heterozygous (%) 36 (36) 26 (28) 15 (37) 77 (33) 
compound heterozygous (%) 4 (4) 7 (8) 1 (2) 12 (5) 
homozygous (%) 5 (5) 3 (3) 0 (0) 8 (4) 
N: total number 
AS: ankylosing spondylitis; PSC: primary sclerosing cholangitis 
*     P=0.001 between Gent and Leuven; P=0.023 between Gent and Liège 
**   P=0.019 between Leuven and Liège 
*** P=0.007 between Liège and Gent; P=0.015 between Liège and Leuven
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Table 2. Prevalence of the different clinical phenotypes according to the presence of sacroiliitis
No SI 
N=179 
SI
N=65 
non-AS SI 
N=49 
AS
N=16 
years 
(range) 
years 
(range) 
P*
years 
(range) 
P*
years 
(range) 
P*
median age
35
(17-80) 
36
(16-67) 
0.90  
 36 
(16-67) 
0.90  
 35.5 
(23-50) 
0.96  
median age at onset of CD 
24
(9-76) 
24
(10-68) 
0.89  
 24 
(10-68) 
0.68  
 26 
(18-38) 
0.64  
median disease duration
7
(0-41) 
9
(0-30) 
0.75  
 9 
(0-30) 
0.68  
 8.5 
(0-26) 
0.94  
N (%) N (%) P* OR 95% CI N (%) P* OR 95% CI N (%) P* OR 95% CI 
disease
duration 
< 5y 
 5y 
64 (36) 
115 (64) 
23 (35) 
42 (65) 
0.96 1.0 0.6-1.8 
18 (37) 
31 (63) 
0.90 1.0 0.5-1.8 
5 (31) 
11 (69) 
0.7 1.2 0.4-3.7 
sex
M
F
73 (41) 
106 (59) 
27 (42) 
38 (58) 
0.92 1.0 0.6-1.8 
19 (39) 
30 (61) 
0.80 0.9 0.5-1.8 
8 (50) 
8 (50) 
0.47 1.5 0.5-4.0 
familial CD 
No 
yes 
149 (83) 
30 (17) 
56 (86) 
9 (14) 
0.58 0.8 0.4-1.8 
43 (88) 
6 (12) 
0.44 0.7 0.3-1.8 
13 (81) 
3 (19) 
0.74 1.1 0.3-4.3 
ileal 
involvement 
no
yes 
33 (18) 
146 (82) 
10 (15) 
55 (85) 
0.58 1.2 0.6-2.7 
8 (16) 
41 (84) 
0.73 1.2 0.5-2.7 
2 (12.5) 
14 (87.5) 
0.74 1.6 0.3-7.3 
colonic 
involvement 
no
yes 
45 (25) 
134 (75) 
16 (25) 
49 (75) 
0.93 1.0 0.5-2.0 
10 (20) 
39 (80) 
0.49 1.3 0.6-2.8 
6 (37.5) 
10 (62.5) 
0.37 0.6 0.2-1.6 
upper GI
involvement 
no
yes 
164 (92) 
15 (8) 
63 (97) 
2 (3) 
0.25 0.3 0.1-1.6 
47 (96) 
2 (4) 
0.54 0.5 0.1-2.1 
16 (100) 
0 (0) 
0.62   
ileal resection 
no
yes 
106 (59) 
73 (41) 
41 (63) 
24 (37) 
0.59 0.9 0.5-1.5 
32 (65) 
17 (35) 
0.44 0.8 0.4-1.5 
9 (56) 
7 (44) 
0.82 1.1 0.4-3.2 
fistulas 
no
yes 
85 (47) 
94 (53) 
36 (55) 
29 (45) 
0.28 0.7 0.4-1.3 
27 (55)  
22 (45) 
0.35 0.7 0.4-1.4 
9 (56) 
7 (44) 
0.50 0.7 0.3-2.0 
abdominal 
fistulas 
no
yes 
155 (87) 
24 (13) 
56 (86) 
9 (14) 
0.93 1.0 0.5-2.4 
42 (86) 
7 (14) 
0.87 1.1 0.4-2.7 
14 (87.5) 
2 (12.5) 
1.0 0.9 0.2-4.3 
perianal 
fistulas 
no
yes 
98 (55) 
81 (45) 
41 (63) 
24 (37) 
0.25 0.7 0.4-1.3 
31 (63) 
18 (37) 
0.29 0.7 0.4-1.3 
10 (62.5) 
6 (37.5) 
0.55 0.7 0.3-2.1 
peripheral 
arthritis 
no
yes 
135 (75) 
44 (25) 
37 (57) 
28 (43) 
0.005 2.3 1.3-4.2 
29 (59) 
20 (42) 
0.025 2.1 1.1-4.1 
8 (50) 
8 (50) 
0.038 3.1 1.1-8.7 
uveitis 
no
yes 
168 (94) 
11 (6) 
55 (85) 
10 (15) 
0.023 2.8 1.1-6.9 
44 (90) 
5 (10) 
0.32 1.7 0.6-5.3 
11 (69) 
5 (31) 
0.005 6.9 2.0-23.5 
erythema 
nodosum 
no
yes 
165 (92) 
14 (8) 
56 (86) 
9 (14) 
0.15 1.9 0.8-4.6 
42 (86) 
7 (14) 
0.17 2.0 0.7-5.2 
14 (87.5) 
2 (12.5) 
0.63 1.7 0.3-8.2 
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No SI 
N=177 
SI
N=62 
non-AS SI 
N=46 
AS
N=16 
N (%) N (%) P* OR 95% CI N (%) P* OR 95% CI N (%) P* OR 95% CI 
smoking 
no
yes 
89 (50) 
88 (50) 
27 (44) 
35 (56) 
0.36 1.3 0.7-2.3 
22 (48) 
24 (52) 
0.77 1.1 0.6-2.1 
5 (31) 
11 (69) 
0.15 2.2 0.7-6.7 
No SI 
N=166 
SI
N=60 
non-AS SI 
N=46 
AS
N=14 
N (%) N (%) P* OR 95% CI N (%) P* OR 95% CI N (%) P* OR 95% CI 
CARD15 
genotype 
wt 
mut 
93 (56) 
73 (44) 
38 (63) 
22 (37) 
0.33 0.7 0.4-1.4 
29 (63) 
17 (37) 
0.39 0.7 0.4-1.5 
9 (64) 
5 (36) 
0.55 0.7 0.2-2.2 
N: number 
SI: sacroiliitis; OR: Odds ratio; CI: confidence interval; wt: wild-type; mut: mutant 
* versus “No SI”
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Table 3. Logistic Regression with the presence of SI, non-AS SI and AS as dependent variable 
SI: sacroiliitis; AS: ankylosing spondylitis 
OR: Odds ratio; CI: confidence interval 
SI versus non-SI non-AS SI versus non-SI AS versus non-SI 
Covariate P OR 95% CI P OR 95% CI P OR 95% CI
Sex 0.69 1.1 0.6-2.3 0.78 1.1 0.5-2.3 0.49 1.6 0.4-5.9 
Disease duration 0.54 0.8 0.4-1.7 0.82 0.9 0.4-2.1 0.40 0.5 0.1-2.3 
Familial CD 0.33 0.6 0.2-1.6 0.26 0.5 0.2-1.6 0.78 0.8 0.2-4.1 
Ileal involvement 0.10 2.2 0.9-5.9 0.19 2.0 0.7-5.7 0.26 3.1 0.4-21.3 
Ileal resection 0.57 0.8 0.4-1.7 0.42 0.7 0.3-1.6 0.98 1.0 0.2-4.0 
Fistulas 0.42 0.8 0.4-1.5 0.36 0.7 0.3-1.5 0.89 1.1 0.3-4.2 
Smoking 0.31 1.4 0.7-2.8 0.56 1.3 0.6-2.7 0.40 1.8 0.5-6.8 
Peripheral arthritis 0.007 2.7 1.3-5.6 0.048 2.3 1.0-5.0 0.017 5.1 1.3-19.4 
Uveitis 0.11 2.3 0.8-6.7 0.56 1.5 0.4-5.2 0.008 9.8 1.8-53.5 
CARD15 genotype 0.19 0.6 0.3-1.3 0.37 0.7 0.3-1.5 0.19 0.4 0.1-1.6 
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CHAPTER 5 
Study of the functional impact of CARD15 polymorphisms 
on peripheral blood monocytes in CD 
CARD15 variants determine a disturbed early response of monocytes to 
adherent-invasive Escherichia coli strain LF82 in Crohn’s disease. 
H Peeters, S Bogaert, D Laukens, P Rottiers, F De Keyser,  
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Abbreviations 
IBD: inflammatory bowel disease; CD: Crohn’s disease; UC: ulcerative colitis; AIEC: 
adherent-invasive Escherichia coli; CARD: caspase activation and recruitment domain; NOD: 
nucleotide-binding oligomerization domain; TLR: toll-like receptor; SNP: single nucleotide 
polymorphism; MDP: muramyl dipeptide; LPS: lipopolysaccharide; PBMC: peripheral blood 
mononuclear cells; LDH: lactate dehydrogenase; CDAI: Crohn’s disease activity index; MOI: 
multiplicity of infection. 
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ABSTRACT 
CARD15 and TLR4 are respectively intracellular and membrane-bound receptors for bacterial 
cell wall components (respectively muramyl dipeptide (MDP) and lipopolysaccharide (LPS)). 
Polymorphisms in CARD15 and TLR4 have been linked with Crohn's disease (CD). Adherent-
invasive Escherichia coli (AIEC), strains with particular adhesion and invasion 
characteristics, have been specifically associated with CD ileal mucosa. The aim of this study 
was to investigate the functional impact of these polymorphisms on monocytes from CD 
patients, in response to MDP, LPS and AIEC strain LF82. Monocytes were isolated from 40 
CD patients using magnetic cell sorting, stimulated with LPS or MDP or infected with AIEC. 
IL-1ȕ, IL-6, IL-8, IL-10, IL-12 and TNFĮ induction was assessed using qRT-PCR, 
Cytometric Bead Array and ELISA. Bacterial intracellular survival and replication was 
assessed using a gentamicin protection assay. Results were linked with the presence of 
CARD15 and TLR4 polymorphisms. Monocytes of patients with CARD15 polymorphisms 
showed an early reduced cytokine response (IL-1ȕ, IL-6 and IL-10) to infection with AIEC, 
which was restored after 20 hours. A gene-dose effect was seen, comparing wild-types, 
heterozygotes and homozygotes. We found no differences in intracellular survival and 
replication of AIEC. Heterozygous carriage of TLR4 polymorphisms did not influence 
monocyte response. In conclusion, CD patients carrying CARD15 polymorphisms show a 
disturbed early inflammatory monocyte response after infection with AIEC strain LF82. For 
the first time, a functional defect was detected in single heterozygous carriers. These findings 
reflect the potential role of a genetically altered host response to disease-related bacteria in the 
pathogenesis of CD. 
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INTRODUCTION
Crohn’s disease (CD) represents a complex multigenic disorder. It is generally thought that in 
genetically susceptible individuals, an inappropriate innate immune response towards 
environmental (bacterial) triggers contributes to the development of chronic intestinal 
inflammation.[1] Polymorphisms in two pathogen associated molecular pattern (PAMP) 
receptors, involved in host/pathogen interactions, have been associated with inflammatory 
bowel disease (IBD).[2][3][4]
The CARD15 gene on chromosome 16 encodes an intracellular protein (CARD15 or NOD2) 
expressed in monocytes, macrophages, dendritic, polymorphonuclear and epithelial cells and 
acting as a receptor for muramyl dipeptide (MDP).[5][6] MDP is a component of 
peptidoglycan and can be found in the cell wall of most bacteria. Three polymorphisms (2 
missense mutations (R702W, G908R) and 1 frameshift mutation (1007fs)) have been 
independently associated with a higher susceptibility for CD.[2][3] The CARD15 protein is 
involved in NF-țB activation (via Rick/Rip2) and apoptosis by two N-terminal Caspase 
Activation and Recruitment Domains.[7] However, its exact role in CD is still unclear. Most 
functional data arose from transfection studies in vitro and pointed to a decreased NFțB
activation (most pronounced for the frameshift mutation) upon stimulation with 
MDP.[5][6][8] A number of ex vivo studies have been performed and confirmed a reduced 
pro-inflammatory activity, however predominantly focussing upon the rare 1007fs 
homozygous patients.[5][9][10]  
Besides, it is still unclear how a decreased NF-țB activation could match with an 
inflammatory condition, characterised by enhanced NF-țB activity. Several hypotheses have 
been postulated including compensatory activation of the adaptive immune system, yet 
unknown anti-inflammatory properties of the NF-țB pathway, a defect in apoptosis of 
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activated immune cells, differences in the epithelial barrier function (e.g. defensins) and 
impaired killing of intracellular/invasive microorganisms.[11]  
A Toll-like receptor 4 (TLR4) gene polymorphism (Asp299Gly) has recently been associated 
with IBD.[4] TLR4 is a membrane-bound PAMP receptor, belonging to the LPS 
(lipopolysaccharide)-signaling complex.[12][13] LPS can predominantly be found in the cell 
wall of Gram negative bacteria. Binding of TLR4 with its ligand also gives rise to NF-țB
activation, albeit via another pathway involving MyD88, IRAK, TRAF6. Transfection studies 
showed again a disturbed NF-țB activation.[14] However, in vivo this LPS 
hyporesponsiveness could only be confirmed in isolated monocytes of the extremely rare 
homozygous carriers of the TLR4 variant.[15][16][17]
The discovery of these CD-associated polymorphisms stressed the importance of enteric flora 
in the pathogenesis of IBD. In animals raised under germ-free conditions, no intestinal 
inflammation can be seen in experimental IBD models.[18] In human IBD, most lesions are 
found in parts of the gastrointestinal tract with the highest bacterial counts.[19] In addition, 
faecal stream diversion has a beneficiary effect on intestinal inflammation whereas re-
exposure with faecal material leads to relapse.[20][21] The use of antibiotics and probiotics in 
the management of IBD also points to a pivotal role for bacterial agents.[22] Moreover, 
differences in the bacterial composition of the faecal microflora between CD patients and 
healthy subjects have been shown.[23] Adherent-invasive Escherichia coli (AIEC), strains 
with particular adhesion and invasion characteristics, have been specifically associated with 
Crohn’s disease.[24][25]  These strains are mainly associated with early ileal lesions in CD 
patients, with a prevalence of 36.4%.[24]  AIEC are able to adhere in vitro to differentiated 
Caco-2 cells, a property that could enable them to colonize the intestinal mucosa.[25] 
Moreover, the AIEC LF82 strain has been proven to invade intestinal epithelial cells.[26] 
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Intracellular survival and even replication of this LF82 strain was also demonstrated in human 
macrophages without inducing host cell death.[27] 
The purpose of this study was to assess the relationship between the presence of CARD15
and/or TLR4 gene polymorphisms and the functional characteristics of peripheral blood 
monocytes in CD patients in response to stimulation with MDP, LPS and infection with 
AIEC.
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MATERIALS AND METHODS 
CARD15 AND TLR4 GENOTYPING
Genomic DNA was extracted from whole blood from 250 CD patients using Qiagen blood 
and cell culture DNA kit (Westburg BV, Leusden, The Netherlands). Genotyping for the 3 
CD-associated CARD15 polymorphisms R702W (SNP8), G908R (SNP12) and 1007fs 
(SNP13) was performed using RFLP-PCR, followed by separation of the DNA fragments on 
a 2.5% agarose gel. Table 1 shows the different CARD15 genotypes in this population. 
Remarkably, none of these 250 patients was homozygous for the 1007fs frameshift mutation. 
The TLR4 Asp299Gly polymorphism was assessed in 159 CD patients by direct sequencing 
of the PCR product in an ABI 3100 analyser (Applied Biosystems, Foster City, CA, USA). 
(forward primer: 5'-CCATTGAAGAATTCCGATTAGC-3’, reverse primer: 5'-ATG 
GTAATAACACCATTGAAGC-3’). Twenty-seven patients (17%) were heterozygous 
carriers of this TLR4 polymorphism. No homozygous carriers could be identified. 
MONOCYTE RESPONSE TO MDP, LPS AND INFECTION WITH AIEC 
Study population 
From this genotyped cohort of CD patients, a total of 40 patients (11 males, 29 females) with 
a mean age of 35 years (range 24-69y) were included for this part of the study. Mean age at 
diagnosis was 26 years (range 9-54y). Ten patients had ileal disease and 16 patients had 
ileocolonic disease, whereas 14 patients only had colonic involvement. Twenty-one patients 
never smoked whereas 7 patients were active smokers and 12 patients were ex-smokers. Mean 
Crohn’s disease activity index (CDAI) was 73 (range 0-253) with 7 patients having a CDAI 
above 150. Nine patients did not take any medication, 8 patients were on 5-ASA or 
sulfasalazine, 17 patients took azathioprine and 1 patient methotrexate whereas 5 patients 
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were on a combination of 5-ASA and azathioprine or methotrexate. The distribution of the 
different CARD15 and TLR4 genotypes in this cohort is shown in table 2. 
Isolation and stimulation of peripheral blood monocytes 
Peripheral blood monocytes were isolated using magnetic cell sorting (MACS) with the 
Human Monocyte Isolation Kit II (Miltenyi Biotec, Amsterdam, The Netherlands), according 
to the manufacturer’s instructions. In summary, the mononuclear cell (PBMC) fraction was 
isolated from 40 ml of venous blood using density gradient centrifugation with Ficoll-Pacque 
(Amersham Biosciences, Roosendaal, The Netherlands). PBMC were incubated with a 
cocktail of biotin-conjugated antibodies against CD3, CD7, CD16, CD19, CD56, CD123 and 
Glycophorin A (directed against T cells, NK cells, B cells, dendritic cells and basophils) for 
10 minutes at 4-8 °C, followed by an indirect magnetic labeling using Anti-Biotin Microbeads 
for 15 minutes at 4-8 °C. Applying this labeled cell suspension onto a MACS LS separation 
column resulted in the negative selection of a highly purified untouched monocyte population.  
The isolated monocytes were suspended at 10
6
 cells/ml in RPMI 1640 medium (Invitrogen, 
Merelbeke, Belgium) supplemented with 0.5% L-glutamine and 10% autologous serum and 
incubated 8 and 20 hours with culture medium (negative control), MDP 100 ng/ml (N-
acetylmuramyl-L-alanyl-D-isoglutamine, Calbiochem, Merck Biosciences Ltd, Nottingham, 
UK) or LPS 10 ng/ml (Ultra Pure E. coli K12 LPS, Invivogen, San Diego, USA). Since 100 
ng/ml MDP and 10 ng/ml LPS induced the highest TNFĮ mRNA induction after 2 hours of 
stimulation in a dose-response study, these concentrations were chosen in the present study. 
Using an E-TOXATE
®
LAL-test (Sigma-Aldrich, Bornem, Belgium), no detectable endotoxin 
contamination could be measured in the used MDP diluted to the working concentration. 
Infection with AIEC LF82 was performed with 10
7
 bacteria/ml (MOI 10) as described 
previously.[26] As this strain is not resistant to the complement found in the incubation 
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medium by the addition of autologous serum, no antibiotic was added during the infection 
period.[25] Cells were collected in RLT buffer (Qiagen Westburg, Leusden, The Netherlands) 
with 1% ȕ-mercapto-ethanol and stored at –80 °C until assayed. Supernatants were harvested 
and stored at –20 °C prior to analysis. 
Cytometric Bead Array immunoassay 
Concentrations of IL-1E, IL-6, IL-8, IL-10, IL-12p70 and TNFD in the culture supernatants 
were measured simultaneously using Cytometric Bead Array (CBA) (Human Inflammation 
Kit, Becton Dickinson (BD), Erembodegem, Belgium) according to the manufacturer’s 
instructions.  The BD CBA technique uses amplified fluorescence detection by flow 
cytometry to measure soluble analytes in a particle-based immuno-assay. Flow cytometric 
analysis was performed using a BD FACSscan. Data acquisition and analysis was performed 
using BD CBA software. Cytokine induction is calculated as the concentration of the cytokine 
in the culture medium after stimulation – the concentration in the culture medium of 
unstimulated monocytes. 
IL-8 ELISA 
IL-8 concentrations were assessed in duplo with a sandwich ELISA technique using the R&D 
DuoSet human IL-8 ELISA kit (R&D Systems, Abingdon, UK). The assay was run according 
to the manufacturer’s instructions.  
Quantitative Real Time – Polymerase Chain Reaction 
Total RNA from monocytes was isolated using RNeasy mini kit (Qiagen Westburg, Leusden, 
The Netherlands) according to the manufacturer’s instructions. Quantitative Real Time – 
Polymerase Chain Reaction (qRT-PCR) was used to measure mRNA induction of IL-1E, IL-6 
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and IL-10 using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for normalization. 
The quantitative PCR reaction was performed in duplo using the SYBR Green I qPCR Core 
Kit (Eurogentec, Seraing, Belgium). All reactions were run in the Biorad iCycler. Melt curve 
analysis confirmed primer specificities.  
MONOCYTE VIABILITY 
To assess the influences of infection with AIEC and CARD15 genotype on monocyte 
viability, lactate dehydrogenase (LDH) concentrations were measured in the supernatant of 
cultured monocytes of 4 CARD15 wild-type and 3 homozygous (2 snp8 and 1 snp12) CD 
patients. Quantification of the release of LDH is a widely accepted method to estimate the 
number of non-viable cells.[27] LDH was measured photometrically using the LDH 
Optimized kit (Roche Diagnostics, Mannheim, Germany) on an automated clinical chemistry 
analyzer following the manufacterer’s instructions.
BACTERIAL SURVIVAL AND REPLICATION IN MONOCYTES 
Survival and replication of AIEC within monocytes were measured using an adapted protocol 
of the previously described gentamicin protection assay.[27] Monocytes of 2 CARD15 wild-
type, 6 heterozygous (3 snp8, 3 snp13) and 2 homozygous (snp8) CD patients were isolated as 
described above and cultured at a concentration of 4 x 10
5
 cells/ml in RPMI 1640 medium 
supplemented with 0.5% L-glutamin and 10% heat-inactived autologous human serum. Heat-
inactivation was obtained by incubating the serum for 30 minutes at 55°C. The monocytes 
were infected and incubated with AIEC for 2 hours at 37°C with 5% CO2.  The cells were then 
washed twice with RPMI and fresh culture medium containing 100ȝg/ml gentamicin was 
added for an additional hour to kill extracellular bacteria. Subsequently the medium was 
removed and replaced by fresh RPMI medium containing 50ȝg/ml gentamicin for longer 
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postinfection periods. At several time points (0, 1, 4 and 24 hours) after gentamicin treatment, 
monocytes were washed and 0.5ml of Triton-X100 (Sigma-Aldrich, Bornem, Belgium) 1% in 
PBS was placed in each well for 10 minutes to lyse the eukaryotic cells. Samples were 
removed, diluted and plated onto Luria Bertani (LB) medium plates to determine the number 
of CFU recovered from the lysed monolayers. Survival was expressed as the percentage of the 
number of intracellular bacteria recovered after 1 hour postinfection (time point 0), defined as 
100%.
STATISTICAL ANALYSIS 
Comparison of cytokine induction and LDH concentration between wild-type patients and 
polymorphism carriers was performed using Mann-Whitney U test. Gene-dose effects 
(correlation of cytokine induction with the number of mutant alleles) were assessed using a 
Spearman’s rho test. Statistical significance was tested two-tailed. A P-value less than 0.05 
was considered to indicate statistical significance. 
Statistical analysis was performed using SPSS software (SPSS inc., Chicago, Illinois, USA). 
ETHICS APPROVAL 
The study was approved by the local Ethics Committee of the Ghent University Hospital. All 
patients signed an informed consent. 
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RESULTS
Monocyte responses to MDP, LPS and AIEC stimulation in the global CD population 
Very low to almost absent cytokine induction was seen in supernatant of unstimulated 
monocytes after 8 hours of culture, whereas gradually higher concentrations were measured 
after respectively MDP stimulation, LPS stimulation and infection with AIEC (Fig 1). The 
highest cytokine levels were found for IL-8, IL-1E, and IL-6, followed by TNFD and IL-10. 
IL-8 concentrations surmounted the upper detection limit of the CBA kit in the chosen 
dilution and were reassessed in a higher dilution using ELISA. IL-12p70 was almost 
undetectable after 8 hours, only a slight induction could be noticed after 20 hours of culture 
after AIEC infection. 
Cytokine induction according to patient characteristics 
There were no significant differences in cytokine production according to age, age at 
diagnosis, sex, disease location, smoking habit, disease activity (CDAI) and medication intake 
between wild-type patients and polymorphism carriers (data not shown). 
Cytokine induction according to CARD15/TLR4 genotype 
CARD15 polymorphisms 
Cytokine secretion 
In culture supernatants of unstimulated monocytes no differences in cytokine concentrations 
were found between CARD15 wild-types (n=18) and polymorphism carriers (n=22) (data not 
shown). An aberrant monocyte response was seen after 8 hours infection with AIEC (Fig 2). 
Monocytes of patients with CARD15 polymorphisms produced significantly less IL-1E
(P=0.01) and IL-6 (P=0.04). Also lower levels of IL-10 were found in these patients (P=0.05).
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No significant differences were found for IL-8 and TNFD. After 20 hours of stimulation this 
aberrant cytokine induction in response to AIEC infection was no longer notable. 
Differences in cytokine induction between both groups after 8 hours of stimulation with MDP 
were not statistically significant (Fig 3).  
No differences could be detected between the 3 different single nucleotide polymorphisms 
(SNPs) (data not shown). The detected differences in monocyte response could not be 
explained by differences in disease activity, medication intake or smoking habit (data not 
shown).
Cytokine mRNA induction 
Quantitative RT-PCR confirmed the lower production of IL-1E by monocytes of patients with 
CARD15 polymorphisms 8 hours after infection with AIEC (P=0.01), with a similar trend for 
IL-6 although not reaching statistical significance (P=0.1) (Fig 4). No significant differences 
were found for IL-10 at the mRNA level at 8 hours. 
Gene-dose effect 
IL-1E and IL-6 induction was significantly inversely correlated with the number of CARD15 
mutant alleles carried (Spearman’s rho IL-1E P<0.01, IL-6 P=0.02) (Fig 5). This gene-dose 
effect 8 hours after infection with AIEC in wild-types, heterozygotes and homozygotes was 
not observed for IL-10, IL-8 and TNFD. After MDP stimulation, no significant correlations 
could be found between the number of copies of CARD15 mutant alleles and cytokine 
induction (data not shown).
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TLR4 polymorphisms
Similar cytokine production was detected in unstimulated monocytes from patients with the 
TLR4 wild-type genotype (n=22) compared to heterozygous carriers (n=18) of the Asp299Gly 
variant. Also after stimulation with LPS or infection with AIEC, no significant differences 
could be found between both groups (Table 3).
There was also no difference in response to AIEC between patients carrying both a CARD15
and TLR4 polymorphisms as compared to patients with CARD15 polymorphisms alone (data 
not shown). 
Monocyte viability 
Infection with AIEC did not affect monocyte viability after 8 and 20 hours (figure 6). The 
mean LDH concentration in the supernatants of unstimulated monocytes did not differ 
significantly from those of monocytes infected with AIEC (after 8 hours of culture 
respectively 66.1 vs 62.5 U/l, P=0.9; after 24 hours of culture respectively 61.2 vs 56.6 U/l, 
P=0.7).
There were also no significant differences in LDH concentration after infection with AIEC 
between CARD15 wild-types and homozygotes after 8 hours (P=0.3) and 24 hours (P=0.6) of 
culture. 
Survival and replication of AIEC within monocytes 
The gentamicin protection assay showed that AIEC were able to survive and replicate within 
the isolated human monocytes (figure 7). After phagocytosis, there is a short period of 
bacterial replication within the cell, followed by a progressive clearance of the AIEC by the 
monocytes. We found however no differences in bacterial survival and replication between 
CARD15 wild-type patients, heterozygous or homozygous polymorphism carriers.  
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DISCUSSION 
This study demonstrates an altered early inflammatory response of monocytes, isolated from 
CD patients with CARD15 polymorphisms, after infection with CD-associated adherent-
invasive E coli. Infection with the LF82 AIEC strain resulted after 8 hours of infection in a 
decreased induction of IL-1E, IL-6 and IL-10. TNFD and IL-8 secretions in response to AIEC 
infection were not influenced by carriage of CARD15 variants. Only minimal secretion of IL-
12 was detected, merely measurable after 20 hours of infection, most probably due to the 
absence of IFNJ in these purified monocyte cultures. IFNJ normally provides a positive loop 
for IL-12 induction.[28][29][30] There were no differences between the 3 different SNPs but 
interestingly, a gene-dose effect was noted for IL-1E and IL-6.  
The reduced cytokine response could not be explained by differences in cellular viability 
since the levels of LDH measured in the supernatant of monocytes from wild-type patients 
and polymorphism carriers were similar. Moreover, this aberrant innate immune response 
towards AIEC seems to be an early phenomenon, since cytokine production is restored after 
20 hours. 
Association of CARD15 polymorphisms with Crohn’s disease is well known and the 
prevalence of these mutations in our CD population is similar to previous findings in the 
Flemish population.[31] Obvious is the very low prevalence of homozygosity (3.6%) with 
even a complete absence of homozygosity for the frameshift mutation in our tested 
population. The exact role of these polymorphisms in CD pathogenesis is still not fully 
understood. A defective MDP-mediated NFNB activation, suggestive for an altered bacterial 
sensing, has been shown in HEK293T cell transfectants.[5][6][8] This reduced NFNB
activation was confirmed twice in macrophages of NOD2
-/-
 mice, although one study of 
Maeda et al demonstrated the opposite in mice homozygous for a CARD15 insertion mutation 
similar to 1007fs.[32][33][34] In man, a similar impaired inflammatory response to MDP was 
124 | CHAPTER 5 
shown in isolated PBMC from patients homozygous for the 1007fs variant.[5][9][10] No 
functional implications of CARD15 polymorphisms have been described in single 
heterozygous carriers.
In this study, AIEC strain LF82 was used since this strain was previously associated with CD 
and can be found in high prevalences in the ileum of patients with Crohn’s disease.[24] AIEC 
strains are adherent to the mucosa and able to invade intestinal epithelial cells. Moreover, the 
LF82 strains can survive and replicate within host macrophages without inducing cell 
death.[26][27] By measuring LDH levels in the supernatant of cultured monocytes we also 
found a similar cell viability in non-infected monocytes and monocytes infected with AIEC.  
We found no significant differences in cytokine induction after MDP stimulation between 
CARD15 wild-types and polymorphism carriers. Previous studies demonstrating an aberrant 
inflammatory response towards MDP have been predominantly described in 1007fs 
homozygotes and no such patients were included in our study.[5][9] Due to the limited 
number of purified monocytes, we chose a single concentration of MDP (100 ng/ml) in this 
proof of principle study, based upon the highest TNFĮ response in a dose-response study. 
However, recent findings suggest that a lower dose of MDP (10 ng/ml) might be more 
suitable to detect differences between CARD15 wild-types and polymorphism 
carriers.[35][36]
Our findings reflect the importance of synergy between NOD2 and TLR immune 
responses.[37][38] Although a study of Watanabe et al pointed at NOD2 as a negative 
regulator of TLR2-mediated cytokine response, the theory of NOD2-TLR synergy was again 
confirmed by two recent studies from Van Heel et al showing a loss of synergistic effect in 
CARD15 homozygotes as compared to wild-types.[35][36][39] PBMC of homozygotes had a 
markedly lower cytokine production when stimulated with a combination of MDP with 
different TLR ligands. The altered immune response after infection with AIEC, reported in 
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our study, could not be detected after MDP stimulation which may support the importance of 
synergy between NOD2 and TLRs. In contrast to MDP alone, AIEC could indeed, being an 
enteroinvasive pathogen, stimulate immune cells through NOD2 and TLRs simultaneously.  
Our study might also help to explain the paradox of a decreased NFNB activation in CARD15
polymorphism carriers in CD. A lower induction of IL-10 but not TNFD, as found in our 
CARD15 polymorphism carriers, leads to a lower (and more inflammatory) IL-10:TNFD ratio. 
Netea et al found a similar change in IL-10:TNFD ratio after stimulation of PBMCs with heat-
killed Bacteroides in patients homozygous for the 1007fs variant.[9] Furthermore, due to a 
defective IL-1E and IL-6 release after phagocytosis of pathogens, a disturbed neutrophil 
activation and chemotaxis can, in combination with a defective secretion of antimicrobial 
defensins by Paneth cells, facilitate further entrance of bacteria into the mucosa.[40] It has 
been demonstrated that Nod2
-/-
 mice are more susceptible to invasion by Listeria
monocytogenes after intragastric challenge.[32] A prolonged survival of these invading 
bacteria in phagocytes in combination with a possible loss of apoptotic activity of these cells 
can also lead to the persistence of intracellular antigens and subsequently to a chronic 
inflammatory stimulus for other immune cells. Different bacterial antigens have been found in 
mucosa of Crohn’s disease patients using immunohistochemistry in a study by Liu et al.[41] 
Moreover, Hisamatsu et al demonstrated a higher survival of S. typhimurium in epithelial cell 
lines transfected with the 1007fs variant.[42] However, in our study we could not detect a 
difference in intracellular survival and replication of AIEC between CARD15 wild-types and 
polymorphism carriers. Whether the (early) altered immune response towards these bacteria, 
as found in the present pilot study, really has significant functional implications needs to be 
further investigated with studies including other cell types (e.g. macrophages, dendritic cells 
and epithelial cells). Further studies are also needed to clarify whether infection with other 
living (invasive) bacteria leads to a similar defective cytokine response. 
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Our study also shows that heterozygous carriership of the TLR4 polymorphism Asp299Gly 
does not influence monocyte response to LPS or AIEC, confirming previous ex-vivo
studies.[15][16][17] Besides, there is still controversy around the association of this variant 
with IBD. In 2004, this TLR4 gene polymorphism was associated with CD and ulcerative 
colitis (UC).[4] However, three other European studies could not fully confirm these 
associations. In a Scottish CD population no association could be found.[43] Török et al 
found a higher prevalence of this polymorphism in German UC patients but not in CD 
whether a recent Greek study demonstrated the opposite.[44][45]
In conclusion, monocytes of CD patients carrying CARD15 polymorphisms show a disturbed 
(early) inflammatory response after infection with adherent-invasive E coli. For the first time 
a functional defect seems to be detected in the most common CARD15 genotypes presently 
described in CD. These findings reflect the importance of an altered innate immune response 
to intracellular bacteria in the pathogenesis of CD. 
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FIGURE LEGENDS 
Fig 1. Cytokine secretion in the supernatant of monocytes of all CD patients (n=40) cultured 
for 8 hours without stimulus or in the presence of MDP, LPS or AIEC. IL1ȕ, IL6, IL10, 
TNFĮ and IL12p70 were assessed using CBA, IL8 using ELISA. 
Fig 2. Comparison of cytokine induction (mean ± SEM) between CARD15 wild-types (n=18) 
and polymorphism carriers (n=22) according to the duration of stimulation (8 or 20 hours 
infection with AIEC). Cytokine induction (ǻ) is defined as the concentration of the cytokine 
in the culture medium after stimulation with substraction of the concentration in the culture 
medium of unstimulated monocytes. Mann-Whitney U test: at 8 hours P=0.01 (IL1ȕ), P=0.04 
(IL6) and P=0.05 (IL10). 
wt: wild-type; mut: mutant 
Fig 3. Comparison of cytokine induction (mean ± SEM) in the supernatant of monocytes 
cultured for 8 hours in the presence of MDP between CARD15 wild-types (n=18) and 
polymorphism carriers (n=22). Cytokine induction (ǻ) is defined as the concentration of the 
cytokine in the culture medium after stimulation with substraction of the concentration in the 
culture medium of unstimulated monocytes. 
wt: wild-type; mut: mutant 
Fig 4. IL1ȕ, IL6 and IL10 mRNA induction (mean ± SEM) 8 hours after infection with AIEC.
Mann-Whitney U test: *P=0.01, ns
a
 P=0.1. 
Fig 5. Cytokine induction (mean ± SEM) in CARD15 wild-types (wt, n=18), heterozygotes 
(het, n=16) and homozygotes (homo, n=6) (8 hours after infection with AIEC). Cytokine 
induction (ǻ) is defined as the concentration of the cytokine in the culture medium after 
stimulation with substraction of the concentration in the culture medium of unstimulated 
monocytes. Spearman’s rho *P<0.01, **P=0.02. 
Fig 6. Concentration of LDH in the supernatant of cultured monocytes from CARD15 wild-
type (n=4) and homozygous (n=3) patients at 8 (a) and 20 (b) hours after infection with AIEC. 
unstim: unstimulated monocytes; AIEC: monocytes infected with AIEC 
Fig 7. AIEC survival and replication within monocytes. Results at 1, 4 and 24 hours after 1h 
of gentamicin treatment are expressed as the number of intracellular bacteria relative to that 
obtained at 1h of gentamicin treatment (time point 0) taken as 100%. 
 CHAPTER 5 | 133 
TABLES
Table 1. Different CARD15 genotypes in a population of 250 CD patients 
CARD15 genotype  
wt single heterozygous comp heterozygous homozygous total 
 snp8 snp12 snp13 snp8/12 snp8/13 snp12/13 snp8 snp12 snp13  
135 46 13 33 5 8 1 5 4 0 250 
54% 36.8% 5.6% 3.6% 100%
wt: wild-type; comp: compound; snp: single nucleotide polymorphism 
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Table 2. . Distribution of the different CARD15 and TLR4 genotypes in the study population 
(n=40) (number of patients). 
TLR4 CARD15
wild-type single heterozygous homozygous 
snp8 snp12 snp13 snp8 snp12 snp13
TLR4
wt 10 2 0 5 3 2 0 
TLR4
-/+ 8 4 2 3 0 1 0 
snp8 : R702W; snp12 : G908R; snp13 : 1007fs 
TLR4
wt
 : TLR4 wild-type 
TLR4
-/+
 : heterozygous TLR4 variant carrier 
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Table 3. Cytokine induction after 8 hours stimulation with LPS or AIEC strain LF82 
according to the presence of TLR4 polymorphisms  
LPS AIEC 
TLR4 wt TLR4 mut P-value TLR4 wt TLR4 mut P-value 
IL-1E 4805
± 862
4210
± 753
0.5 26504 
± 3538
23368
± 2869
0.5
IL-6 26553
± 1894
26953
± 1690
0.8 21937 
± 2824
26946
± 4163
0.6
IL-8 51050
± 6215
51677
± 5815
0.9 39391 
± 7438
58055
± 8466
0.2
IL-10 152
± 21
132
± 32
0.3 437 
± 78
364
±  90
0.5
TNFD 873
± 248
1448
± 387
0.2 5029 
± 1325
6229
± 1627
0.4
Cytokine induction after 8 hours of culture in pg/ml (mean conc ± SEM) 
Cytokine induction is calculated as the concentration of the cytokine in the culture medium 
after stimulation – the concentration in the culture medium of unstimulated monocytes. 
TLR4 wt : TLR4 wild-type patients; TLR4 mut : TLR4 polymorphism carriers 
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Figure 3
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Figure 4
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Figure 5
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Summary
Carriage of CARD15 gene polymorphisms and the serological marker anti-
Saccharomyces cerevisiae antibodies (ASCA) are two markers for Crohn’s dis-
ease (CD). Similar phenotypes have been associated with both markers. In the
present study we analysed whether both markers were associated with each
other and, if so, whether this association could be explained by a direct link or
by an indirect association with those phenotypes. Therefore, we included 156
consecutive Caucasian CD patients and assessed the prevalence of the three
common single nucleotide polymorphisms in the CARD15 gene. Serum sam-
ples were analysed for IgA and IgG ASCA by ELISA. CD patients with
CARD15 polymorphisms were more frequently ASCA positive (OR 2·7 (1.4–
5.2); P = 0·002) and had higher titres for ASCA IgA (P = 0·005) and ASCA IgG
(P < 0·001) compared to patients carrying the wild type polymorphisms. Mul-
tivariate analysis demonstrated that this association was independent from
ileal disease, penetrating disease and stricturing disease, the need for resective
bowel surgery, familial cases, smoking habits and early age at onset. Homozy-
gotes or compound heterozygotes for CARD15 polymorphisms had signiﬁ-
cantly more frequent ASCA positivity compared to single heterozygotes (OR
9·1 (1.1–74.2), Pc (corrected P-value) = 0·030). These data indicate that there
is a signiﬁcant association between the carriage of CARD15 polymorphisms
and ASCA, independent of the described phenotypes. Moreover, ASCA posi-
tivity is more frequent in CD patients carrying 2 CARD15 polymorphisms
compared to single heterozygotes.
Keywords: ASCA, CARD15, Crohn’s disease, caucasian, antibodies
Introduction
Although the exact pathogenesis of Crohn’s disease (CD)
remains unclear, it is well accepted that an impaired microbial
immune response, triggered by environmental and genetic
factors, is important [1–4]. Recently, 3 polymorphisms in the
CARD15 gene (two missense mutations (R702W and G908R)
and one frame shift mutation (1007fs)), were independently
associated with CD [5,6]. It has been estimated that heterozy-
gotes have a 3-fold risk to develop CD and homozygotes or
compound heterozygotes a 40-fold risk to develop the disease
[5,6]. Genotype-phenotype studies showed different possible
associations of these CARD15 polymorphisms with ileal and
stricturing disease [2,7–10], familial cases [11] and early
onset of disease [12].
Anti-Saccharomyces cerevisiae antibodies (ASCA) are
directed against the cell wall mannan of Saccharomyces cere-
visiae, commonly known as baker’s or brewer’s yeast [13].
ASCA are considered as a serological marker for CD. How-
ever, their pathophysiological role is not yet clear [14]. Sen-
sitivity and speciﬁcity of ASCA for CD range from 39% to
65% and 80% to 97·5% [15–18], respectively. Combinations
of ASCA with other serological markers as pANCA, I2 and
OmpC antibodies are under investigation to obtain a better
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serological diagnostic tool for IBD [19]. In CD patients,
ASCA are linked with earlier onset of disease [16], ileal
involvement, penetrating and stricturing disease and need
for resective bowel surgery [19–22]. One study also pointed
at a possible negative association with smoking behaviour
[23]. Previous family and twin studies already suggested a
genetic inﬂuence on ASCA formation. Indeed, family and
twin studies revealed that unaffected twins and unaffected
relatives have higher ASCA titres compared to healthy con-
trols [20,24–27]. The aim of the present study was to analyse
whether CARD15 and ASCA are related and if so, whether
this association can be explained by a direct link or an asso-
ciation by phenotypes.
Materials and methods
Study population and assessment of clinical 
characteristics
The study population consisted of 156 consecutive, Cauca-
sian CD patients (57 male, 99 female). The diagnosis of CD
was based on clinical, endoscopical, histological and/or
radiological ﬁndings. All patients were seen by a gastroen-
terologist. Family and personal medical history, onset of dis-
ease, localizations of inﬂammation, amount and types of
surgical interventions, history or current presence of ﬁstulae,
past and present intake of medication and smoking habits
were recorded. Familial Crohn’s disease was considered when
at least one ﬁrst, second or third degree relative also had a
proven Crohn’s disease. The speciﬁc anatomical localization
was based on documented areas of macroscopical and/or
microscopical inﬂammation and was subdivided into 3 cat-
egories: ileal, ileocolonic or colonic disease. Penetrating dis-
ease was deﬁned by the history or actual presence of ﬁstulae,
abscesses or perforations. Fistulae secondary to surgery were
excluded. Stricturing disease was considered in those
patients without ﬁstulae, who had radiological or surgical
evidence for stenosis.
Additionally, we tested ASCA in 188 controls including 24
osteoarthritis patients, 56 rheumatoid arthritis patients and
108 blood donors of whom 87 could also be typed for
CARD15 variants.
Detection of ASCA by ELISA
The Medizym ASCA kits (Medipan Diagnostica, Germany)
were used. Tests were performed according to instructions
from the manufacturer, including the use of cut-offs that
were determined at 20 U/ml for both IgA and IgG ASCA.
Brieﬂy, serum was diluted 1 : 50 and applied to the microtitre
plates (100 ml/well), coated with cell wall mannan from a
mixture of different Saccharomyces strains. The plates were
incubated for one hour at 37∞C. To remove unbound serum
components, plates were washed ﬁve times. Consequently
100 ml of conjugate, speciﬁc for either IgG of IgA, coupled
with horseradish peroxidase was added, followed by an incu-
bation period of 30 min at 37∞C. The plates were washed
again ﬁve times, after which substrate was added (3,3¢,5,5¢-
tetramethylbenzidine in citrate buffer containing hydrogen
peroxide). Plates were incubated in the dark at room tem-
perature for 10 min. The reaction was stopped using a stop
solution containing sulphuric acid, turning the colour of the
solution from blue to yellow. Plates were read at a wavelength
of 450 nm.
ASCA IgG and IgA levels were determined using a stan-
dard curve, for which the manufacturer supplied calibrators.
Study personnel were blinded for diagnosis during these
assays. Each sample was tested in duplo and 2 positive con-
trol samples were run on each plate. The mean values for the
IgG-samples were 60 U/ml and 29 U/ml with a coefﬁcient of
variation (CV%) of 2% and 4·5%, respectively. The mean
values for the ASCA IgA samples were 18 U/ml and 28 U/ml
with a CV% of 6·9% and 5·6%, respectively. The mean CV%
between duplo’s of all samples was 3·15% for ASCA IgA and
4·23% for ASCA IgG. Unless otherwise speciﬁed, ASCA were
considered positive when either ASCA IgA or IgG was
positive.
Genotyping of R702W, G908R and 1007fs and 
sequencing
Genomic DNA was extracted from whole blood using
Qiagen blood and cell culture DNA kit (Qiagen, Germany).
All patients were genotyped for R702W, G908R and 1007fs
using a RFLP-PCR technique, followed by separation on
2·5% agarose gel. The missense mutation R702W (GenBank
accession number G67950) abolishes the restriction site for
MspI (5¢-CAGCCCTGATGACATTTCTCTT-3¢ and 5¢-AGC
CGCTCCTCCTGCATCTCGTA-3¢), resulting in an intact
130-bp band for mutant alleles compared to two bands of
54- and 76-bp for wild type alleles. The missense mutation
G908R (GenBank accession number G67951) creates a
restriction site for HinP1l. The frame shift mutation 1007fs
(GenBank accession number G67955) creates a restriction
site for NlaIV (5¢-CTGAGCCTTTGTTGATGAGC-3¢ and 5¢-
TCTTCCAACCACATCCCCATT-3¢). The presence of a
mutant allele results in two bands of 219 and 41 base pairs,
while the wild type allele produces a single 260-bp product.
Statistical analysis
Statistical analysis was performed using SPSS software (SPSS
inc., Chicago, Illinois, USA). Groups were compared with
Mann–Whitney U-test because normality was not achieved.
Dichotomous data were analysed using Pearson’s c2 test or
with Fisher’s exact test when the expected count was less than
ﬁve in at least one cell. Odds ratios were calculated with their
corresponding 95% conﬁdence interval (CI). When indi-
cated, a corrected P-value (Pc) was calculated using Bonfer-
roni’s correction. We also calculated conditional odds ratios
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and their corresponding 95% CI by binary logistic
regression.
Ethics
The study was approved by the local ethics committee. All
patients gave written informed consent.
Results
Patients characteristics
Thirty-eight patients had ileal disease, 79 patients had ileo-
colonic disease and 39 patients had only colonic involve-
ment. Seventy-three patients needed resective small bowel
surgery, 92 patients had penetrating disease and 33 patients
had stricturing disease. Thirty patients had at least one
affected relative. Forty patients were ex-smokers and 44
patients smoked at the time of evaluation. Mean age was
38 years (range 18–80 years) and mean age at diagnosis was
27 years (range 9–66 years). In 48 patients, onset of disease
was before the age of 20.
Prevalence of CARD15 mutations
Seventy-seven (49·3%) of 156 CD patients carried CARD15
polymorphisms. Forty-three CD patients carried at least
one R702W polymorphism, 14 patients carried at least one
G908R polymorphism and 27 patients carried at least one
1007fs polymorphism. Fourteen patients carried two poly-
morphisms of which 7 patients were homozygous and 7
patients compound heterozygous (Table 1). In a local control
population, 19/87 (21·8%) controls carried at least one
CARD15 variant.
Prevalence of ASCA positivity
Eighty-two (52·6%) CD patients were ASCA positive, 71
(45·5%) patients had ASCA IgA and 57 (36·5%) patients
ASCA IgG. In a control population, 5/188 (2·6%) tested pos-
itive for ASCA (3/24 OA patients, 0/56 RA patients and 2/108
blood donors), confriming the high speciﬁcity of the test.
Only 1/87 controls who were typed for CARD15 polymor-
phisms had ASCA. This control carried the 1007fs CARD15
polymorphism.
Univariate analysis of association between CARD15
genotype and ASCA positivity
Fifty of 77 (64·9%) carriers of CARD15 polymorphisms had
positive ASCA IgA or IgG, in contrast to 32 (40·5%) of 79
wild type patients (OR 2·7; 95% CI (1.4–5.2), P = 0·002).
Forty-four (57·1%) of 77 carriers of CARD15 polymor-
phisms were positive for ASCA IgA versus 27 of (34·2%) 79
wild type patients (OR 2·87; 95% CI (1.49–5.50), P = 0·004)
and 37 (48·1%) of 77 carriers tested positive for ASCA IgG
versus 20 (25·3%) of 79 wild type patients (OR 2·7; 95% CI
(1.4–5.4), P = 0·003) (Table 2).
Carriage of 1 versus 2 CARD15 polymorphisms and 
ASCA positivity
Carriers of 2 CARD15 polymorphisms were more frequently
ASCA positive compared to patients who carried only 1
polymorphism: 13 (93%) of 14 patients who carried 2
CARD15 variants were ASCA positive compared to 37
(58·7%) of 63 carriers of 1 polymorphism (OR 9·135, 95%
CI (1.1–74.2), P = 0·015, Pc = 0·030). When looking at ASCA
IgA and ASCA IgG separately, we could again ﬁnd higher
prevalences of ASCA IgA or ASCA IgG in those patients who
Table 1. Number of patients carrying R702W, G908R or 1007fs 
polymorphisms.
CD patients (n = 156)
n (%) 
R702W heterozygotes 33 (21·3%)
G908R heterozygotes 9 (5·8%)
1007fs heterozygotes 21 (13·5%)
R702W homozygotes 4 (2·6%)
G908R homozygotes 3 (1·9%)
R702W + G908R compound heterozygotes 1 (0·6%)
G908R + 1007fs compound heterozygotes 1 (0·6%)
R702W + 1007fs compound heterozygotes 5 (3·2%)
Number of CD patients carrying the different CARD15 polymor-
phisms. There were no patients homozygous for 1007fs.
Table 2. ASCA status in relation to the carriage of CARD15 polymorphisms.
ASCA positivity (IgA or IgG) ASCA IgA positive ASCA IgG positive
Carriage of CARD15 polymorphisms
No 32 (40·5%) P = 0·002 27 (34·2%) P = 0·004 20 (25·3%) P = 0·003
Yes 50 (64·9%) 44 (57·1%) 37 (48·1%)
Total 82 (52·6%) 71 (45·5%) 57 (36·5%)
ASCA positivity for ASCA IgA or IgG, ASCA positivity for ASCA IgA and ASCA positivity for ASCA IgG in relation to the carriage of CARD15
polymorphisms.
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ASCA. The fact that data on a possible association between
carriage of CARD15 polymorphisms and ASCA are so dis-
parate might be explained by differences in environmental
factors and different genetic backgrounds. Associations
between genetic markers and serologic markers have previ-
ously been described for several diseases. In insulin depen-
dent diabetes, disease associated autoantibodies are
associated with susceptibility HLA class II alleles [30]. Coe-
liac associated antibodies can identify healthy ﬁrst-degree
relatives who express coeliac associated HLA haplotypes
[31]. In rheumatoid arthritis, rheumatoid factor is associ-
ated with the HLA shared epitope and the -2849 IL-10 pro-
moter polymorphism [32,33]. Carriage of different HLA
class II alleles is associated with a speciﬁc antibody response
to nuclear antigens, in particular anti-SSA/Ro52, both in pri-
mary Sjögren’s syndrome and lupus [34,35] and may be
more strongly associated with the antibody subsets than with
the disease status itself [36]. Other nuclear antibodies (anti-
SSB/La), associated with HLA class II genes, have also
recently been linked with carriage of polymorphisms in the
genes for transforming growth factor b and tumour necrosis
factor a in patients with primary Sjögren’s syndrome [37].
Different hypotheses can be generated to explain how the
carriage of different HLA types or different gene polymor-
phisms on the promoters of cytokines, might inﬂuence anti-
body responses [33,35]. How the different polymorphisms
on the CARD15 gene are involved in the antibody response
against mannan from Saccharomyces cerevisiae is still unclear.
The CARD15 gene encodes for the Nod2/CARD15 protein, a
member of the Apaf-1/Ced-4 family of apoptosis regulators
and an intracellular protein expressed in monocytes, mac-
rophages, epithelial cells, granulocytes and dendritic cells.
Nod2 activates the NF-kB pathway after stimulation by bac-
terial products. Initial reports suggested lipopolysaccharide
as a possible ligand for Nod2, but recently, 2 independent
groups highlighted muramyl dipeptide as the major activa-
tor of the Nod2-receptor [6,38–41]. The activation of the
NF-kB–pathway is followed by an enhanced production and
secretion of proinﬂammatory cytokines [42].
It has been suggested that the described polymorphisms
in the CARD15 gene give rise to an impaired NF-kB activa-
tion by a deﬁcient recognition of microbial antigens. This
might result in an impaired killing of intracellular microbes,
which leads to inﬂammation [38,40]. Whether ASCA is just
a side-effect of this inﬂammation or whether ASCA have
themselves a pathological role by cross-reactivity with self-
antigens in human gut or other tissues is still unknown
[43].
In conclusion, our data suggest that there is an association
between the presence of CARD15 gene polymorphisms and
the serological marker ASCA in a West-European CD popu-
lation. This could be interpreted in a double way. CARD15,
as an immune response gene, may modulate in some way
humoral immunity predisposing to the generation of ASCA.
Or, carriage of CARD15 polymorphisms and ASCA may be
both associated with a particular, as yet undeﬁned, pheno-
typical subset of CD. However, we proved in the present
study that the association between carriage of CARD15 poly-
morphisms and ASCA could not be explained by an indirect
link with the common CARD15 and ASCA related
phenotypes.
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ASCA. The fact that data on a possible association between
carriage of CARD15 polymorphisms and ASCA are so dis-
parate might be explained by differences in environmental
factors and different genetic backgrounds. Associations
between genetic markers and serologic markers have previ-
ously been described for several diseases. In insulin depen-
dent diabetes, disease associated autoantibodies are
associated with susceptibility HLA class II alleles [30]. Coe-
liac associated antibodies can identify healthy ﬁrst-degree
relatives who express coeliac associated HLA haplotypes
[31]. In rheumatoid arthritis, rheumatoid factor is associ-
ated with the HLA shared epitope and the -2849 IL-10 pro-
moter polymorphism [32,33]. Carriage of different HLA
class II alleles is associated with a speciﬁc antibody response
to nuclear antigens, in particular anti-SSA/Ro52, both in pri-
mary Sjögren’s syndrome and lupus [34,35] and may be
more strongly associated with the antibody subsets than with
the disease status itself [36]. Other nuclear antibodies (anti-
SSB/La), associated with HLA class II genes, have also
recently been linked with carriage of polymorphisms in the
genes for transforming growth factor b and tumour necrosis
factor a in patients with primary Sjögren’s syndrome [37].
Different hypotheses can be generated to explain how the
carriage of different HLA types or different gene polymor-
phisms on the promoters of cytokines, might inﬂuence anti-
body responses [33,35]. How the different polymorphisms
on the CARD15 gene are involved in the antibody response
against mannan from Saccharomyces cerevisiae is still unclear.
The CARD15 gene encodes for the Nod2/CARD15 protein, a
member of the Apaf-1/Ced-4 family of apoptosis regulators
and an intracellular protein expressed in monocytes, mac-
rophages, epithelial cells, granulocytes and dendritic cells.
Nod2 activates the NF-kB pathway after stimulation by bac-
terial products. Initial reports suggested lipopolysaccharide
as a possible ligand for Nod2, but recently, 2 independent
groups highlighted muramyl dipeptide as the major activa-
tor of the Nod2-receptor [6,38–41]. The activation of the
NF-kB–pathway is followed by an enhanced production and
secretion of proinﬂammatory cytokines [42].
It has been suggested that the described polymorphisms
in the CARD15 gene give rise to an impaired NF-kB activa-
tion by a deﬁcient recognition of microbial antigens. This
might result in an impaired killing of intracellular microbes,
which leads to inﬂammation [38,40]. Whether ASCA is just
a side-effect of this inﬂammation or whether ASCA have
themselves a pathological role by cross-reactivity with self-
antigens in human gut or other tissues is still unknown
[43].
In conclusion, our data suggest that there is an association
between the presence of CARD15 gene polymorphisms and
the serological marker ASCA in a West-European CD popu-
lation. This could be interpreted in a double way. CARD15,
as an immune response gene, may modulate in some way
humoral immunity predisposing to the generation of ASCA.
Or, carriage of CARD15 polymorphisms and ASCA may be
both associated with a particular, as yet undeﬁned, pheno-
typical subset of CD. However, we proved in the present
study that the association between carriage of CARD15 poly-
morphisms and ASCA could not be explained by an indirect
link with the common CARD15 and ASCA related
phenotypes.
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ABSTRACT  
Background & aims: Crohn’s disease (CD) is a multifactorial disorder involving both genetic 
and environmental factors. This study aimed at identifying and characterizing new candidate 
susceptibility genes for CD by integrating known disease loci with gene expression variation 
in non-inflamed colon biopsies of CD patients. 
Methods: Sixteen CD patients and 11 controls were subjected to microarray analysis. 
Expression of metallothionein (MT) was analyzed in intestine and blood by quantitative PCR 
and immunohistochemistry. MT-knockdown HT29 cells were generated by small interfering 
RNA. MT1M, and its transcriptional regulator MRE-binding transcription factor 1 (MTF1),
were screened for mutations by sequencing. 
Results: Eighteen differentially expressed baseline genes were identified. We focused on the 
reduced expression of MT in intestine and blood of CD patients with colonic involvement. 
We showed that MT induction was not impaired in these patients. To model lowered MT 
expression in epithelial cells, we created MT-knockdown HT29 cells. These showed a 
reduced IL8 secretion in response to bacterial challenge, suggesting deficient inflammatory 
responses in the CD colon. No mutations were found in MT1M exons and its promoter region. 
A polymorphism in MTF1 (IVS1-128A>T) was associated with disease location. Gene-gene 
interaction of MTF1 and CARD15 predisposes individuals to a high risk for ileal disease. 
Conclusions: Combining microarray screening with genetic linkage data is an effective tool 
for identifying novel candidate susceptibility genes. We showed that deficient basal MT 
expression in CD patients with colonic involvement is genetically determined. The IVS1-
128A>T polymorphism in MTF1 is linked to disease location and serves as a new disease-
modifying gene.
 CHAPTER 8 | 177 
INTRODUCTION
The strong influence of genetic determinants in Crohn’s disease (CD, MIM 266600) has been 
shown by familial clustering, and by the high concordance rate in monogenic twins. First-
degree relatives of affected individuals show a 20 to 50-fold higher risk for developing CD. 
Moreover, affected siblings frequently develop the disease at similar ages, and concordance 
rates reach 80% for disease site, behaviour and presence of extra-intestinal manifestations
1, 2
.
The mode of inheritance of CD is complex, and the number of genes predisposing to CD or 
modifying its course is currently unknown. However, it is not expected that a single risk gene 
is sufficient for disease development.  
Two complementary approaches are used to identify determinants underlying genetically 
complex traits such as CD: candidate gene association studies and genetic linkage. In the 
candidate gene approach, genes that might be involved are screened for polymorphisms in a 
limited number of patients, and then frequencies in large populations of patients and controls 
are compared. In genetic linkage, candidate regions are identified by scanning the entire 
chromosome with microsatellite markers. These so-called disease loci can rarely be narrowed 
down to less than a few megabases. Nevertheless, if the candidate region contains a 
manageable number of genes, a candidate gene is chosen on the basis of a known property, 
e.g. function or tissue-specific expression. Unfortunately, mapping CD loci is hampered by 
phenotypic variability, genetic heterogeneity across populations, uncontrolled environmental 
influences, reduced penetrance, and limited statistical power in such studies. Nevertheless, 
several CD loci have been corroborated by more than one independent study. The most 
frequently identified locus for CD is 16q12 (IBD1), which led to the mapping of the first gene 
to be firmly associated with CD, called CARD15
3, 4
. Today, there is evidence for more than 20 
loci, but the identity of the causative genes remains largely unknown
5
. In addition, success in 
finding susceptibility genes has been limited by the modest effect of individual genes on the 
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complex phenotype. 
We applied a complementary approach to identify new potential susceptibility genes. Because 
much of the variation in gene expression is genetically transmitted
6
,  we evaluated variation of 
gene expression in unaffected biopsies from CD patients, and combined these results with 
known linkage data. For this purpose, we looked at gene expression in biopsies taken from 
non-inflamed regions of the colon from CD patients and healthy controls. We selected genes 
that show variation in baseline expression and that are also located near a locus for CD. We 
focused on characterizing one of the candidate genes, metallothionein (MT), and the 
consequences of its altered expression. This led to the identification of a new disease-
modifying gene, MTF1, located at 1p33 (IBD7).
MATERIALS AND METHODS 
Patients and biopsies. CD was diagnosed according to clinical, endoscopic and histological 
criteria. Patients were classified according to the Vienna classification
7
. Disease location, 
however, was defined as the maximal spread of inflammation during the entire follow-up. We 
thus defined three subgroups: pure colonic involvement (C), both ileal and colonic 
involvement (IC), and ileal involvement only (I). For RNA extraction, 3 colon biopsies from 
each of 54 CD patients and 30 controls were collected during colonoscopy. All biopsies were 
taken from endoscopically normal regions of the sigmoid, immediately placed in RNAlater 
(Ambion, Cambridgeshire, UK) and stored at -80°C.  For immunohistochemical analysis, 
colon biopsies were collected from 22 CD patients and 8 controls. Additional ileal biopsies 
were collected from 12 CD patients and 8 controls. Biopsy specimens were immersed in 4% 
formalin (Labonord, France).  
 RNA extraction. Total RNA was extracted from biopsies using the RNeasy Mini Kit (Qiagen, 
Westburg BV, The Netherlands) with on-column DNAse treatment (Qiagen). Needle 
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homogenization was performed. The quality of RNA used for microarray analysis was 
checked on the Agilent 2100 Bioanalyzer (Agilent Technologies, Germany). Total RNA from 
3 ml of whole blood was extracted using the RNeasy Midi Kit (Qiagen) following lysis of red 
blood cells with erythrocyte lysis buffer (Qiagen). Concentration and purity (ratio 
OD260/OD280 between 1.8 and 2.2) of the RNA used for quantitative real-time PCR was 
checked on a spectrophotometer (UV-1601, Shimadzu Benelux, Belgium). 
Microarray hybridization, scanning and analysis. The construction of the focus microarray 
chip, containing 6,779 expressed sequence tags and specifically designed for the study of 
colonic gene expression, has been described
8
. Total RNA (5 µg) was amplified using a 
modified protocol for in vitro transcription
9
. Probe labelling, hybridization, washing and 
scanning were carried out at the MicroArray Facility (MAF, Leuven, Belgium) of the 
Flanders Interuniversity Institute for Biotechnology (VIB) as described on 
http://www.microarrays.be/service.htm. Images were analyzed with ArrayVision (Imaging 
Research Inc., Canada). Each hybridization was repeated in a dye swap experiment. Spot 
intensities were measured, corrected for local background, and those that exceeded the 
background by more than two standard deviations (SD) were included in the analysis. For 
each gene, ratios of red (Cy-5) to green (Cy-3) intensities (I) were calculated and normalized 
via a Lowess Fit of the log2 ratios [log2(ICy-5 / ICy-3)] over the log2 total intensity [log2(ICy-
5 × ICy-3)].
A mixture of RNA from 5 CD patients, 5 non-CD inflammatory controls and 5 healthy 
controls served as reference RNA for comparison of the microarray datasets. This reference 
sample provides a positive hybridization signal at each probe element on the microarray, 
which is essential when calculating and comparing fluorescence ratios. The data were 
imported into GeneMaths

 XT (Applied Maths, Belgium). Weighted mean ratios and their 
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corresponding error (pixel SD) were calculated from the dye swap. Data were normalized 
over all arrays, and missing values were imputed using k-nearest neighbour algorithm (20 
neighbours). GeneMaths

 XT was used to perform all subsequent analyses.   
Quantitative real-time PCR (qPCR). One Pg of total RNA was converted to single stranded 
complementary DNA (cDNA) by reverse transcription (Superscript, Gibco, Invitrogen, 
Belgium) with oligo dT priming. One tenth of the cDNA was used in real-time quantification 
using the SYBR green kit (Eurogentec, Belgium) and 300 nM of each primer. A two-step 
program was run on the iCycler (BioRad Laboratories, Belgium). Cycling conditions were 
95°C for 10 minutes and 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. Melting 
curve analysis and direct sequencing of amplicons on the ABI3700 analyzer (Perkin Elmer, 
Applied Biosystems, Belgium) confirmed primer specificities. All reactions were run in 
duplicate and normalized to glyceraldehyde phosphate dehydrogenase (GAPDH) levels. 
GAPDH was chosen after checking the expression stability of a set of housekeeping genes in 
biopsies of CD patients and controls using the Genorm software
10
. Primers were designed 
using the Beacon Designer software (PREMIER Biosoft International, USA). Sequences of all 
primer sets are listed in Table 1. 
Immunohistochemistry. Colon and ileum biopsies fixed in formalin were embedded in 
paraffin according to standard procedures. Sections were rehydrated by serial immersion in 
xylene and ethanol. Immunostaining was performed on a NexES IHC automated staining 
system (Ventana Medical Systems, France) using a 1:10 dilution of a mouse monoclonal anti-
metallothionein antibody (clone E9, Zymed Laboratories, Sanbio, The Netherlands). An 
isotype-specific irrelevant antibody (X0931, DakoCytomation, Belgium) was used to control 
for non-specific binding of the primary antibody. Slides were blindly scored by two 
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pathologists. Semi-quantitative scoring was based on staining intensity and the number of 
positive cells. 
Induction assays. The mononuclear cell fraction (PBMC) was isolated from 30 ml of venous 
blood by density gradient centrifugation in Ficoll-Pacque (Amersham Biosciences, The 
Netherlands). PBMCs were seeded in 6-well plates at 10
6
 cells per well in RPMI medium 
(Gibco, Invitrogen) supplemented with 10% FCS. The next day, they were stimulated with 
200 PM ZnSO4 (Sigma, Belgium), 2 PM dexamethasone (Sigma), 10 ng/ml recombinant 
human IL6 (Peprotech, Campro Scientific, The Netherlands), 1000 U/ml human recombinant 
TNF(produced in-house) or 200 U/ml human recombinant IFNJ(Biosource Europe, 
Belgium) The cells were lysed in 350 Pl RLT buffer (Qiagen) after 3, 6 or 24 hours. To 
induce oxidative stress, PBMCs were incubated with 100 PM H2O2 (Sigma), which was 
washed off with PBS after 10 minutes. Cells were lysed after 2, 4 or 6 hours. Total RNA was 
isolated using the Rneasy Mini Kit (Qiagen), and converted to cDNA for subsequent qPCR. 
Normalized Ct values were corrected for background at each time point (e.g. dCt induced, t1 - dCt 
un-induced, t1), and plotted against time (0, 3, 6 and 24 hours, or 0, 2, 4 and 6 hours for H2O2). 
Induction was calculated as the area under the curve (AUC) for the three time points (AUCs 
are shaped as triangles and rectangles, and their summation or integration gives the same 
result):
AUC = 
0

3
(m1.x)dx + 
3

6
(m2.x + b)dx +
6

24
(m3.x + c)dx, 
where m1 = the slope of the 0-3 line, m2 = the slope of the 3-6 line, m3 = the slope of the 6-
24 line, b = the y-intercept of the 3-6 line, and c =  the y-intercept of the 6-24 line. 
HT29 human colon epithelial cells (American Type Culture Collection (ATTC) HTB38) and 
MT-knockdown cells (HT29MTkd) were seeded in 24-well plates at 10
6
 cells per well in 
RPMI supplemented with 10% FCS. The following day, cells were infected in triplicate at 
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multiplicities of infection (MOI) of 100 with adherent-invasive Escherichia coli strain LF82, 
isolated from a patient with CD, (a gift from A. Darfeuille-Michaud)
11
 for 1 hour, followed by 
gentamycin treatment (100 Pg/ml) for 1 hour. Supernatants were collected after 8, 24 and 48 
hours of infection/induction. 
Small interfering RNA (siRNA). The short hairpin RNA (shRNA) fused to an H1 promoter 
was synthesized by PCR on the pSUPER vector (Tronolab, Switzerland), using primers: 5’-
CAA TCT CTT GAA TTG CAC TTG CAG GAG CCG GGG GGA TCT GTG GTC TCA 
TAC AGA ACT TAT AA-3’ and 5’-CCA TCG ATT TCC AAA AAC CGG CTC CTG CAA 
GTG CAA TCT CTT GAA TTG C-3’. The sequence in bold is a 19-mer that specifically 
targets MT, and is present in MT1B, MT1E, MT1H, MT1J and MT1M. The PCR fragment 
was cloned in pLVTH-siGFP (Tronolab, Switzerland). To produce virus for delivery of the 
shRNA, HEK293T cells (ATCC CRL1573) were transfected by the calcium phosphate 
method with 3 Pg pCMV-d8.91 (Tronolab, Switzerland), 1.5 Pg PMDG2 (Tronolab, 
Switzerland) and 1.5 Pg of the shRNA construct. After 48 hours, supernatant containing viral 
particles was harvested, and put through a 0.45 Pm filter. One day before viral transduction, 
HT29 cells were seeded at 5x10
4
 cells per well in a 24-well plate. They were overlaid with 
viral supernatant, and centrifuged for 1 hour at 32°C. This procedure was repeated with 72-
hour viral supernatant. Cells expressing high levels of GFP were subsequently sorted with the 
EPICS altra cell sorter (Beckman Coulter, The Netherlands).
Cytometric Bead Array immunoassay. Concentrations of IL1E, IL6, IL8, IL10, IL12p70 
and TNF in the culture supernatants were measured simultaneously using Cytometric Bead 
Array (CBA) (Human Inflammation Kit, Pharmingen, Becton Dickinson, Belgium) according 
to the manufacturer’s instructions.  Concentrations of the cytokines were obtained by 
 CHAPTER 8 | 183 
comparing the mean fluorescence intensity of the samples with that of the corresponding 
standard curves. Flow cytometric analysis was performed using a BD FACS scan. Data 
acquisition and analysis was done using BD CBA software. 
IL8 ELISA. IL8 concentrations in supernatants were assessed in dilution series by sandwich 
ELISA. Microtiter plates (Nunc, USA) were coated with 2 Pg/ml anti-IL8 antibody 
(Pharmingen) in PBS for 2 hours at RT, and non-specific binding sites were blocked with 
0.1% casein-PBS at 4°C overnight. Dilution series of the supernatant (1:2) were incubated for 
2 hours at RT in 0.1% casein-PBS, and detected with 1:1000 biotinylated anti-IL8 antibody 
(Pharmingen) and 1:500 streptavidin-HRP (Pharmingen) in 0.1% casein-PBS for 1 hour. 
Substrate was added and the reaction was stopped after 30 minutes with 1 M H2SO4. Plates 
were read at 450 and 595 nm in a microplate reader (BioRad).  
Mutation screening of MT1M and MTF1. Genomic DNA was extracted from whole blood 
using the Qiagen blood and cell culture DNA kit. The sequence encompassing the MT1M
gene and ~600 bases upstream of the transcription start site was PCR-amplified in 25 
randomly selected CD patients and 6 controls (forward primer: 5’-GAG GCC GAC CAG 
TGT TC-3’, reverse primer: 5’-AGT CTC TGG ATG AAA ATG TGA G-3’). The PCR 
product was sequenced with BigDye Terminator v3.1 Cycle Sequencing kit and analyzed on 
an ABI3700 analyzer (Applied Biosystems) with the former and the following primers: exon 
1: 5’-CCC AGC CCA GCC CAG GAC CG-3’; exon 2: 5’-TCA CTG CCC ACT GCG TTT 
TTC TC-3’; exon 3: 5’-CAA GTC TAC TGC TAC CTC TC-3’. 
Mutation analysis of MTF1 was performed in 95 randomly selected CD patients using 
flanking intronic primers for all exons and overlapping primers for 1 kb of the upstream 
regulatory region.  PCR primers were designed using the SNPbox software
12
. A total of 28 
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primer sets were used (primer sequences are available on request). PCR fragments were 
sequenced with BigDye Terminator v3.1 Cycle Sequencing kit (Perkin-Elmer, Applied 
Biosystems), and analyzed on an ABI3730 DNA analyzer (Applied Biosystems). The 
sequencing trace files were analyzed for the presence of variants using novoSNP
13
.
CARD15 and MTF1 genotyping. The 3 CD-associated CARD15 polymorphisms R702W 
(SNP8), G908R (SNP12) and 1007fs (SNP13), as well as MTF1 IVS1-128A>T, were 
genotyped in a cohort of 222 randomly selected CD patients and 63 controls using RFLP-PCR 
as previously described
14
. MTF1 IVS1-128A>T genotyping was also done by RFLP-PCR. A 
fragment containing the polymorphism was amplified with the following primers: forward 5’-
TAA GAC TCA ATT GAT TCA GGG ACG AGA GC-3’, reverse 5’-CAG TTG TGA GAA 
ATG AAA ACG TAA TGA C-3’. The PCR product was precipitated with SeeDNA 
(Amersham Biosciences), digested with DraI, and restriction fragments were analyzed on a 
2% agarose gel. The presence of the IVS1-128T allele abolishes a DraI site, resulting in a 
band of 271 bp, instead of 251 bp in the presence of the IVS1-128A allele.
Statistical analysis. Statistical analyses were performed using SPSS software (SPSS inc., 
USA). Differences between groups in immunohistochemical scores and induction AUCs were 
calculated using the Mann-Whitney U test. Correlations between metric data were calculated 
using Pearson’s Rho, and those between rank data with Spearman’s Rho. Rank data for 
histological scores were 0-1 = 1, 1-2 = 2, 2-3 = 3 and for RNA levels <1,000 = 1, 1,000-
10,000 = 2, >10,000 = 3. Odds ratios and their 95% confidence intervals (CI) were calculated 
with Pearson’s F² test. Logistic regression was used to evaluate independence and interaction 
between parameters. Significance of differences in ELISA IL8 concentrations between time-
series were calculated using a general linear model, error bars are calculated from 3 dilutions. 
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Two-tailed probabilities were calculated, and P-values of less than 0.05 were considered 
statistically significant. 
RESULTS
Identification of potential candidate genes for CD. Gene expression in normal colon 
biopsies of 16 CD patients and 11 healthy controls (Table 2) was analyzed on a focus 
microarray chip containing 6,779 expressed sequence tags. We aimed at identifying potential 
candidate susceptibility genes for subsequent validation and mutation screening. This process 
was performed in two steps. First, we characterized genes that were differentially expressed 
between CD patients and controls using an independent t-test (P<0.01, N=240). We then 
selected the genes that were located near a chromosomal region that has been linked to CD in 
at least two independent studies (Table 3). We also included the loci that were found in a 
study performed on a Flemish cohort
15
, because the patients in our study live in this area of 
Belgium. We employed an arbitrary distance of 5 megabases around markers that showed the 
highest linkage. The exact chromosomal locations of the markers and genes were explored 
using the genome browser at http://genome.ucsc.edu. In this way, 18 genes were selected 
(Table 4), and all clones of the respective genes were sequence verified and annotated 
correctly. 
Metallothioneins are down-regulated in colon, ileum and whole blood of CD patients 
with colonic involvement.  
Metallothionein RNA expression. In the microarray screen we found two closely related 
metallothionein (MT) transcripts, MT1F and MT1M, that were down-regulated in CD 
patients. Although other genes may show lower P-values, we chose to focus on these genes, 
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because they are located near the  IBD1 locus,  which has been  linked to CD in almost every 
linkage analysis, 
and which contains CARD15. Metallothioneins are involved in a variety of metal scavenging 
processes, and they possess both bactericidal and anti-inflammatory activities
16, 17
. In humans, 
at least 18 MT gene isoforms exist (MT1A-MT1X, MT2A, MT3 and MT4), but only MT1 and 
MT2 are inducible. We performed a detailed expression study on different MT isoforms using 
qPCR on an independent population of 38 CD patients and 19 controls. Because of the high 
sequence homology between MT isoforms, we first determined whether both MT1M and 
MT1F were specifically down-regulated. To this end, we designed primers for MT1M and 
MT1F, as well as for MT1E, MT1J and MT2A (Table 1).
Primer specificities were confirmed by the presence of a single melting peak after 
denaturation of the amplicons, and by direct sequencing. The expression of MT1M in CD 
patients with colonic involvement (subgroups C and IC) was significantly less than in patients 
with pure ileal involvement (P=0.0244, Figure 1) and in controls (P=0.0076). Furthermore, 
the expression of MT1M in all biopsies tested was significantly correlated with expression of 
the other isoforms tested (Table 5). This indicates that at least these MT isoforms share the 
same regulatory machinery for basal expression in the colon. The highest expression in colon 
biopsies was observed for MT1E, followed by MT2A>MT1J>MT1F>MT1M. 
Basal transcript levels of MT1F were measured in whole blood of 15 CD patients and 13 
controls, and were found to be down-regulated in CD patients with colonic involvement 
(P=0.026, Figure 2). MT1M levels were too low for reliable quantitative measurement. None 
of the patients and none of the controls had elevated C-reactive protein levels at the time of 
blood sampling. Therefore, changes in MT expression due to systemic inflammation is not 
likely
18
.
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Metallothionein protein expression. MT protein expression was evaluated semi-
quantitatively in colon and ileum biopsies of CD patients and controls using 
immunohistochemical staining with a mouse monoclonal anti-metallothionein antibody 
(cloneE9, Zymed Laboratories). This antibody however, cannot distinguish between MT 
isoforms, because all of them have the epitope it recognizes. Overall, the expression of MT in 
colon was significantly lower than in the ileum (P=0.042). No conclusions could be drawn 
about MT expression in the colon, because the scores rarely reached 2. Compared to controls, 
a significant decrease in MT protein expression was found in CD patients with colonic 
involvement (subgroups C and IC) in ileum biopsies, again indicating a possible fundamental 
defect in MT expression in these patients (data not shown). A correlation was found between 
RNA expression as assessed by qPCR and the immunohistochemical score of protein 
expression (Spearman’s Rho: 0.826, P=0.001, N=12). This finding is interesting because in 
each individual, the biopsies used for RNA extraction and those used for staining were not 
obtained at the same time, again indicating a stable inherent basal expression of MT. 
Epithelial cells were primarily positive for MT staining. The strongest expression was found 
at the base of the villi, within paneth cells, and in rapidly proliferating epithelial cells in the 
crypts (Figure 3). 
Metallothionein induction in response to oxidative stress is higher in CD patients.
Because MT expression is decreased in the colon, ileum and whole blood of CD patients with 
colonic involvement, we examined whether this was due to impaired induction. We 
stimulated PBMC isolated from 10 CD patients (subgroups C: 2, IC: 4, I: 4) and 9 controls 
with known MT inducers (10 ng/ml IL6, 1000 U/ml TNF, 200 PM ZnSO4, 200 U/ml IFNJ
and 2 PM dexamethasone), and measured MT1M expression by qPCR. No difference in 
induction was found between CD patients and controls. However, induction following 
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exposure to 100 PM H2O2 for 10 minutes was significantly higher in CD patients, 
independently of the disease location (P=0.0015, Figure 4).
Colonic epithelial cells defective in metallothionein expression secrete less IL8 in 
response to LPS or adherent-invasive E. coli. Because we observed MT expression mainly 
in epithelial cells, we investigated whether a low basal expression of MT in epithelial cells 
has consequences upon challenge with bacteria. We used small interfering RNA (siRNA) to 
create HT29 colonic epithelial cells deficient in MT expression (HT29MTkd). Although the 
siRNA sequence was targeted against MT1B, MT1E, MT1H, MT1J and MT1M, the RNA 
expression of most MT isoforms was lowered approximately twofold as assessed by qPCR 
(Figure 5).   Diminished protein expression was shown by immunofluorescence using the 
monoclonal anti-metallothionein antibody (data not shown). Cytokine secretion in response to 
stimulation with adherent-invasive E. Coli (AIEC LF82) was tested with the Human 
inflammation kit (Becton Dickinson). We could only measure IL8 secretion after bacterial 
challenge with this technique. The secretion of IL8 was significantly lower in HT29MTkd 
cells than in normal HT29 cells (P<0.001, Figure 6). 
Screening for mutations in the MT1M gene. We screened the complete MT1M gene (~1.4 
kb) and its promoter region (~600 bases upstream of the transcriptional start site), using 
NM_176870 as reference sequence, in 25 CD patients and 6 controls. Two intronic 
polymorphisms, IVS1-366C>T and IVS2-49C>T, and one 3’ untranslated region (3’UTR) 
polymorphism, c.286A>G, were found. The absence of promoter or coding mutations in 
MT1M that would cause its down-regulation was not too surprising, since the down-regulation
was not confined to MT1M. Better candidates for mutation screening are probably upstream 
factors regulating all MT isoforms, and so we proceeded in that direction. 
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A polymorphism in the first intron of the MTF1 transcription factor gene is associated 
with ileal disease. One of the best-characterized transcription factors regulating MT 
expression is MRE-binding transcription factor 1 or MTF1, an essential zinc finger protein 
that binds to specific DNA motifs termed metal-response elements (MRE). Furthermore, this 
protein is responsible for both basal and inducible expression of MT
19
, and the gene  is 
located  at  1p33 (IBD7),  a locus  that has  been linked to  CD in a  Flemish  population 
15
.
We show that expression of the transcription factor MTF1 in blood of CD patients and 
controls correlates with the expression of MT1F (Pearson’s Rho: 0.572, P=0.001, N=20). All 
11 exons and the promoter region (~1000 bp upstream of the transcription start site) were 
screened for mutations in 95 CD patients, using NM_005955 as a reference sequence. Two 
missense mutations were found: c.198C>G (Asp63Glu) in 4 patients, and c.1253G>A 
(Glu385Lys) in 2 patients. The functional relevance of these mutations still needs to be 
investigated.  Moreover, a potential polymorphism at the splice site junction between exons 8 
and 9, c.1270A>G, was frequently found. Yet no alternative splice variant could be detected 
in cDNA from blood of patients with different genotypes (data not shown). Here, we focused 
on a polymorphism in the first intron of MTF1, IVS1-128A>T, because of its potential 
influence  on gene  expression
20
.    No difference in frequency between a cohort of 222 CD 
patients and 63 controls was detected (data not shown). However, genotype-phenotype  
analysis  revealed that IVS1-128A>T  had  considerable influence  on the  location of disease: 
the IVS1-128T  allele was  associated with ileal disease (subgroups I and IC). In the presence 
of the IVS1-128T allele, 139/166 patients (84%) had ileal disease, compared to 38/56 (68%) 
of those with the AA genotype (OR: 2.4, CI: 1.216-4.891, P=0.011). Because we observed 
that CARD15 mutations were also highly correlated with ileal disease (subgroups I and IC, 
P<0.0001), which has also been observed by others
21-23
, we investigated whether the 
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combined presence of CARD15 and MTF1 risk genotypes had a substantially higher impact 
on disease location than either of them alone.  The odds ratio for developing ileal disease 
(subgroups I and IC) in CARD15 mutation carriers is 4.2 (CI: 1.980-9.098) and in IVS-128T 
allele carriers 2.4 (CI: 1.216-4.891). Moreover, logistic regression revealed significant 
interaction between the two genetic markers: carriage of an IVS-128T allele increased the risk 
of ileal disease by 12% in CARD15 wild type patients (from 60 to 72%, Figure 7), and in 
carriers of CARD15 mutations by 23% (from 74 to 97%). This means that both genes 
contribute to the location of inflammation, and mutually interact. 
The IVS-128A>T polymorphism is located in the first intron of MTF1, which is located 
within the 5’UTR. It is not contained within a CpG island. A search for transcription factor 
binding sites using the transcription factor database (TRANSFAC) revealed a potential 
binding site for GATA binding protein 4 (GATA4). 
Based on these findings, we speculate that carriers of the IVS-128AA genotype express less 
tissue MT compared to carriers of the IVS-128T allele. Therefore, the genotype was weighed 
against the level of MT1M expression in biopsies of all patients and controls of whom the 
genotype was known. We could not show a significant association of MT1M expression and 
genotype, although the expected trend does exist (IVS-128AA (N=11) vs. IVS-128AT and TT 
(N=32), P=0.195).
DISCUSSION 
Identification of susceptibility genes, their interaction, and their relationship to specific 
clinical manifestations is an important step in understanding CD and developing improved 
clinical management or therapy. We used an alternative, hypothesis-independent strategy to 
identify novel candidate genes. Transcriptome analysis of non-inflamed colon biopsies of CD 
patients and controls revealed 18 novel potential candidate genes localized to CD loci.
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Many genome-wide linkage studies of CD have been performed
24
. This led to the 
identification of the first gene strongly associated with CD, CARD15
3, 4
. Nevertheless, despite 
its strong association with CD, CARD15 is difficult to relate causally to CD. Polymorphisms 
show very limited penetrance, occurring in approximately 40% of patients (predominantly 
those with ileal disease), as well as in 15% of healthy individuals. Furthermore, linkage to 
chromosome 16 was still observed in CD patients not carrying common CARD15 mutations
25-
27
. An alternative explanation is that polymorphisms in CARD15 are not in themselves causal, 
but modify the immune response in inflammatory lesions elicited by some other mechanism. 
An interesting theory based on evolutionary benefit was suggested by Hugot and co-
workers
28
. They stated that a mutated CARD15 protein would have been beneficial during the 
outbreak of the plague in Europe, but it somehow represents a disadvantage in the 
pathogenesis of CD. The identification of CARD15 and the insights into its role in innate 
immunity and CD pathology highlight the importance of mapping susceptibility genes
29
.
Two of the 18 potential candidate genes we identified belong to the family of closely related 
metallothioneins (MT).  They are located in tandem within the IBD1 locus and arose by non-
processed gene duplications
30
. Furthermore, they are involved in protecting cells against toxic 
levels of metal ions, radicals and bacterial infections. Four MT classes exist in humans, but 
only MT1 and MT2 isoforms are inducible by cytokines, hormones, metals and stress in 
general
31
. We showed that MT was significantly down-regulated in CD patients with colonic 
involvement as compared to healthy controls. In addition, detailed expression analysis of 
different MT isoforms revealed that their expression is highly correlated at basal level. Low 
RNA expression levels were linked to reduced protein expression. Furthermore, we provide 
evidence that a low expression level of MT in CD patients with colonic involvement results 
from a genetic predisposition rather than from an early inflammation event. Indeed, the down-
regulation was not only found in colon but also in ileum biopsies, both sampled from non-
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inflamed areas, as well as in whole blood samples regardless of C-reactive protein levels.   
Remarkably, MT RNA levels correlated with protein expression in biopsies that were not time 
matched, contributing to the idea that MT expression is stable and potentially inherited. Two 
studies have previously shown an up-regulation of MT in CD
32, 33
, while we and others found 
a down-regulation
34-37
. Moreover, MT quantification in CD based on radioimmunoassay
38
,
microarray
39
 and silver-saturation assay
40
 also reported a down-regulation. 
We further demonstrated that although basal MT levels were reduced in CD patients with 
colonic involvement, they are still inducible by conventional stimuli in peripheral blood. 
Unexpectedly, MT induction with oxidative stress was higher in CD patients, independent of 
disease location.  Relative overreaction in CD patients might reflect the fact that basal low 
levels of MT result in more free hydroxide radicals that can activate the MT transcription 
factor, MTF1, resulting in the overall increased transcription of MT
41
.
In order to clarify the potential functional consequence of reduced basal levels, we generated 
MT-knockdown colonic epithelial HT29 cells using small interfering RNA. We report that, in 
response to bacterial challenge with a CD-associated E. coli strain
11
, reduced expression of 
MT in epithelial cells correlated with reduced IL8 secretion. This observation is in accordance 
with the recent finding that IL8 up-regulation is impaired in response to acute trauma to colon 
and skin of CD patients
42
. IL8 is a potent chemoattractant and activator of neutrophils, which 
respond rapidly to different types of infections, and play an essential role in the inflammatory 
response. They release antimicrobial peptides as well as reactive oxygen intermediates that 
may cause tissue damage. We hypothesize that the intestinal epithelial cell lining of CD 
patients with colonic involvement expresses less MT and initially secretes less IL8 in 
response to bacteria. This might secure an exaggerated secondary, compensatory immune 
response.
It is unlikely that polymorphisms in the MT genes themselves would be responsible for their 
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low expression, since we showed that they are down-regulated as a group. Yet, in our 
knockdown model for MT, we see a similar decrease in expression of MT isoforms that were 
not targeted with the short hairpin RNA. Thus, the possibility of a positive feedback loop for 
MT expression via its own transcriptional regulator cannot be ruled out
43
. We could not find 
coding or promoter polymorphisms in MT1M, but other isoforms need to be screened. 
Alternatively, epigenetic mechanisms such as DNA methylation might be responsible for the 
down-regulation of MT genes in CD patients
44
.
In searching for mutations in MTF1 (IBD7), a transcription factor that regulates basal 
expression of MT, we focused on a polymorphism within the first intron, IVS1-128A>T, 
because regulating regions are frequently found there. This polymorphism predisposes to 
inflammation at specific sites in the intestine. Disease location is a phenotypic characteristic 
that remains stable over time. Similar to CARD15, the association of MTF1 with ileal disease 
offers a new candidate disease-modifying gene, rather than a disease-predisposing gene
45
. In 
addition, the two genes interact to bring about ileal disease.
The links of CARD15 and MTF1 with disease location might reflect the functions of these 
proteins at their sites of expression: CARD15 is expressed in paneth cells of the ileum, and 
the expression of MT in ileum is much higher than in colon. Both proteins are probably 
crucially involved in maintaining a low bacterial count in the ileum. A fully functional 
CARD15 or MTF1 might be crucial in this process. However, they might be disadvantageous 
in the colon, where bacterial load is high. In the colon, a weakly functional CARD15 can be 
beneficial, because inappropriately intense immune responses will not be elicited. Greater MT 
expression in the colon can also be beneficial because it can lead to efficient clearance of 
mucosal infection. 
The association of the IVS1-128T allele in MTF1 with higher MT expression needs 
investigation. We could not show an association in our samples, however, we did not make 
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associations in selected subgroups, because of the limited number of samples. In vitro assays 
using reporter gene constructs will provide direct information of the transcriptional 
functionality of these alleles. We must keep in mind, however, that to fully understand the 
genetic contribution of IVS-128A>T in CD, the haplotype structure surrounding this 
polymorphism needs to be determined. The mutation causing altered transcription of MTF1 
could be located elsewhere within the same haplotype block. MTF1 regulates basal expression 
of MT
19
. Therefore, a difference in MTF1 expression will be directly linked to altered MT 
expression. Indeed, we showed a correlation between MT1F and MTF1 levels in peripheral 
blood. The IVS-128T allele is located within a potential binding site for GATA4, a 
transcription factor that is expressed in the ileal enterocytes in the small intestine, but not in 
the colon
46
. Therefore, a primary goal in this context is to study GATA4 binding to the MTF1
gene.
Loss of MTF1 in mouse embryonic fibroblasts results in enhanced collagen deposition, which 
is an important complication of CD
47
. In these fibroblasts, transforming growth factor-beta is 
activated. This protein has potent anti-inflammatory properties, but at the same time it drives 
the process of fibrosis in the deeper layers of the gut
48
. Nonetheless, we could not find an 
association between the IVS-128A>T polymorphism and stricturing disease, indicating that 
additional risk factors influence this particular phenotype. Interestingly, though, the IVS-128T 
allele in MTF1 is associated with CD of the ileum, which has a higher likelihood of stricturing 
than does colonic CD.
We used microarray screenings in unaffected tissues for human genetic studies. A similar 
study was performed by Lawrance and colleagues, with the exception that they used 
moderately inflamed resected colonic tissue
39
. We used non-inflamed tissue to target basal 
differences in gene expression due to genetic variation, and not due to inflammation-related 
events. Significant evidence was found for the genetic transmission of variation in gene 
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expression
49, 50
. The variation in expression level is highest among unrelated individuals, and 
smallest between monozygotic twins, indicating that germ-line differences contribute to 
variation in gene expression
51, 52
.
In summary, screening unaffected colon biopsies by microarrays proved to be useful in the 
identification of new candidate genes for CD. A cluster of MT genes located at IBD1 is 
consistently down-regulated in CD patients with colonic involvement. Subsequently, we 
identified a new disease-modifying gene, MTF1, that is associated with ileal disease, and 
together with CARD15 serves as a good predictor of disease location in CD patients. 
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TABLES
Table 1. Sequences of qPCR primer sets 
Gene
symbol 
Reference 
sequence
Forward primer Reverse primer 
GAPDH NM_002046 TGC ACC ACC AAC TGC TTA GC GGC ATG GAC TGT GGT CAT GAG 
MT1A NM_005946 GCA AAG GGG CAT CAG AGA AGT G AAA TAC AGT AAA TGG GTC AGG GTT G 
MT1B NM_005947 AAG TGC TGC TGC TCT TGC TG TGG TTG CTC TAT TTA TGT CTG GGA G 
MT1E NM_175617 GCA TCC TCT GGG TCT GGG TTC AAC AGC AGC CTG GGG AAG AAG 
MT1F NM_005949 GCG ACT GAT GCC AGG ACA AC CAC AGG AAA AGG AAT GTA GCA AAT G 
MT1G NM_005950 GCA AAG GGG CAT CGG AGA AGT G AAG GGA ATG TAG CAA AGG GGT CAA G 
MT1J AF348994 GCT GTG CCT GAT GTG GGA AC AAA TGC AGC AAA TGG CTC AGT ATT G 
MT1M NM_176870 CTG CAA AGG GAC GTT GGA GAA C CAG CAA ATG GCT CAG TAT CGT ATT 
MT2A NM_005953 AAA GGG GCG TCG GAC AAG TG GAA TAT AGC AAA CGG TCA CGG TCA G 
MTF1 NM_005955 TAA GAC TCA ATT GAT TCA GGG ACG AGA GC CAG TTG TGA GAA ATG AAA ACG TAA 
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Table 2. Clinical characteristics of CD patients analyzed by microarrays  
Patient Sex Familial  
CD
Age of 
onset 
Behaviour Disease 
location
CARD15
status
Operations Medication 
1 F no A1 B1 IC wt no immunosuppressives 
2 M no A1 B3 IC ND no no 
3 M no A2 B1 IC mutant no 5-ASA 
4 F yes A1 B3 IC wt resection corticosteroids 
5 M no A1 B3 IC mutant fistula 5-ASA 
6 F no A1 B2 C mutant resection Remicade 
7 M no A2 B2 I wt resection 5-ASA 
8 F no A1 B3 IC wt resection immunosuppressives 
9 F yes A1 B3 IC wt fistula immunosuppressives 
10 F yes A2 B2 I wt resection immunosuppressives 
11 F no A1 B3 IC mutant fistula immunosuppressives 
12 M yes A1 B2 I wt no 5-ASA 
13 F no A1 B3 C wt resection immunosuppressives 
14 F no A1 B1 IC wt no 5-ASA 
15 F no A1 B3 IC wt fistula, 
resection
corticosteroids
16 F no A1 B3 IC wt fistel 5-ASA 
A1: <40 years; A2:  40 years; B1: non-stricturing, non-penetrating; B2: stricturing; B3: 
penetrating; disease location is defined as maximal extension of inflammation during total 
follow-up of patients with I: ileal involvement only, C: colonic involvement only, IC: ileal 
and colonic involvement; mutant CARD15: carriage of at least one mutant allele for SNP8, 
SNP12 or SNP13 (according to Hugot et al. 2001); wt CARD15: not carrying a mutant allele 
for SNP8, SNP12 or SNP13; 5-ASA: 5-aminosalicylates. 
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Table 3. Chromosomal positions with significant linkage to CD 
IBD
locus
Chromosomal 
position
Marker at highest 
lod score 
Population Reference 
IBD7 1p13.1 D1S252 Flemish IBD Vermeire et al. 2004 
IBD7 1p33-32.3 D1S197 Flemish IBD Vermeire et al. 2004 
IBD7 1p36.13-36.11 D1S552-D1S234 Non-Jewish American IBD Cho et al. 1998 
1q21.3 D1S305 Flemish IBD Vermeire et al. 2004 
IBD9 3p14.2-14.1 D3S1766-D3S1285 Canadian IBD Rioux et al. 2000 
IBD9 3p21.31 D3S1573 North European IBD Satsangi et al. 1996
IBD9 3p24.1-22.3 D3S1266-D3S1298 North European IBD Hampe et al. 2001
IBD9 3p26.3 D3S1297 American IBD Duerr et al. 2002 
IBD9 3p26.1-25.3 D3S3591 North European IBD Hampe et al. 2001 
IBD9 3p26.2-26.1-25.3 D3S3706-D3S3591 North European IBD Hampe et al. 2001 
3q25.1-26.31 D3S1279-D3S3725 North European CD Van Heel et al. 2003 
3q26.31 D3S3053-D3S2427 American IBD Cho et al. 1998 
4q25 D4S406 Finnish IBD Paavola-Sakki et al. 2003 
4q25 D4S406 Flemish IBD Vermeire et al. 2004 
4q25 D4S2623 American IBD Cho et al. 1998 
IBD5 5q31.1-31.3 D5S816-D5S1480 Canadian CD Rioux et al. 2000 
IBD5 5q33-35  Jewish American CD Ma et al. 1999 
IBD3 6p D6S197 North European CD Shaw et al. 2003 
IBD3 6p21.31 D6S291 European IBD Dechairo et al. 2001 
IBD3 6p22.2 D6S2439 Caucasian CD Barmada et al. 2004 
IBD3 6p22.2-21.2 D6S1281-D6S1019 Canadian IBD Rioux et al. 2000 
IBD3 6p23-22.3-22.2 D6S289-D6S276 North European IBD Hampe et al. 1999 
IBD3 6p22.3 D6S461 North European IBD Hampe et al. 1999b 
6q24.1 D6S314 Flemish IBD Vermeire et al. 2004 
6q25.2-26 D6S2436-D6S305 Caucasian IBD Barmada et al. 2004 
7q21.11 D7S669 North European IBD Satsangi et al. 1996
7q32.1-31.33 D7S40-D7S648 American IBD Duerr et al. 2000 
8q12.1-13.1 D8S1113-D8S1136 Caucasian IBD Barmada et al. 2004 
8q24.13 D8S198 Flemish IBD Vermeire et al. 2004 
10p12.1 D10S197 Flemish IBD Vermeire et al. 2004 
10p12.1 D10S197 North European CD Shaw et al. 2003 
10p12.31-12.32-12.1 D10S548-D10S197 North European CD Hampe et al. 1999 
11q22.1-22.3 D11S35-D11S927 Flemish IBD Vermeire et al. 2004 
IBD2 12q12 GATA91H06 Caucasian IBD Barmada et al. 2004 
IBD2 12q14.1 D12S83 North European IBD Satsangi et al. 1996 
IBD2 12q21.1-21.2 D12S303-D12S326 North European CD Hampe et al. 1999 
IBD2 12q21.1-21.33 D12S303-D12S351 European CD Curran et al. 1998 
IBD2 12q23.3 D12S78 Finnish CD Paavola-Sakki et al. 2003 
IBD4 14q11.2  American CD Ma et al. 1999 
IBD4 14q11.2 D14S261 American CD Duerr et al. 2000 
IBD4 14q11.2 D14S50 Flemish IBD Vermeire et al. 2004 
IBD4 14q11.2 D14S261  multicenter (IBDIGC) Pierik et al. 2005 
IBD4 14q12 D14S80 Flemish IBD Vermeire et al. 2004 
IBD4 14q13.1 D14S49 Flemish IBD Vermeire et al. 2004 
15q26.1 D15S652 Caucasian IBD Vermeire et al. 2004 
15q26.1-26.2 D15S652-D15S816 Caucasian IBD Barmada et al. 2004 
IBD8 16p11.2-12.1 D16S409-D16S753 Australian CD Cavanaugh et al. 1998 
IBD8 16p12.1 D16S3145  European CD Hampe et al. 2002 
IBD8 16p12.1 D16S769 American CD Brant et al. 1998 
IBD8 16p13.13 D16S748 American CD Cho et al. 1998 
IBD1 16q  English IBD Parkes et al. 1996 
IBD1 16q  American CD Brant et al. 2000 
IBD1 16q12.2 D16S306 European CD, IBD Hampe et al. 2002 
IBD1 16q12.1 D16S409 Ashkenazi Jews CD Akolkar et al. 2001 
IBD1 16q12.2 D16S408 Italian CD, IBD Annese et al. 1999
IBD1 16q12.2 D16S408 Italian IBD Forabosco et al. 2000 
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IBD1 16q12.1 D16S411 American non-Jewish CD Ohmen et al. 1996 
IBD1 16q12.1 D16S411-D16S419 multicenter (IBDIGC) Cavanaugh et al. 2001 
IBD1 16q12.1 D16S3136, D16S3117, D16S770 European CD Zouali et al. 2001 
IBD1 16q12.1 D16S409-D16S411 European CD Hampe et al. 1999
IBD1 16q12.1-12.2 D16S409, D16S419 Caucasian CD Hugot et al. 1996 
IBD1 16q12.1-12.2 D16S409-D16S408 European CD Curran et al. 1998 
18p11.31 D18S62 Flemish IBD Vermeire et al. 2004 
IBD6 19p13  UK Caucasian Low et al. 2004
IBD6 19p13.3 D19S591-GATA21G05 Canadian CD Rioux et al. 2000 
IBD6 19p13.3-13.2 D19S1034-D19S586 American IBD Cho et al. 1998 
 20p12.3 D20S192 Flemish IBD Vermeire et al. 2004 
 22q11.23-12.1 D22S315-D22S421 North European IBD Hampe et al. 1999 
 22q12.1 D22S689 Caucasian IBD Barmada et al. 2004
 22q13.31 D22S274 Flemish IBD Vermeire et al. 2004 
 Xp22.11-21.2 DXS1226-DXS1214 North European CD Van Heel et al. 2003 
 Xp21.2-21.3 DXS1202-DXS1214 North European IBD Hampe et al. 1999 
 Xq21.32 DXS1203 Flemish IBD Vermeire et al. 2001 
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Table 4. Differentially expressed genes in colon biopsies of CD patients located near a locus 
for CD 
Unigene Gene 
symbol 
Gene description Chromosomal 
location
Expression in 
CD
P-value 
Hs.486246 PHTF1 putative homeodomain transcription factor 1 1p13 n 0.000099 
Hs.77955 MEF2D MADS box transcription enhancer factor 2, polypeptide D 1q22 p 0.0035 
Hs.106674 BAP1 BRCA1 associated protein 3p21.31-p21.2 p 0.0017 
Hs.438691 GMPPB GDP-mannose pyrophosphorylase B 3p21.31 p 0.0013 
Hs.302047 PLCL3 phospholipase C-like 3 3q25.31 p 0.0048 
Hs.318567 NDRG1 N-myc downstream regulated gene 1 8q24.3 p 0.00038 
Hs.84072 TM4SF3 transmembrane 4 superfamily member 3 12q12.1 n 0.0046 
Hs.85951 XPOT exportin, tRNA (nuclear export receptor for tRNAs) 12q14.1 n 0.0021 
Hs.419776 NAP1L1 nucleosome assembly protein 1-like 1 12q21.1 p 0.0088 
Hs.159481 GALGT UDP-N-acetyl-alpha-D-galactosamine 12q13.3 p 0.00054 
Hs.438737 MT1F metallothionein 1F  16q12.2 p 0.001 
Hs.188518 MT1M metallothionein 1M 16q12.2 p 0.00058 
Hs.100914 CEP192 Centrosomal protein 192kDa 18p11.21 n 0.000042 
Hs.512640 PRKCSH protein kinase C substrate 80K-H 19p13.2 p 0.00042 
Hs.134074 SLC35E1 solute carrier family 35, member E1  19p13.11 n 0.006 
Hs.437     TCF15 transcription factor 15 (basic helix-loop-helix)  20p13 p 0.0024 
Hs.102336 ARHGAP8 Rho GTPase activating protein 8  22q13.31 p 0.0093 
Hs.28491 SAT spermidine/spermine N1-acetyltransferase Xp22.1 n 0.0035 
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Table 5. Correlations of MT isoform expression in colon biopsies of CD patients and controls 
 MT1E MT1F MT1J MT1M MT2A 
MT1E        Pearson R 1 0.631 0.496 0.500 0.499 
P-value  <0.01 <0.01 <0.01 0.058 
N  65 55 66 15 
MT1F        Pearson R  1 0.589 0.378 0.784 
P-value   <0.01 <0.01 <0.01 
N   55 62 15 
MT1J         Pearson R   1 0.609 0.805 
P-value    <0.01 <0.01 
N    53 13 
MT1K        Pearson R    1 0.615 
P-value     <0.05 
N     15 
MT12A      Pearson R     1 
P-value      
N      
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FIGURES
Figure 1. MT1M expression is down-regulated in colon biopsies of CD patients with colonic 
involvement. CD colitis: subgroups IC + C (N=20), CD ileitis: subgroup I (N=18), control 
(N=19).
Figure 2. MT1F expression in blood is down-regulated in CD patients with colonic 
involvement. CD colitis: subgroups IC + C (N=11), CD ileitis: subgroup I (N=4), control 
(N=13).
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Figure 3. Metallothionein staining of representative samples of non-inflamed ileal biopsies of 
(A) a control and (B) a CD patient. Control ileum shows strong immunoreactivity for MT in 
epithelial cells, with stronger reactivity in the proliferative cells of the crypts and at the base 
of the villi. In CD patients, MT expression is significantly decreased. Bar = 100µm. 
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Figure 4. MT1M RNA induction in response to oxidative stress is higher in CD patients 
(N=10) than in controls (N=9), irrespective of the disease location (P=0.0015).
Figure 5. The RNA expression of different MT isoforms in HT29MTkd cells is down-
regulated in comparison to HT29. The solid line represents a twofold change in expression. 
The short hairpin RNA was targeted at MT1B, MT1E, MT1H, MT1J and MT1M (black bars), 
but the other isoforms tested (MT1A, MT1F, MT1G, MT1X and MT2A) also show reduced 
expression.
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Figure 6. IL8 secretion in response to bacterial challenge is lower in MT-knockdown cells 
(HT29MTkd) than in HT29 cells. +AIEC: stimulated with adherent-invasive E. coli LF82 
MOI 100; unst: unstimulated (P<0.001).
Figure 7. The presence of the MTF1 IVS-128T allele and CARD15 mutations contribute to 
ileal disease. Percentages represent number of patients positive or negative for CARD15
mutations that are positive or negative for the IVS-128T allele. Logistic regression revealed a 
gene-gene interaction between CARD15 and MTF1.
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General discussion and summary 
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Crohn’s disease (CD) and spondyloarthropathies (SpA) are considered to be mutually related, 
complex, multigenic disorders. A disturbed immunological response towards unknown 
environmental factors results within genetically predisposed individuals in the development of 
chronic, uncontrolled intestinal and/or joint inflammation (1-3).  
Over the last decade, important progress was made regarding genetic research of both disease 
entities. Genome screening led to the identification of several susceptibility loci containing 
multiple possible candidate genes (4-8).  
Linkage and association studies contributed to the discovery of CARD15 on chromosome 16q 
as the first CD-related gene (9-11). Three CARD15 gene polymorphisms have been associated 
with CD and can be found in 30 to 45% of CD patients. Functional studies showed a disturbed 
immunological response of the host cell towards bacterial cell wall components in the 
presence of these genetic variants (12-15). A dysregulated mucosal homeostasis with a 
decreased production of pro-inflammatory cytokines and anti-bacterial defensins can lead to 
an increased influx and the intramucosal persistence of intestinal bacteria or microbial 
antigens, leading to secondary, chronic gut inflammation (16, 17). These findings confirm the 
role of a reduced tolerance towards bacterial flora in the development of this chronic intestinal 
disease, as already demonstrated in numerous previous animal and human studies (18-20).  
The relation between HLA-B27 carriership and the risk for SpA, in particular AS, is well 
known (21). However, the role of this genetic factor is much less important in CD-associated 
AS and asymptomatic SI (22, 23). Recently, several non-MHC related susceptibility loci, 
including a locus at 16q, have also been identified in SpA populations (7, 8). 
Several clinical and immunological findings point to an important link between CD and SpA 
(2, 24). Articular inflammation (peripheral and/or axial arthropathy) is common in CD and is 
classified as spondyloarthropathy (25). On the other hand, (subclinical) gut inflammation, 
with similar histological features as in CD, has been described in two thirds of SpA patients. 
The presence of histological, chronic inflammatory lesions in ileum and/or colon of SpA 
patients was identified as a risk factor for the future development of clinically overt Crohn’s 
disease (26-33). Furthermore, several immunological alterations have been found in intestinal 
mucosa and synovium of CD and SpA patients, leading to the presumption of (re)circulation 
of inflammatory cells between gut and joint (34-40).
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The aim of the present work was to investigate the role of genetic alterations in the gut-joint 
axis of CD and SpA. 
1. CARD15 polymorphisms predispose to the presence of subclinical, chronic gut 
inflammation in patients with SpA. 
Following the identification of a linkage region in ankylosing spondylitis on chromosome 16, 
several studies have been performed to investigate the CARD15 gene as a putative 
susceptibility gene for SpA or AS (41-49). No associations with these CD-associated 
polymorphisms could be found in these populations. However, the presence of subclinical 
chronic gut inflammation was not taken into account, whereas exactly this subgroup of SpA 
patients is at risk to develop clinical CD (50).
In Chapter 2 we showed that the presence of chronic gut inflammation in SpA patients is
associated with the CD-related polymorphisms in the CARD15 gene. This finding provided 
for the first time genetic evidence for the relation between CD and SpA. Furthermore, it 
suggests a possible role for a genetically disturbed handling of intestinal bacteria or bacterial 
products in the etiopathogenesis of this chronic rheumatic disorder. In the past, the hypothesis 
of a possible infectious (enterogenous) trigger for the development of SpA has been put 
forward on numerous occasions. Both bacterial antigens and DNA have been found in 
synovial fluid of mainly reactive arthritis patients, but also in patients with undifferentiated 
SpA, AS and PsA (51-55). Furthermore, carriership of Klebsiella pneumoniae in the gut was 
once identified as a possible risk factor for the future development of AS (56). A disturbed 
immunological response, as demonstrated in the presence of CARD15 polymorphisms, may 
lead to an augmented influx of bacteria from the gut lumen and may contribute to an intestinal 
origin of articular inflammation, in particular since inflammatory cells and bacterial antigens 
presumably circulate between gut and joint.  
The majority of SpA patients with gut inflammation remain asymptomatic and do not develop 
clinically overt CD (50). This finding raises the question whether CARD15 polymorphisms 
are not merely linked with the development of (subclinical) gut inflammation than to clinical 
CD as such. 
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2. The role of CARD15 polymorphisms in the development of articular inflammation of 
CD.
The exact pathogenesis of extraintestinal manifestations in IBD is still not clarified (57). The 
circulation of enterogenous bacteria or antigens between the gut and organs at distance might 
also be important in IBD, in particular in view of the recent findings on the functional role of 
CARD15 polymorphisms. This hypothesis is corroborated by the finding that in ReA, where 
intestinal bacteria play an essential role in the development of articular inflammation, also 
other extraintestinal and extraarticular foci of inflammation can often be found (skin, 
conjunctiva, iris, urethra and heart) (58).
Previous genotype-phenotype studies could not demonstrate an association between 
extraintestinal manifestations and the presence of CARD15 polymorphisms (59-63). However, 
only few data are available on the association with specific articular manifestations and in 
particular no information was available on axial involvement (59, 60). Sacroiliitis, often 
asymptomatic and not HLA-B27 related, is considered to be the most frequent extraintestinal 
manifestation of CD (22). Moreover, a study of relatives of AS patients suggested a non-
HLA-B27 related genetic factor in the link between intestinal and axial inflammation (64). 
In Chapter 3, we investigated the association of CARD15 polymorphisms with different 
rheumatologic manifestations of CD. This study showed a higher prevalence of radiological 
sacroiliitis in CD patients with CARD15 polymorphisms. Similar to previous association 
studies, we found no association with peripheral arthritis (59, 60). The possible link between 
these genetic variants and axial inflammation is also reflected by previous findings in SpA 
patients. Chronic gut inflammation in SpA, associated with CARD15 polymorphisms as 
demonstrated by the previous study, is mostly seen in patients with axial involvement (65). 
Moreover, the presence of chronic ileitis and/or colitis in non-AS SpA patients is even 
considered to be a risk factor for the future evolution towards AS (66).
Data on the association of radiological sacroiliitis with specific phenotypes of the disease are 
scarce. Therefore we performed a multicenter study of this frequent extraintestinal 
manifestation in cooperation with Leuven and Liège in order to investigate potentially 
associated clinical features and the relationship with CARD15 polymorphisms (chapter 4). 
We found an association between the presence of radiological SI and the development of 
peripheral arthritis. Furthermore, CD patients with clinical AS had a higher chance of 
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developing uveitis. These findings suggest common characteristics in the origin of these 
extraintestinal manifestations.  
In this second study, we could however not confirm the link between CARD15
polymorphisms and sacroiliitis. Reproducibility of genetic association studies is a 
considerable problem in genetic research of complex, multigenic diseases. Potential 
confounding factors leading to inconsistent results between studies, include lack of statistical 
power, population stratification, genetic heterogeneity, environmental interactions, genotype 
and phenotype quality control and the choice of statistical models (67-70). Looking at the 
different association studies concerning CARD15 polymorphisms, conflicting results often 
arose, even within ethnically similar populations (5, 13).  
Both studies in this thesis included phenotypically and ethnically similar populations of CD 
patients, who were enrolled independent of the presence or history of articular manifestations. 
CARD15 genotyping and scoring of the sacroiliac radiographs have been blindly performed 
and the known associations between CARD15 polymorphisms and ileal and fibrostenosing 
disease were confirmed in both cohorts. Furthermore, the results of the univariate analysis 
showing an association between sacroiliitis and the presence of CARD15 variants in the first 
study, were confirmed by multivariate analysis. The lack of explanation for the inconsistent 
findings in these studies reflects once more the problem of genetic association studies of 
complex diseases. When performing such studies, one should strive for large, ethnically and 
phenotypically homogeneous and well defined patient populations or, preferably, for 2 
independent and well balanced cohorts within one and the same study.  
Despite the inconsistent results on sacroiliitis and CARD15 polymorphisms, the genetically 
predestined circulation of inflammatory cells and insufficiently cleared micro-organisms or 
bacterial components, as a cause of inflammation at distance of the gut, remains an interesting 
hypothesis in both IBD and SpA (20, 38). In view of the multigenic character of both disease 
entities, presumably various genetic defects play a role in a disturbed handling of intestinal 
flora and the transport of bacterial antigens to other organs. It is still unclear how exactly 
components of the bacterial flora might be transported from the intestinal mucosa via the 
blood circulation to organs at distance.
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3. CARD15 polymorphisms induce a disturbed cellular and humoral immunological  
response towards microorganisms. 
CARD15 plays an important role in the innate immune response of the host towards 
intraluminal microorganisms (71, 72). The intracytoplasmic protein CARD15 acts as a 
receptor for muramyl dipeptide, a component of peptidoglycan, which can be found in the cell 
wall of most bacteria (73). A disturbed immunological response of the host cell towards this 
bacterial antigen has been associated with the CD-related CARD15 polymorphisms in several 
functional studies (in vitro as well as ex vivo) (12-15). However, the results from these studies 
were predominantly focussed upon the (rare) homozygous carriers of these genetic variants, 
more specifically of the frameshift mutation. Single heterozygotes are much more common 
and until now no clear functional defect could be demonstrated in such patients.  
In chapter 5 we investigated the role CARD15 polymorphisms in the response of peripheral 
blood monocytes, isolated from CD patients, towards adherent-invasive E. coli (AIEC). This 
bacterial strain, specifically associated with CD, was isolated from the ileum of CD patients 
and is able to invade the host cell and to survive and even replicate intracellularly (74-79). 
After infection of the monocytes with these AIEC, a disturbed early cytokine secretion (IL-1ȕ,
IL-6 and IL-10) was observed in patients carrying CARD15 polymorphisms. Although the 
effect was most pronounced in homozygotes, we were also able to demonstrate for the first 
time a functional defect in the (much more frequent) single heterozygous carriers of these 
genetic variants. Further research will have to show whether this early disturbed 
immunological response can also be found in other cell types (intestinal macrophages, 
dendritic and epithelial cells) and after infection with other invasive or non-invasive bacteria. 
This study also reflects the importance of synergy between CARD15 and TLRs (80-83). As 
opposed to infection with AIEC, which can stimulate monocytes via both CARD15 and 
TLRs, no clearly altered response could be found after stimulation with MDP alone. Van Heel 
et al recently showed that TLR-agonists trigger a stronger response in the presence of 
CARD15 stimulation and that this synergistic effect is lost in homozygous carriers of 
CARD15 polymorphisms (84, 85).  
After binding of (AIEC-derived) MDP and LPS to respectively CARD15 and TLR4 receptors 
of CARD15 mutant monocytes/macrophages, this abrogated CARD15-TLR4 synergy can 
significantly contribute to the observed downregulation of the inflammatory monocyte 
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response to AIEC. In combination with the reduced expression of antibacterial defensins (as 
previously described by Wehkamp et al) in CARD15 polymorphism carriers, a reduced 
secretion of IL-1ȕ and IL-6, as observed in the present study, may in turn via defective 
neutrophil recruitment and infiltration facilitate the mucosal influx of intestinal bacteria, 
leading to a secondary inflammatory response (figure 1) (16, 86-89). The lower (and hence 
more pro-inflammatory) IL-10/TNFĮ ratio after AIEC infection of these monocytes also 
directly contributes to this ultimate mucosal inflammation. Whether an increased mucosal 
influx of intestinal bacteria also leads to the circulation of bacterial antigens towards organs at 
distance is yet unknown but remains an interesting working hypothesis for future studies. 
Further research will be focussed upon the correlation of a disturbed immunological response 
towards AIEC and the mucosal influx and circulation of bacteria or bacterial components with 
the development of extraintestinal manifestations. 
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Figure 1. Hypothetical diagram of the functional role of CARD15 polymorphisms in the 
pathogenesis of Crohn-related mucosal inflammation in the presence of AIEC. 
CARD15 polymorphisms also seem to influence humoral response. We found a clear 
association between the presence of these genetic variants and antibodies directed towards
Saccharomyces cerevisiae in CD patients (chapter 6). ASCA IgA and IgG are considered to 
be specific serological markers for CD, but these antibodies can also be detected in patients 
with SpA (90-94). In this study, we found the highest ASCA titers in homozygotes and 
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compound heterozygotes, but also heterozygous carriers of CARD15 polymorphisms were 
clearly more ASCA positive compared to wild-type patients.  
A genetic influence on the origin of these antibodies against baker’s or brewer’s yeast was 
already suggested by several family and twin studies demonstrating higher ASCA titers in 
unaffected relatives and twins of CD patients (95-100). A similar association between 
CARD15 polymorphisms and ASCA has also been described in another study with similar 
ethnic background (101). 
It is still unclear whether ASCA represent cross-reactive auto-autobodies or whether they are 
merely the consequence of an aberrant response toward baker’s or brewer’s yeast (102). This 
uncertainty around the exact role of ASCA in CD (or SpA) makes it difficult to speculate on 
the mechanism whereby CARD15 polymorphisms can lead to the formation of these 
antibodies. Nevertheless, in view of the known association between these genetic variants and 
an altered immune response towards micro-organisms and bacterial components, a disturbed 
(secondary serological) response towards (components of) Saccharomyces cerevisiae might 
well be possible. 
4. The search for new molecular targets in the association between CD and SpA. 
Clinical findings and common immunological alterations in CD and SpA clearly show an 
association between these two chronic inflammatory disorders (24, 103). Moreover, SpA with 
subclinical chronic gut inflammation could actually serve as a unique model for studying 
early CD (2). In order to confirm the association between CD and SpA at the gut 
transcriptome level, we used macro- and micro-arrays. Gene expression was analyzed in 
macroscopically non-inflamed colonic biopsies from CD patients, SpA patients (with or 
without chronic gut inflammation) and healthy controls, in order to detect differentially 
expressed genes (Chapter 7). First of all, we found that the gut transcriptome in the global 
SpA population was different from that in healthy controls. Furthermore, SpA patients with 
subclinical chronic gut inflammation cluster with CD patients, suggesting similarities in 
genetic expression profiles and corroborating the evidence for the relation between CD and 
SpA. We presented a set of 95 genes, which were differentially expressed in the gut of CD 
patients and SpA patients with subclinical chronic gut inflammation. 
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Since the variation in gene expression can be genetically determined, the search for 
differentially expressed genes could lead to the discovery of new putative candidate 
susceptibility or disease-modifying genes (104). Results of transcriptome analysis in CD 
patients and healthy controls were linked with replicated susceptibility loci for CD, 
identifying 18 potential candidate genes located within these loci (Chapter 8). We focused 
upon 2 metallothionein (MT) isoforms MT1F and MT1M, encoded by genes within the IBD1 
locus (chromosome 16q) and involved in metal scavenging processes and bactericidal and 
anti-inflammatory activities (105, 106). Basal MT expression was significantly downregulated 
in the blood and ileal and colonic biopsies of CD patients with colonic involvement, 
suggesting that a genetic predisposition is more likely than a secondary inflammatory event. 
Reduced expression of MT in MT-knockdown colonic epithelial HT29 cells correlated with 
reduced IL-8 secretion, a potent chemo-attractant and activator of neutrophils, playing an 
essential role in the inflammatory response. The reduced expression of MT in intestinal 
epithelial cells and a disturbed IL-8 secretion in response to bacteria might lead to an 
exaggerated secondary, compensatory immune response. Mutation screening revealed a 
polymorphism (IVS1-128A>T) within the MRE-binding transcription factor 1 or MTF1 gene 
(IBD7 locus), encoding the main transcription factor regulating MT expression (107). In 
blood of CD patients and controls, the expression of the transcription factor MTF1 was 
significantly correlated with the expression of MT1F. The IVS1-128A>T polymorphism had 
considerable influence on the location of the disease. In particular, the presence of the IVS1-
128T allele was associated with ileal disease in a cohort of 222 CD patients and this 
association was even corroborated in the simultaneous presence of CARD15 polymorphisms. 
The correlation between the presence of this MTF1 polymorphism and the expression of 
MTF1 and metallothioneins still needs to be investigated further. 
Summary
Next to the known clinical and immunological links between CD and SpA, we demonstrate in 
this work a genetic connection between these two disorders. Carriership of CD-related 
CARD15 polymorphisms in SpA patients is associated with the presence of chonic gut 
inflammation, similar to CD. Whether these genetic variants in CD and SpA also play a direct 
role in the origin of inflammation at distance of the gut, is not certain. The frequent 
association between axial involvement, peripheral arthritis and uveitis in CD, suggests 
however common etiological factors underlying these different extraintestinal manifestations. 
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In view of the multigenic character of CD and SpA, presumably several genes play a role in 
the disturbed handling of bacterial flora and the possible circulation of antigens between the 
intestine and the joint. Further research in both disease entities is mandatory to investigate 
how bacterial components are transported to extraintestinal organs.
Functional study of isolated monocytes of CD patients demonstrated for the first time a 
disturbed immunological response in single heterozygous carriers of CARD15
polymorphisms, representing the largest group of mutation carriers. Monocytes of these 
patients showed an aberrant early cytokine secretion after infection with AIEC, a bacterial 
strain specifically associated with CD. Moreover, these polymorphisms also seem to induce a 
disturbed humoral response, reflected by the association with anti-Saccharomyces cerevisiae
antibodies.
We also confirmed the link between CD and SpA at the transcriptome level. Remarkable 
similarities were noted in the genetic expression profile of non-inflammatory colonic biopsies 
of CD patients and SpA patients with chronic intestinal inflammation using array analyses.
Finally, we demonstrated that the search for differential gene expression may lead to the 
identification of new disease-modifying genes with a role in the pathogenesis of the disease. 
Metallothioneins are substantially down-regulated in CD patients with colonic involvement. 
Furthermore, we identified a polymorphism in MTF1, a gene for the main transcriptional 
regulator for MT, which also was related with disease location in CD.  
In conclusion, this work provides new proof for the close (etiopatho)genetic relationship 
between CD and SpA, presents new insights in the functional role of CD-associated CARD15
polymorphisms and describes an alternative approach (via differential gene expression) to 
identify new potential susceptibility or disease-modifying genes. 
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De ziekte van Crohn en spondyloarthropathieën worden beschouwd als onderling verwante, 
complexe, multigene aandoeningen. Een gestoord immunologisch antwoord op ongekende 
omgevingsfactoren geeft in genetisch voorbeschikte personen aanleiding tot de ontwikkeling 
van chronische, ongecontroleerde darm- en/of gewrichtsinflammatie.  
Gedurende de laatste decade is er aanzienlijke vooruitgang geboekt in het genetisch 
onderzoek van beide ziekte-entiteiten. Uitgebreide genoomscreening heeft geleid tot de 
identificatie van verschillende susceptibiliteitsloci, waarin tal van mogelijke kandidaatgenen 
verborgen zitten.
Genetische linkage- en associatiestudies droegen vervolgens bij tot de ontdekking van 
CARD15 op chromosoom 16q als eerste Crohn-gerelateerd gen. Drie CARD15 polymorfismen 
werden met CD in verband gebracht en komen voor in 30 tot 45% van de CD patiënten. 
Functionele studies toonden aan dat deze genetische varianten aanleiding geven tot een 
gestoorde immunologische respons van de gastheercel op bacteriële celwandcomponenten. 
Een ontregelde mucosale homeostase met verminderde productie van pro-inflammatoire 
cytokines en anti-bacteriële defensines kan leiden tot een grotere influx en intramucosaal 
persisteren van intestinale bacteriën of microbiële antigenen met secundaire, chronische 
darminflammatie tot gevolg. Deze bevindingen bevestigden de rol van een verminderde 
tolerantie tegen bacteriële flora in de ontwikkeling van deze chronische darmziekte, zoals 
reeds voordien aangetoond in talrijke dierexperimentele en humane studies.  
Het verband tussen HLA-B27 dragerschap en het risico op SpA, meer bepaald AS, is goed 
gekend. De rol van deze genetische factor is echter veel minder sterk in CD-geassocieerde AS 
en asymptomatische SI. Recent werden nu ook verschillende non-MHC gerelateerde 
susceptibiliteitsloci geïdentificeerd in SpA populaties, onder andere op chromosoom 16q. 
Meerdere klinische en immunologische gegevens bevestigen de link tussen CD en SpA. Zo 
kunnen CD patiënten een axiale en/of perifere artropathie ontwikkelen welke onderdeel 
uitmaken van het SpA concept. Anderzijds treft men echter bij twee derden van de SpA 
patiënten ook (subklinische) darminflammatie aan, met gelijkaardige histologische kenmerken 
als bij CD. De aanwezigheid van chronisch inflammatoire kenmerken in ileum en/of colon 
van SpA patiënten vormt dan ook een verhoogd risico voor het later ontwikkelen van een 
klinisch manifeste ziekte van Crohn. Daarnaast werden ook verschillende immunologische 
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wijzigingen aangetroffen in de intestinale mucosa en synovium van CD en SpA patiënten, 
welke een (re)circulatie van inflammatoire cellen tussen darm en gewricht doen vermoeden.  
Het was de bedoeling van dit werk om de rol van genetische alteraties in het verband tussen 
gewricht en darm in CD en SpA te onderzoeken. 
1. CARD15 polymorfismen predisponeren tot subklinische chronische 
darminflammatie in patiënten met SpA. 
Na de identificatie van een susceptibiliteitslocus op chromosoom 16q voor AS, hebben tal van 
associatiestudies de rol van CARD15 polymorfismen in SpA en AS nagekeken. Een 
verhoogde prevalentie van deze genetische varianten kon in deze populaties niet worden 
aangetoond. Er werd hierbij echter geen rekening gehouden met de aan- of afwezigheid van 
chronische darminflammatie, nochtans de risicofactor bij uitstek voor het ontwikkelen van 
CD in deze reumatologische populaties. 
In hoofdstuk 2 tonen we aan dat de aanwezigheid van subklinische chronische 
darminflammatie in SpA geassocieerd is met CD-gerelateerde polymorfismen in het CARD15 
gen. Deze bevinding levert voor het eerst ook genetische argumenten voor het verband tussen 
CD en SpA en suggereert een potentiële rol voor een gestoorde omgang met intestinale 
bacteriën of bacteriële bestanddelen in de etiopathogenese van deze chronische reumatische 
aandoeningen. Reeds lang wordt de hypothese van een mogelijk infectieuze (enterogene) 
trigger voor het ontstaan van SpA naar voor geschoven. Zowel bacteriële antigenen als DNA 
werden teruggevonden in het synoviaal vocht van voornamelijk ReA patiënten, doch ook bij 
patiënten met ongedifferentieerde SpA, AS en PsA. Daarenboven werd dragerschap van 
Klebsiella pneumoniae in de darm ooit als mogelijke risicofactor voor de ontwikkeling van 
AS naar voor geschoven. Een gestoorde immunologische afweer in de darmmucosa, zoals 
aangetoond bij CARD15 polymorfismen, zou kunnen leiden tot een verhoogde locale influx 
van bacteriën en een intestinale oorsprong van articulaire inflammatie, temeer daar 
inflammatoire cellen en bacteriële antigenen vermoedelijk kunnen circuleren tussen darm en 
gewricht.
Het merendeel van de SpA patiënten met darminflammatie ontwikkelen geen klinisch 
manifeste CD. Meteen rijst dan ook de vraag of CARD15 polymorfismen niet eerder met 
(subklinische) intestinale inflammatie geassocieerd zijn dan met echte CD op zich.  
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2. De rol van CARD15 polymorfismen in de ontwikkeling van articulaire inflammatie 
in CD. 
De exacte pathogenese van extra-intestinale manifestaties in IBD is nog steeds niet 
opgehelderd. De circulatie van enterogene bacteriën of antigenen tussen de darm en organen 
op afstand lijkt echter ook in IBD potentieel belangrijk, mede gezien de recente bevindingen 
rond de functionele rol van CARD15 polymorfismen. Deze hypothese wordt versterkt door de 
bevinding dat in ReA, waar enterogene bacteriën een primordiale rol spelen in de 
ontwikkeling van gewrichtsinflammatie, vaak ook nog andere extra-articulaire en -intestinale 
haarden van inflammatie worden aangetroffen (huid, conjunctiva, iris, urethra en hart). 
Genotype-fenotype studies hebben in het verleden geen associatie van CARD15
polymorfismen met extra-intestinale manifestaties aangetoond. Er zijn echter slechts weinig 
gegevens beschikbaar over de associatie met specifieke articulaire manifestaties en in het 
bijzonder over axiale aantasting ontbreekt elke informatie. Sacroiliitis, vaak asymptomatisch 
en niet HLA-B27 gerelateerd, wordt als de meest frequente extra-intestinale manifestatie van 
CD beschouwd. Bovendien suggereerde onderzoek bij verwanten van AS patiënten een niet-
HLA-B27 gebonden genetische factor in de associatie tussen intestinale en axiale 
inflammatie. 
In hoofdstuk 3 onderzochten we de associatie van CARD15 polymorfismen met verschillende 
reumatologische manifestaties van CD. Deze studie toonde een hogere prevalentie van 
radiologische sacroiliitis in CD patiënten met CARD15 polymorfismen. Conform vroegere 
associatiestudies, vonden we geen verband met perifere artritis. De mogelijke link tussen deze 
genetische varianten en axiale inflammatie komt ook tot uiting bij SpA patiënten. Chronische 
darminflammatie is bij deze patiënten, zoals in de vorige studie aangetoond, geassocieerd met 
CARD15 polymorfismen en komt duidelijk het meest voor bij patiënten met axiale aantasting. 
Bij niet-AS SpA patiënten vormt de aanwezigheid van chronische ileitis en/of colitis zelfs een 
belangrijke risicofactor voor de latere evolutie naar AS.
Gegevens over de associatie van radiologische sacroiliitis met specifieke fenotypes van CD 
zijn schaars. Bijgevolg werd in samenwerking met Leuven en Luik een multicentrische studie 
rond deze frequente extra-intestinale manifestatie opgezet, waarbij gekeken werd naar 
eventueel geassocieerde klinische kenmerken en het verband met CARD15 varianten 
(hoofdstuk 4). We vonden een verband tussen de aanwezigheid van radiologische SI en het 
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ontwikkelen van perifere artritis. Daarenboven hadden CD patiënten met klinische AS 
eveneens een verhoogde kans op het doormaken van uveitis. Deze gegevens suggereren 
gemeenschappelijke kenmerken in het ontstaan van deze extra-intestinale manifestaties.  
In deze 2
de
 studie kon het verband tussen CARD15 polymorfismen en sacroiliitis weliswaar 
niet worden bevestigd. Reproduceerbaarheid van genetische associatiestudies blijkt een 
aanzienlijk probleem in het huidig genetisch onderzoek van complexe, multigene 
aandoeningen. Talrijke factoren, zoals genetische heterogeniteit, statistische power, 
omgevingsfactoren, inhomogene populaties, gebrek aan kwaliteitscontrole op geno- en 
fenotypering evenals de keuze van statistische modellen kunnen leiden tot inconsistente 
resultaten tussen studies. Ook in CARD15 associatiestudies werden frequent tegenstrijdige 
bevindingen beschreven zelfs in etnisch gelijkaardige populaties.
Beide studies in deze thesis omvatten fenotypisch en ethnisch gelijkaardige populaties CD 
patiënten, die onafhankelijk van de aanwezigheid of voorgeschiedenis van articulaire 
symptomen werden geïncludeerd. Zowel de CARD15 genotypering als het scoren van de 
sacro-iliacale radiografieën werden blind uitgevoerd en de gekende associaties tussen 
CARD15 polymorfismen en ileale en fibrostenoserende ziekte werden ook in beide cohortes 
bevestigd. Daarenboven werd in de 1
ste
 studie de associatie tussen sacro-iliitis en CARD15
polymorfismen in univariate analyse bevestigd in een multivariaat statistisch model. Het 
gebrek aan een duidelijke verklaring voor de inconsistente resultaten tussen beide studies 
weerspiegelt opnieuw het probleem van genetische associatiestudies in complexe 
aandoeningen. Bij het uitvoeren van dergelijk onderzoek streeft men dus best naar grote, 
etnisch en fenotypisch homogene en goed afgelijnde patiëntenpopulaties of bij voorkeur naar 
2 onafhankelijke en goed uitgebalanceerde cohortes binnen dezelfde studie.  
Onafgezien van de inconsistente resultaten over het verband tussen sacro-iliitis en CARD15
polymorfismen, blijft de genetisch voorbeschikte circulatie van inflammatoire cellen en 
onvoldoende geklaarde micro-organismen of bacteriële componenten, als oorzaak van 
inflammatie op afstand van de darm een interessante werkhypothese in zowel IBD als SpA. 
Gezien het multigene karakter van beide ziektebeelden spelen vermoedelijk meerdere 
genetische defecten een rol in de gestoorde omgang met de intestinale flora en het transport 
van bacteriële antigenen naar andere organen. Het is evenwel nog onduidelijk hoe 
componenten van de bacteriële flora eventueel vanuit de intestinale mucosa via de bloedbaan 
naar organen op afstand worden getransporteerd. 
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3. CARD15 polymorfismen leiden tot een gestoord cellulair en humoraal 
immunologisch antwoord tegen micro-organismen. 
CARD15 speelt een belangrijke rol in het aangeboren afweersysteem van de gastheer 
tegenover intraluminele micro-organismen. Het intracytoplasmatisch gelegen eiwit CARD15 
fungeert als receptor voor muramyl dipeptide (MDP), een onderdeel van peptidoglycan, welke 
als celwandbestanddeel in de meeste bacteriën wordt teruggevonden. Een gestoord 
immunologisch antwoord van de gastheercel op dit bacteriële antigen werd in verschillende 
functionele studies (in vitro en ex vivo) met de CD-gerelateerde CARD15 polymorfismen in 
verband gebracht. De resultaten van deze studies waren echter meest uitgesproken in de 
(zeldzamere) homozygote dragers van deze genetische varianten, meer bepaald van de 
frameshift mutatie. Single heterozygoten komen echter veel frequenter voor en tot op heden 
kon geen functioneel defect in dergelijke patiënten worden aangetoond.  
In hoofdstuk 5 onderzochten we in CD patiënten de rol van CARD15 polymorfismen op de 
respons van perifere bloedmonocyten tegen adherent-invasieve E. coli (AIEC). Deze 
bacteriële streng, specifiek met CD geassocieerd, werd geïsoleerd uit ileum van CD patiënten 
en is in staat in de gastheercel binnen te dringen, te overleven en zelfs te vermenigvuldigen. 
Na infectie van de monocyten met deze AIEC, werd een gestoorde vroegtijdige 
cytokinesecretie (IL-1ȕ, IL-6 en IL-10) waargenomen in patiënten met CARD15
polymorfismen. Hoewel het effect meest uitgesproken was in homozygoten, kon voor het 
eerst ook een functioneel defect worden aangetoond in de (veel frequentere) heterozygote 
dragers van deze genetische varianten. Verder onderzoek zal moeten uitwijzen of dit vroeg 
gestoord immunologisch antwoord ook kan worden aangetroffen in andere celtypes 
(intestinale macrofagen, dendritische cellen en epitheelcellen) en na infectie met andere, al 
dan niet invasieve bacteriën.
Deze studie weerspiegelt ook het belang van synergie tussen CARD15 en TLRs. In 
tegenstelling tot AIEC, die monocyten kunnen stimuleren via zowel CARD15 als TLRs, kon 
geen duidelijk gestoorde respons worden teruggevonden na stimulatie met MDP alleen. Van 
Heel et al toonden recent aan dat TLR-agonisten een sterkere respons uitlokken in 
aanwezigheid van CARD15 stimulatie en dat dit synergistisch effect verdwijnt bij 
homozygote dragers van CARD15 polymorfismen.  
Na binding van het MDP en LPS van de AIEC bacterie aan respectievelijk CARD15- en 
TLR4 receptoren in monocyten/macrofagen met een mutant CARD15-gen, kan het ontbreken 
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van CARD15-TLR4 synergie in aanzienlijke mate bijdragen tot de geobserveerde 
downregulatie van de inflammatoire respons van deze monocyten op dit micro-organisme. 
Samen met de gedaalde expressie van antibacteriële defensines in dragers van CARD15
polymorfismen (beschreven door Wehkamp et al), kan een verminderde secretie van Il-1ȕ en 
IL6, zoals waargenomen in de huidige studie, via een deficiënte recrutering en infiltratie van 
neutrofielen leiden tot een verhoogde mucosale influx van intestinale bacteriën met een 
secundaire, inflammatoire respons tot gevolg. De lagere (en dus meer pro-inflammatoire) IL-
10/TNFĮ ratio na infectie van deze monocyten met AIEC draagt dan eveneens rechtstreeks bij 
tot de uiteindelijke mucosale ontstekingsreactie. Of een toegenomen mucosale influx van 
intestinale bacteriën ook leidt tot de circulatie van bacteriële antigenen naar organen op 
afstand is nog onduidelijk maar vormt een interessante werkhypothese voor toekomstige 
studies. Verder onderzoek zal zich toespitsen op de correlatie van een gestoorde 
immunologische respons tegen AIEC en de mucosale influx en circulatie van bacteriën of 
bacteriële bestanddelen met het ontwikkelen van extra-intestinale manifestaties. 
CARD15 polymorfismen lijken echter ook een invloed te hebben op de humorale respons. We 
vonden een duidelijk verband tussen de aanwezigheid van deze genetische varianten en 
antilichamen tegen Saccharomyces cerevisiae in patiënten met CD (Hoofdstuk 6). ASCA 
IgA en/of IgG worden beschouwd als specifieke serologische merkers voor CD doch deze 
antilichamen worden ook aangetroffen bij patiënten met SpA. In deze studie vonden we de 
hoogste ASCA titers bij homozygoten en compound heterozygoten, maar ook heterozygote 
dragers van CARD15 polymorfismen waren duidelijk meer ASCA positief vergeleken met 
wild-type patiënten.
Een genetische invloed op het ontstaan van deze antilichamen tegen bakkers- of brouwersgist 
werd vroeger reeds gesuggereerd door verschillende familie- en tweelingstudies, die in 
onaangetaste verwanten en tweelingen van CD patiënten hogere ASCA titers beschreven. Een 
gelijkaardig verband tussen CARD15 polymorfismen en ASCA werd ook in een andere studie 
met gelijkaardige ethnische achtergrond beschreven. 
Het is tot op heden onduidelijk of ASCA kruisreactieve auto-antilichamen vertegenwoordigen 
dan wel het gevolg zijn van een aberrant antwoord tegen bakkers- of brouwersgist. Deze 
onzekerheid over de exacte rol van ASCA in CD (of SpA) maakt speculatie omtrent het 
mechanisme waarbij  CARD15 polymorfismen leiden tot de vorming van deze antilichamen 
moeilijk. Niettemin lijkt, gezien het verband tussen deze genetische varianten en een 
gestoorde immuunrespons tegen micro-organismen en bacteriële componenten, een gestoord 
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(secundair serologisch) antwoord tegen (componenten van) Saccharomyces cerevisiae zeker 
mogelijk.
4. Onderzoek naar nieuwe moleculaire targets in het verband tussen CD en SpA. 
Gebaseerd op de vroeger beschreven klinische en immunologische bevindingen bij CD en 
SpA, werd SpA met subklinische chronische darminflammatie als uniek preklinisch model 
naar voor geschoven voor de studie van vroegtijdige ziekte van Crohn. Om de associatie 
tussen beide ziektebeelden eveneens op transcriptoomniveau te bevestigen, hebben we 
gebruik gemaakt van macro- en micro-arrays. De globale genetische expressie in 
macroscopisch niet-geïnflammeerde colonbiopten werd geanalyseerd bij CD patiënten, SpA 
patiënten (met of zonder chronische darminflammatie) en gezonde controlepersonen 
(Hoofdstuk 7). Eerst en vooral werd aangetoond dat het darmtranscriptoom in SpA patiënten 
verschilt van gezonde controles. Bovendien vonden we een duidelijke clustering tussen SpA 
patiënten met chronische darminflammatie en CD patiënten. Deze bevinding suggereert 
overeenkomsten in het genetische expressieprofiel van beide groepen patiënten en versterkt 
eens te meer het bewijs voor het verband tussen CD en SpA. We beschreven hierbij een set 
van 95 genen, welke differentieel tot expressie kwamen in de darm van CD patiënten en SpA 
patiënten met chronische darminflammatie. 
Gezien variatie in genetische expressie ook genetisch bepaald kan zijn, kan de zoektocht naar 
differentieel tot expressie gebrachte genen leiden tot de ontdekking van mogelijk nieuwe 
kandidaatgenen met een rol in de pathogenese of het ziekteverloop van deze aandoeningen. 
Resultaten van transcriptoomanalyse in CD patiënten en gezonde controles werden gelinkt 
met gerepliceerde susceptibiliteitsloci voor CD. Aldus werden 18 potentiële kandidaatgenen
binnen deze loci geïdentificeerd (Hoofdstuk 8). De aandacht werd toegespitst op 2 
metallothioneine (MT) isovormen MT1F en MT1M, gecodeerd door genen in de IBD1-locus 
(chromosoom 16q) en betrokken bij “metal scavenging” processen en bactericide en anti-
inflammatoire activiteiten. De basale MT expressie was significant gedaald in het bloed en 
ileum- en colonbiopten van CD patiënten met colonaantasting, suggestief voor een genetische 
predispositie eerder dan inflammatie als oorzaak. Een verminderde expressie van MT in MT-
knockdown colonepitheel HT29 cellen correleerde met een verlaagde secretie van IL-8, een 
sterk chemo-attractant voor en activator van neutrofielen, welke een essentiële rol vervullen in 
de inflammatoire respons. De gedaalde expressie van MT in intestinale epitheelcellen en de 
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gestoorde IL-8 secretie in het antwoord op bacteriën kan leiden tot een overdreven secundaire, 
compensatoire immunologische respons. Mutatiescreening bracht een polymorfisme (IVS1-
128A>T) in het MRE-binding transcription factor 1 of MTF1 gen (IBD7 locus) aan het licht. 
Dit gen codeert voor de belangrijkste transcriptiefactor in de regeling van MT expressie. In 
bloed van CD patiënten en controles was de expressie van de transcriptiefactor MTF1 
significant gecorreleerd met de expressie va MT1F. Het IVS1-128A>T polymorfisme had een 
belangrijke invloed op de localisatie van de ziekte. De aanwezigheid van het IVS1-128T allel 
was specifiek geassocieerd met ileale aantasting in een cohorte van 222 CD patiënten en dit 
verband werd zelfs nog versterkt in de gelijktijdige aanwezigheid van CARD15
polymorfismen. De correlatie tussen de aanwezigheid van dit MTF1 polymorfisme en de 
expressie van MTF1 en metallothioneines dient echter nog verder te worden onderzocht.
Globale samenvatting
In dit werk tonen we aan dat er, naast klinische en immunologische links, ook een genetisch 
verband bestaat tussen CD en SpA. Dragerschap van Crohn-gerelateerde CARD15
polymorfismen is ook in SpA patiënten geassocieerd met de aanwezigheid van chronische 
darminflammatie. Of deze genetische varianten in CD en SpA ook rechtstreeks een rol spelen 
in het ontstaan van inflammatie op afstand van de darm, staat niet vast. Het frequent 
samengaan van axiale aantasting, perifere artritis en uveitis in CD patiënten geeft wel aan dat 
gemeenschappelijke etiologische factoren aan de basis liggen van verschillende 
extraintestinale manifestaties. Gezien het multigene karakter van CD en SpA spelen 
vermoedelijk meerdere genen een rol in een gestoorde omgang met bacteriële flora en het 
mogelijks circuleren van antigenen tussen darm en gewricht. Verder onderzoek in beide 
ziektebeelden is onontbeerlijk om na te gaan hoe bacteriële componenten naar extra-
intestinale organen worden getransporteerd.
Functioneel onderzoek in geïsoleerde monocyten van CD patiënten toont voor het eerst aan 
dat ook in heterozygote dragers van CARD15 varianten, de grootste groep van mutatiedragers, 
een gestoorde immunologische respons kan worden genoteerd. Monocyten van dergelijke 
patiënten vertonen een aberrante vroegtijdige cytokinesecretie na infectie met AIEC, een 
bacteriële streng die specifiek met CD werd geassocieerd. Bovendien blijken deze 
polymorfismen ook een gestoord humoraal antwoord te induceren, zoals blijkt uit de 
associatie met anti-Saccharomyces cerevisiae antilichamen.  
Het verband tussen CD en SpA werd verder eveneens op transcriptoomniveau bevestigd. 
Gebruik makend van array analyses, werden opvallende gelijkenissen opgemerkt in het 
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genetische expressieprofiel van niet-inflammatoire colonbiopten in CD patiënten en SpA 
patiënten met chronische darminflammatie,  
We toonden ook aan dat de zoektocht naar differentieel tot expressie gebrachte genen kan 
leiden tot de identificatie van nieuwe kandidaatgenen met een rol in de pathogenese en het 
ziekteverloop. De expressie van metallothioneines is aanzienlijk verlaagd in CD-patiënten met 
colonaantasting. Verder werd in CD een polymorfisme geïdentificeerd in MTF1, het gen voor 
de belangrijkste transcriptionele regulator van MT, dat eveneens met de ziektelocalisatie in 
verband stond.
Samengevat kunnen we stellen dat dit werk nieuw bewijs levert voor de (etiopatho)genetische 
link tussen CD en SpA, nieuwe inzichten brengt in de functionele rol van CD-geassocieerde 
CARD15 polymorfismen en een alternatieve benadering beschrijft om (via differentiële 
genexpressie) nieuwe, potentiële kandidaat susceptibiliteits- of “disease-modifying” genen te 
identificeren.  
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